Wait O
5 O
weeks O
after O
stopping O
escitalopram B-drug
before O
starting O
a O
non-selective B-group
MAO I-group
inhibitor I-group
. O

However O
, O
coadministration O
of O
escitalopram B-drug
( O
20 O
mg O
) O
and O
ritonavir B-drug
( O
600 O
mg O
) O
, O
a O
potent O
inhibitor O
of O
CYP3A4 O
, O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
escitalopram B-drug
. O

This O
loss O
of O
microtubules O
on O
cooling O
the O
nerves O
and O
their O
reappearance O
on O
rewarming O
was O
a O
rapid O
process O
; O

The O
potential O
for O
increased O
sedation O
when O
guanfacine B-drug
is O
given O
with O
other O
CNS-depressant B-group
drug I-group
should O
be O
appreciated O
. O

The O
potential O
effects O
of O
increased O
plasma O
concentrations O
of O
midazolam B-drug
or O
other O
benzodiazepines B-group
metabolized O
via O
CYP3A4 O
( O
alprazolam B-drug
, O
triazolam B-drug
) O
should O
be O
considered O
when O
coadministering O
these O
agents O
with O
Aprepitant B-drug
. O

Oral O
anticoagulant B-group
agents I-group
: O
Pharmacokinetic O
drug-drug O
interactions O
between O
Argatroban B-drug
and O
warfarin B-drug
( O
7.5 O
mg O
single O
oral O
dose O
) O
have O
not O
been O
demonstrated O
. O

Drug/Laboratory O
Test-Interactions O
None O
observed O
. O

The O
ratios O
of O
the O
AUCs O
of O
unbound O
valproate B-drug
to O
the O
AUCs O
of O
the O
total O
valproate B-drug
were O
11.1 O
% O
, O
13.0 O
% O
, O
and O
11.5 O
% O
, O
with O
coadministration O
of O
0 O
, O
1200 O
, O
and O
2400 O
mg/day O
of O
Felbatol B-brand
, O
respectively O
. O

The O
results O
of O
the O
ERMBT O
after O
2 O
weeks O
of O
rifabutin B-drug
and O
rifampin B-drug
therapy O
were O
increased O
187 O
and O
156 O
% O
, O
respectively O
. O

Interations O

CANCIDAS B-brand
reduced O
the O
blood O
AUC0-12 O
of O
tacrolimus B-drug
by O
approximately O
20 O
% O
, O
peak O
blood O
concentration O
( O
Cmax O
) O
by O
16 O
% O
, O
and O
12-hour O
blood O
concentration O
( O
C12hr O
) O
by O
26 O
% O
in O
healthy O
subjects O
when O
tacrolimus B-drug
( O
2 O
doses O
of O
0.1 O
mg/kg O
12 O
hours O
apart O
) O
was O
administered O
on O
the O
10th O
day O
of O
CANCIDAS B-brand
70 O
mg O
daily O
, O
as O
compared O
to O
results O
from O
a O
control O
period O
in O
which O
tacrolimus B-drug
was O
administered O
alone O
. O

This O
combinational O
action O
in O
reversing O
vancomycin O
resistance O
of O
enterococci O
highlights O
novel O
drug O
targets O
and O
has O
importance O
in O
the O
design O
of O
new O
therapeutic O
regimes O
against O
resistant O
pathogens O
. O

Concurrent O
use O
of O
macrolides B-group
and O
warfarin B-drug
in O
clinical O
practice O
has O
been O
associated O
with O
increased O
anticoagulant O
effects O
. O

Serial O
plasma O
and O
urine O
samples O
for O
measurement O
of O
amprenavir B-drug
, O
rifabutin B-drug
, O
and O
rifampin B-drug
and O
their O
25-O-desacetyl B-drug_n
metabolites I-drug_n
, O
were O
measured O
by O
high-performance O
liquid O
chromatography O
. O

Nevirapine I-drug
and O
rifampin B-drug
should O
not O
beadministered O
concomitantly O
becausedecreases O
in O
nevirapine B-drug
plasmaconcentrations O
may O
reduce O
the O
efficacy O
ofthe O
drug O
. O

Antibiotics B-group
: O
In O
vitro O
and/or O
in O
vivo O
data O
show O
that O
clarithromycin B-drug
, O
erythromycin B-drug
, O
and O
troleandomycin B-drug
markedly O
inhibit O
the O
metabolism O
of O
cisapride B-drug
, O
which O
can O
result O
in O
an O
increase O
in O
plasma O
cisapride B-drug
levels O
and O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O

The O
treatment O
of O
ewes O
with O
an O
intravenous O
( O
IV O
) O
injection O
of O
trichlorfon B-drug_n
, O
insufficient O
to O
produce O
significant O
inhibition O
of O
erythrocyte O
acetylcholinesterase O
( O
AChE O
) O
activity O
, O
appeared O
to O
produce O
additive O
effects O
with O
those O
produced O
by O
subsequent O
treatment O
with O
4 O
mg O
of O
coumaphos/kg/day B-drug_n
. O

Consequently O
, O
it O
is O
recommended O
not O
to O
exceed O
a O
single O
2.5 O
mg O
Vardenafil B-drug
dose O
in O
a O
72-hour O
period O
when O
used O
in O
combination O
with O
ritonavir B-drug
. O

Castor B-drug
oil I-drug
( O
4 O
ml/kg O
, O
p.o O
. O
) O

Probenecid B-drug
: O
Probenecid B-drug
increases O
both O
free O
and O
bound O
ketoprofen B-drug
by O
reducing O
the O
plasma O
clearance O
of O
ketoprofen B-drug
to O
about O
one-third O
, O
as O
well O
as O
decreasing O
its O
protein O
binding O
. O

Nevertheless O
, O
caution O
is O
indicated O
in O
the O
coadministration O
of O
escitalopram B-drug
and O
drugs O
metabolized O
by O
CYP2D6 O
. O

Capsules O
INDOCIN B-brand
50 O
mg O
t.i.d O
. O
produced O
a O
clinically O
relevant O
elevation O
of O
plasma O
lithium B-drug
and O
reduction O
in O
renal O
lithium B-drug
clearance O
in O
psychiatric O
patients O
and O
normal O
subjects O
with O
steady O
state O
plasma O
lithium B-drug
concentrations O
. O

Therefore O
, O
increased O
monitoring O
of O
digoxin B-drug
is O
recommended O
when O
initiating O
, O
adjusting O
, O
or O
discontinuing O
COREG B-brand
. O

Cimetidine B-drug
, O
caffeine B-drug
, O
and O
erythromycin B-drug
may O
increase O
plasma O
levels O
of O
Clozapine B-drug
, O
potentially O
resulting O
in O
adverse O
effects O
. O

Analysis O
of O
16,16-dimethylprostaglandin B-drug_n
E2-induced O
diarrhea O
in O
cecectomized O
rats O
. O

Response O
to O
sympathomimetic B-group
agents I-group
may O
be O
enhanced O
by O
colchicine B-drug
. O

Therefore O
, O
digoxin B-drug
serum O
levels O
should O
be O
monitored O
. O

The O
clinical O
significance O
of O
these O
findings O
is O
unknown O
. O

Increases O
in O
prothrombin O
time O
have O
been O
noted O
in O
patients O
receiving O
long- O
term O
warfarin B-drug
therapy O
after O
flutamide B-drug
was O
initiated O
. O

. O

Methotrexate B-drug
: O
Caution O
should O
be O
used O
if O
diflunisal B-drug
is O
administered O
concomitantly O
with O
methotrexate B-drug
. O

dosage O
adjustments O
may O
be O
necessary O
. O
) O

While O
all O
the O
selective O
serotonin B-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
, O
e.g. O
, O
fluoxetine B-drug
, O
sertraline B-drug
, O
and O
paroxetine B-drug
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O

Fulvestrant B-drug
was O
not O
mutagenic O
or O
clastogenic O
in O
multiple O
in O
vitro O
tests O
with O
and O
without O
the O
addition O
of O
a O
mammalian O
liver O
metabolic O
activation O
factor O
( O
bacterial O
mutation O
assay O
in O
strains O
of O
Salmonella O
typhimurium O
and O
Escherichia O
coli O
, O
in O
vitro O
cytogenetics O
study O
in O
human O
lymphocytes O
, O
mammalian O
cell O
mutation O
assay O
in O
mouse O
lymphoma O
cells O
and O
in O
vivo O
micronucleus O
test O
in O
rat O
. O

Concomitantly O
given O
thiazide B-group
diuretics I-group
did O
not O
interfere O
with O
the O
absorption O
of O
a O
tablet O
of O
digoxin B-drug
. O

After O
1 O
h O
, O
atracurium B-drug
was O
discontinued O
and O
hoof O
twitch O
allowed O
to O
recover O
to O
75 O
% O
. O

Depression O
is O
reaching O
epidemic O
proportions O
in O
the O
western O
world O
. O

When O
these O
drugs O
are O
administered O
to O
or O
withdrawn O
from O
patients O
receiving O
Starlix B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
changes O
in O
glycemic O
control O
. O

When O
amiloride B-drug
HCl O
is O
administered O
concomitantly O
with O
an O
angiotensin-converting B-group
enzyme I-group
inhibitor I-group
, O
the O
risk O
of O
hyperkalemia O
may O
be O
increased O
. O

No O
interactions O
have O
been O
observed O
between O
nizatidine B-drug
and O
theophylline B-drug
, O
chlordiazepoxide B-drug
, O
lorazepam B-drug
, O
lidocaine B-drug
, O
phenytoin B-drug
, O
and O
warfarin B-drug
. O

Coadministration O
of O
valdecoxib B-drug
with O
doses O
higher O
than O
40 O
mg O
QD O
omeprazole B-drug
has O
not O
been O
studied O
. O

In O
the O
second O
experiment O
, O
non-diabetic O
and O
streptozotocin-induced O
diabetic O
rats O
were O
fasted O
, O
and O
the O
same O
procedures O
were O
followed O
for O
estimation O
of O
glucose B-drug
tolerance O
30 O
min O
after O
glucose B-drug
overload O
. O

Digoxin B-drug
, O
Methotrexate B-drug
, O
Cyclosporine B-drug
: O
Diclofenac B-drug
, O
like O
other O
NSAIDs B-group
, O
may O
affect O
renal O
prostaglandins O
and O
increase O
the O
toxicity O
of O
certain O
drugs O
. O

Studies O
have O
shown O
that O
the O
bioavailability O
of O
isoniazid B-drug
is O
reduced O
significantly O
when O
administered O
with O
food O
. O

Drug-Drug O
Interactions O
Albuterol B-drug
- O
STRATTERA B-brand
should O
be O
administered O
with O
caution O
to O
patients O
being O
treated O
with O
systemically-administered O
( O
oral O
or O
intravenous O
) O
albuterol B-drug
( O
or O
other O
beta2 B-group
agonists I-group
) O
because O
the O
action O
of O
albuterol B-drug
on O
the O
cardiovascular O
system O
can O
be O
potentiated O
resulting O
in O
increases O
in O
heart O
rate O
and O
blood O
pressure O
. O

Drugs O
Which O
Require O
a O
Dose O
Reduction O
When O
Coadminstered O
With O
VIRACEPT B-brand
Antimycobacterial B-group
agents I-group
: O
rifabutin B-drug

phosphokinase O

Acetaminophen B-drug
: O
In O
normal O
volunteers O
, O
concomitant O
administration O
of O
diflunisal B-drug
and O
acetaminophen B-drug
resulted O
in O
an O
approximate O
50 O
% O
increase O
in O
plasma O
levels O
of O
acetaminophen B-drug
. O

In O
a O
single-dose O
crossover O
study O
examining O
lansoprazole B-drug
30 O
mg O
and O
omeprazole B-drug
20 O
mg O
each O
administered O
alone O
and O
concomitantly O
with O
sucralfate B-drug
1 O
gram O
, O
absorption O
of O
the O
proton B-group
pump I-group
inhibitors I-group
was O
delayed O
and O
their O
bioavailability O
was O
reduced O
by O
17 O
% O
and O
16 O
% O
, O
respectively O
, O
when O
administered O
concomitantly O
with O
sucralfate B-drug
. O

Pharmacokinetics O
. O

Saquinavir B-drug
: O
Coadministration O
of O
saquinavir B-drug
( O
using O
an O
experimental O
soft-gelatin O
capsule O
formulation O
of O
saquinavir B-drug
1200mg O
) O
with O
VIRACEPT B-brand
resulted O
in O
an O
18 O
% O
increase O
in O
nelfinavir B-drug
plasma O
AUC O
and O
a O
4-fold O
increase O
in O
saquinavir B-drug
plasma O
A.C O
. O

This O
is O
based O
on O
the O
results O
from O
3 O
clinical O
studies O
using O
histamine B-drug
induced O
skin O
wheals O
and O
flares O
coupled O
with O
population O
pharmacokinetic O
analysis O
. O

CONCLUSIONS O
. O

Other O
: O
There O
appears O
to O
be O
no O
pharmacokinetic O
interaction O
between O
acitretin B-drug
and O
cimetidine B-drug
, O
digoxin B-drug
, O
or O
glyburide B-drug
. O

While O
all O
the O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
, O
e. O
g. O
, O
fluoxetine B-drug
, O
sertraline B-drug
, O
and O
paroxetine B-drug
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O

Substrate O
of O
CYP2D6 O
( O
minor O
) O
, O
3A4 O
( O
major O
) O
; O

this O
interaction O
is O
not O
expected O
to O
be O
of O
clinical O
importance O
. O

Other O
TNFa-blocking B-group
agents I-group
( O
including O
REMICADE B-brand
) O
used O
in O
combination O
with O
anakinra B-drug
may O
also O
result O
in O
similar O
toxicities O
. O

There O
have O
been O
reports O
of O
positive O
test O
results O
using O
the O
Bio-Rad O
Laboratories O
Platelia O
Aspergillus O
EIA O
test O
in O
patients O
receiving O
piperacillin/tazobactam B-drug
injection O
who O
were O
subsequently O
found O
to O
be O
free O
of O
Aspergillus O
infection O
. O

MAO B-group
Inhibitors I-group
: O
DURAGESIC B-brand
is O
not O
recommended O
for O
use O
in O
patients O
who O
have O
received O
MAOI B-group
within O
14 O
days O
because O
severe O
and O
unpredictable O
potentiation O
by O
MAO B-group
inhibitors I-group
has O
been O
reported O
with O
opioid B-group
analgesics I-group

INDOCIN B-brand
reduces O
basal O
plasma O
renin O
activity O
( O
PRA O
) O
, O
as O
well O
as O
those O
elevations O
of O
PRA O
induced O
by O
furosemide B-drug
administration O
, O
or O
salt O
or O
volume O
depletion O
. O

In O
a O
study O
in O
which O
patients O
with O
active O
RA O
were O
treated O
for O
up O
to O
24 O
weeks O
with O
concurrent O
ENBREL B-brand
and O
anakinra B-drug
therapy O
, O
a O
7 O
% O
rate O
of O
serious O
infections O
was O
observed O
, O
which O
was O
higher O
than O
that O
observed O
with O
ENBREL B-brand
alone O
( O
0 O
% O
) O
. O

The O
antimicrobial O
effect O
of O
a O
benzoxazinorifamycin B-drug_n
, O
KRM-1648 B-drug_n
, O
either O
alone O
or O
in O
combination O
with O
ofloxacin B-drug
, O
was O
evaluated O
in O
vitro O
against O
two O
type O
strains O
and O
six O
clinical O
isolates O
of O
Mycobacterium O
ulcerans O
. O

The O
combination O
of O
therapeutic O
doses O
of O
intravenous O
dantrolene B-drug
sodium I-drug
and O
verapamil B-drug
in O
halothane B-drug
a-chloralose O
anesthetized O
swine O
has O
resulted O
in O
ventricular O
fibrillation O
and O
cardiovascular O
collapse O
in O
association O
with O
marked O
hyperkalemia O
. O

Phenylbutazone B-drug
: O
Phenylbutazone B-drug
causes O
increase O
( O
by O
about O
80 O
% O
) O
in O
the O
free O
fraction O
of O
etodolac B-drug
. O

These O
drugs O
include O
the O
thiazides B-group
and O
other O
diuretics B-group
, O
corticosteroids B-group
, O
phe-nothiazines O
, O
thyroid B-group
products I-group
, O
estrogens B-group
, O
oral O
contraceptives B-group
, O
phenytoin B-drug
, O
nicotinic B-drug
acid I-drug
, O
sympathomimet-ics O
, O
calcium B-group
channel I-group
blocking I-group
drugs I-group
, O
and O
isoniazid B-drug
. O

Fulvestrant B-drug
caused O
an O
increased O
incidence O
of O
fetal O
abnormalities O
in O
rats O
( O
tarsal O
flexure O
of O
the O
hind O
paw O
at O
2 O
mg/kg/day O
IM O
; O

CIMETlDINE B-drug
: O
Cerivastatin B-drug
plasma O
concentrations O
were O
not O
affected O
by O
co-administration O
of O
cimetidine B-drug
. O

DIAMOX B-brand
modifies O
phenytoin B-drug
metabolism O
with O
increased O
serum O
levels O
of O
phenytoin B-drug
. O

In O
vitro O
studies O
indicate O
that O
, O
at O
therapeutic O
concentrations O
of O
salicylate B-group
( O
300 O
m O
g/mL O
) O
, O
the O
binding O
of O
ketorolac B-drug
was O
reduced O
from O
approximately O
99.2 O
% O
to O
97.5 O
% O
, O
representing O
a O
potential O
twofold O
increase O
in O
unbound O
ketorolac B-drug
plasma O
levels O
. O

increased O
norepinephrine-induced O
platelet O
aggregability O

Ergot-containing O
drugs O
have O
been O
reported O
to O
cause O
prolonged O
vasospastic O
reactions O
. O

No O
formal O
clinical O
studies O
have O
been O
conducted O
to O
assess O
if O
there O
is O
an O
interactive O
effect O
on O
bone O
loss O
between O
systemic B-group
corticosteroids I-group
and O
Accutane B-brand
. O

Erythromycin B-drug
: O
In O
healthy O
individuals O
, O
plasma O
concentrations O
of O
atorvastatin B-drug
increased O
approximately O
40 O
% O
with O
coadministration O
of O
atorvastatin B-drug
and O
erythromycin B-drug
, O
a O
known O
inhibitor O
of O
cytochrome O
P450 O
3A4 O
. O

to O
contend O
with O
. O

Cysteine B-drug
was O
covalently O
linked O
to O
carbodiimide O
activated O
NaCMC B-drug_n
. O

Warfarin B-drug
: O
Meclofenamate B-drug
sodium I-drug
enhances O
the O
effect O
of O
warfarin B-drug
. O

The O
mean O
changes O
were O
observed O
to O
be O
less O
than O
1 O
second O
in O
both O
instances O
, O
however O
, O
and O
are O
unlikely O
to O
be O
clinically O
important O
. O

SUBJECTS O
: O
Twelve O
healthy O
male O
volunteers O
. O

When O
these O
products O
are O
administered O
concomitantly O
, O
prothrombin O
time O
or O
other O
suitable O
coagulation O
test O
should O
be O
closely O
monitored O
. O

Angiomax B-brand
should O
be O
used O
with O
caution O
in O
patients O
with O
disease O
states O
associated O
with O
an O
increased O
risk O
of O
bleeding O
. O

The O
syndrome O
requires O
immediate O
medical O
attention O
and O
may O
include O
one O
or O
more O
of O
the O
following O
symptoms O
: O
excitement O
, O
hypomania O
, O
restlessness O
, O
loss O
of O
consciousness O
, O
confusion O
, O
disorientation O
, O
anxiety O
, O
agitation O
, O
motor O
weakness O
, O
myoclonus O
, O
tremor O
, O
hemiballismus O
, O
hyperreflexia O
, O
ataxia O
, O
dysarthria O
, O
incoordination O
, O
hyperthermia O
, O
shivering O
, O
pupillary O
dilation O
, O
diaphoresis O
, O
emesis O
, O
and O
tachycardia O
. O

Probenecid B-drug
: O
As O
with O
other O
b-lactam B-group
antibiotics I-group
, O
probenecid B-drug
inhibits O
the O
renal O
excretion O
of O
cefdinir B-drug
, O
resulting O
in O
an O
approximate O
doubling O
in O
A.C. O
a O
54 O
% O
increase O
in O
peak O
cefdinir B-drug
plasma O
levels O
, O
and O
a O
50 O
% O
prolongation O
in O
the O
apparent O
elimination O
half-life O
. O

Future O
trends O
are O
also O
predicted O
. O

Coadministration O
of O
Aprepitant B-drug
with O
these O
drugs O
or O
other O
drugs O
that O
are O
known O
to O
be O
metabolized O
by O
CYP2C9 O
, O
such O
as O
phenytoin B-drug
, O
may O
result O
in O
lower O
plasma O
concentrations O
of O
these O
drugs O
. O

efavirenz B-drug
concentration O

Indinavir I-drug

Lack O
of O
an O
effect O
of O
azithromycin B-drug
on O
the O
disposition O
of O
zidovudine B-drug
and O
dideoxyinosine B-drug
in O
HIV-infected O
patients O
. O

Although O
increased O
plasma O
concentrations O
( O
AUC O
0-24 O
hrs O
) O
of O
loratadine B-drug
and/or O
descarboethoxyloratadine B-drug
were O
observed O
following O
coadministration O
of O
loratadine B-drug
with O
each O
of O
these O
drugs O
in O
normal O
volunteers O
( O
n O
= O
24 O
in O
each O
study O
) O
, O
there O
were O
no O
clinically O
relevant O
changes O
in O
the O
safety O
profile O
of O
loratadine B-drug
, O
as O
assessed O
by O
electrocardiographic O
parameters O
, O
clinical O
laboratory O
tests O
, O
vital O
signs O
, O
and O
adverse O
events O
. O

The O
conjugates O
so O
formed O
often O
appear O
in O
the O
urine O
as O
mercapturic O
acids O
or O
other O
thioether O
products O
. O

Agents O
that O
have O
been O
found O
, O
or O
are O
expected O
to O
have O
decreased O
plasma O
levels O
in O
the O
presence O
of O
EQUETROTM B-brand
due O
to O
induction O
of O
CYP O
enzymes O
are O
the O
following O
: O
Acetaminophen B-drug
, O
alprazolam B-drug
, O
amitriptyline B-drug
, O
bupropion B-drug
, O
buspirone B-drug
, O
citalopram B-drug
, O
clobazam B-drug
, O
clonazepam B-drug
, O
clozapine B-drug
, O
cyclosporin B-drug
, O
delavirdine B-drug
, O
desipramine B-drug
, O
diazepam B-drug
, O
dicumarol B-drug
, O
doxycycline B-drug
, O
ethosuximide B-drug
, O
felbamate B-drug
, O
felodipine B-drug
, O
glucocorticoids B-group
, O
haloperidol B-drug
, O
itraconazole B-drug
, O
lamotrigine B-drug
, O
levothyroxine B-drug
, O
lorazepam B-drug
, O
methadone B-drug
, O
midazolam B-drug
, O
mirtazapine B-drug
, O
nortriptyline B-drug
, O
olanzapine B-drug
, O
oral O
contraceptives B-group
( O
3 O
) O
, O
oxcarbazepine B-drug
, O
Phenytoin B-drug
( O
4 O
) O
, O
praziquantel B-drug
, O
protease B-group
inhibitors I-group
, O
quetiapine B-drug
, O
risperidone B-drug
, O
theophylline B-drug
, O
topiramate B-drug
, O
tiagabine B-drug
, O
tramadol B-drug
, O
triazolam B-drug
, O
valproate B-drug
, O
warfarin B-drug
( O
5 O
) O
, O
ziprasidone B-drug
, O
and O
zonisamide B-drug
. O

The O
pharmacokinetics O
of O
nelfinavir B-drug
are O
not O
altered O
to O
a O
clinically O
significant O
degree O
when O
it O
is O
administered O
with O
a O
light O
meal O
1 O
hour O
after O
VIDEX B-brand
. O

. O

Caution O
should O
be O
used O
if O
naproxen B-drug
is O
administered O
concomitantly O
with O
methotrexate B-drug
. O

It O
is O
recommended O
to O
avoid O
concurrent O
administration O
of O
ethambutol B-drug
with O
aluminum B-drug
hydroxide I-drug
containing O
antacids B-group
for O
at O
least O
4 O
hours O
following O
ethambutol B-drug
administration O
. O

*Increased O
and O
decreased O
prothrombin O
time O
responses O
have O
been O
reported O
. O

Epinephrine B-drug
should O
be O
used O
cautiously O
in O
patients O
with O
hyperthyroidism O
, O
hypertension O
and O
cardiac O
arrhythmias O
. O

Atracurium B-drug
infusion O
was O
continued O
for O
a O
third O
hour O
, O
and O
then O
hoof O
twitch O
was O
again O
allowed O
to O
recover O
spontaneously O
to O
75 O
% O
. O

Patients O
should O
report O
to O
their O
practitioners O
any O
new O
rashes O
, O
itching O
, O
mouth O
sores O
, O
or O
unusual O
taste O
while O
taking O
auranofin B-drug
. O

and O
the O
remaining O
25.9 O
% O
( O
95 O
% O
CI O
, O
+/- O
9.3 O
) O
by O
monitoring O
and O
follow-up O
of O
patients O
. O

immunosuppressant B-group
agents I-group
concentration O

MAO B-group
inhibitors I-group
should O
be O
used O
with O
caution O
in O
patients O
receiving O
hydralazine B-drug
. O

In O
vitro O
studies O
have O
shown O
CASODEX B-brand
can O
displace O
coumarin B-group
anticoagulants O
, O
such O
as O
warfarin B-drug
, O
from O
their O
protein-binding O
sites O
. O

chlorpropamide B-drug
; O

The O
benzodiazepines B-group
, O
including O
alprazolam B-drug
, O
produce O
additive O
CNS O
depressant O
effects O
when O
co-administered O
with O
other O
psychotropic B-group
medications I-group
, O
anticonvulsants B-group
, O
antihistaminics B-group
, O
ethanol B-drug
, O
and O
other O
drugs O
which O
themselves O
produce O
CNS O
depression O
. O

Digitalis B-group
glycosides I-group
enhanced O
possibility O
of O
arrhythmias O
or O
digitalis B-group
toxicity O
associated O
with O
hypokalemia O
. O

In O
the O
presence O
of O
ouabain B-drug
( O
10 O
( O
-5 O
) O
M O
) O
, O
PTX B-drug_n
( O
10 O
( O
-8 O
) O
M O
) O
failed O
to O
cause O
the O
first O
contraction O
; O

no O
other O
specific O
drug O
interaction O
studies O
were O
performed O
. O

INFORMATION O
TO O
BE O
PROVIDED O
TO O
THE O
PATIENT O
OR O
GUARDIAN O
See O
illustrated O
Information O
For O
The O
Patient O
or O
Guardian O
section O
. O

Therefore O
, O
to O
maximize O
the O
effects O
of O
fexofenadine B-drug
, O
it O
is O
recommended O
that O
ALLEGRA B-brand
should O
be O
taken O
with O
water O

Patients O
were O
intravenously O
injected O
a O
chylomicron-like O
emulsion O
doubly O
labeled O
with O
14C-cholesteryl O
oleate O
and O
3H-triolein O
at O
baseline O
and O
after O
treatments O
. O

increased O
levels O
of O
fibrinogen B-drug
and O
fibrinogen B-drug
activity O
; O

Warfarin B-drug
: O
The O
effects O
of O
warfarin B-drug
and O
NSAIDs B-group
on O
GI O
bleeding O
are O
synergistic O
, O
such O
that O
users O
of O
both O
drugs O
together O
have O
a O
risk O
of O
serious O
GI O
bleeding O
higher O
than O
users O
of O
either O
drug O
alone O
. O

A O
greater O
understanding O
of O
pain O
mechanisms O
will O
aid O
in O
elucidating O
the O
role O
of O
antihistaminics B-group
in O
analgesia O
. O

In O
vitro O
, O
propranolol B-drug
appears O
to O
be O
displaced O
from O
its O
binding O
sites O
by O
diltiazem B-drug
. O

For O
example O
, O
the O
plasma O
nitrosourea B-group
AUC O
was O
reduced O
by O
factors O
of O
1.05 O
and O
9.6 O
for O
MEC O
values O
of O
1 O
and O
2 O
micrograms O
ml-1 O
respectively O
. O

Proquin B-brand
XR I-brand
should O
be O
administered O
at O
least O
4 O
hours O
before O
or O
2 O
hours O
after O
these O
products O
. O

Rifampin B-drug
markedly O
increases O
the O
metabolic O
clearance O
of O
amprenavir B-drug
, O
and O
coadministration O
is O
contraindicated O
. O

CNS-Active O
Drugs O
Ethanol B-drug
: O
Sonata B-brand
10 O
mg O
potentiated O
the O
CNS-impairing O
effects O
of O
ethanol B-drug
0.75 O
g/kg O
on O
balance O
testing O
and O
reaction O
time O
for O
1 O
hour O
after O
ethanol B-drug
administration O
and O
on O
the O
digit O
symbol O
substitution O
test O
( O
DSST O
) O
, O
symbol O
copying O
test O
, O
and O
the O
variability O
component O
of O
the O
divided O
attention O
test O
for O
2.5 O
hours O
after O
ethanol B-drug
administration O
. O

Additionally O
, O
BREVIBLOC B-brand
should O
not O
be O
used O
to O
control O
supraventricular O
tachycardia O
in O
the O
presence O
of O
agents O
which O
are O
vasoconstrictive O
and O
inotropic O
such O
as O
dopamine B-drug
, O
epinephrine B-drug
, O
and O
norepinephrine B-drug
because O
of O
the O
danger O
of O
blocking O
cardiac O
contractility O
when O
systemic O
vascular O
resistance O
is O
high O
. O

Digoxin B-drug
: O
The O
concomitant O
administration O
of O
DynaCirc B-brand
( O
isradipine B-drug
) O
and O
digoxin B-drug
in O
a O
single-dose O
pharmacokinetic O
study O
did O
not O
affect O
renal O
, O
nonrenal O
and O
total O
body O
clearance O
of O
digoxin B-drug
. O

In O
vitro O
studies O
indicate O
that O
valdecoxib B-drug
is O
a O
moderate O
inhibitor O
of O
CYP O
2C19 O
( O
IC50 O
= O
6 O
g/mL O
or O
19 O
M O
) O
and O
2C9 O
( O
IC50 O
= O
13 O
g/mL O
or O
41 O
M O
) O
, O
and O
a O
weak O
inhibitor O
of O
CYP O
2D6 O
( O
IC50 O
= O
31 O
g/mL O
or O
100 O
M O
) O
and O
3A4 O
( O
IC50 O
= O
44 O
g/mL O
or O
141 O
M O
) O
.. O

If O
the O
drugs O
are O
used O
together O
, O
caution O
should O
be O
exercised O
because O
unexpected O
hypotension O
could O
result O
from O
beta-blocker O
inhibition O
of O
the O
sympathetic O
reflex O
response O
to O
fenoldopam B-drug
. O

Because O
cholestyramine B-drug
binds O
bile O
acids O
, O
cholestyramine B-drug
resin B-group
may O
interfere O
with O
normal O
fat O
digestion O
and O
absorption O
and O
thus O
may O
prevent O
absorption O
of O
fat B-group
soluble I-group
vitamins I-group
such O
as O
A O
, O
D O
, O
E O
, O
and O
K O
. O

. O

Chapter O
5 O
focuses O
on O
metabolic O
effects O
, O
specifically O
lipid O
metabolism O
, O
carbohydrate O
metabolism O
and O
diabetes O
, O
coagulation O
factors O
, O
and O
blood O
pressure O
. O

Therapeutic O
concentrations O
of O
digoxin B-drug
, O
warfarin B-drug
, O
ibuprofen B-drug
, O
naproxen B-drug
, O
piroxicam B-drug
, O
acetaminophen B-drug
, O
phenytoin B-drug
andtolbutamide O
did O
not O
alter O
ketorolac B-drug
tromethamine I-drug
protein O
binding O
. O

6 O
. O

[ O
Importance O
of O
pharmacogenetics O
] O
; O
Pharmacogenetics O
deals O
with O
the O
differences O
in O
effect O
of O
drugs O
caused O
by O
genetic O
variation O
. O

INSPRA B-brand
should O
not O
be O
used O
with O
drugs O
described O
as O
strong O
inhibitors O
of O
CYP3A4 O
in O
their O
labeling O
. O

* O
No O
longer O
marketed O
in O
the O
US O
. O

The O
peripheral O
vasoconstriction O
caused O
by O
high O
doses O
of O
dopamine B-drug
HCl I-drug
is O
antagonized O
by O
alpha-adrenergic B-group
blocking I-group
agents I-group
. O

Dosage O
reduction O
of O
Cerubidine B-brand
may O
be O
required O
when O
used O
concurrently O
with O
other O
myelosuppressive O
agents O
. O

In O
amiodarone-treated B-drug
patients O
who O
require O
additional O
antiarrhythmic B-drug
therapy O
, O
the O
initial O
dose O
of O
such O
agents O
should O
be O
approximately O
half O
of O
the O
usual O
recommended O
dose O
. O

Increased O
thyroid-binding O
globulin O
( O
TBG O
) O
leading O
to O
increased O
circulating O
total O
thyroid O
hormone O
levels O
, O
as O
measured O
by O
protein-bound O
iodine O
( O
PBI O
) O
, O
T4 O
levels O
( O
by O
column O
or O
by O
radioimmunoassay O
) O
or O
T3 O
levels O
by O
radioimmunoassay O
. O

Drug O
Interactions O
, O
General O
: O
Although O
there O
have O
been O
no O
formal O
interaction O
studies O
, O
intravenous O
fenoldopam B-drug
has O
been O
administered O
safely O
with O
drugs O
such O
as O
digitalis B-group
and O
sublingual O
nitroglycerin B-drug
. O

The O
AUC O
of O
ciprofloxacin B-drug
was O
decreased O
an O
average O
of O
15-fold O
in O
12 O
healthy O
subjects O
given O
ciprofloxacin B-drug
and O
didanosine-placebo B-drug
tablets O
concurrently O
. O

Allopurinol B-drug
: O
The O
AUC O
of O
didanosine B-drug
was O
increased O
about O
4-fold O
when O
allopurinol B-drug
at O
300 O
mg/day O
was O
coadministered O
with O
a O
single O
200-mg O
dose O
of O
VIDEX B-brand
to O
two O
patients O
with O
renal O
impairment O
( O
CLcr=15 O
and O
18 O
mL/min O
) O
. O

ulcerans O
was O
between O
0.012 O
and O
0.025 O
mg/l O
, O
while O
corresponding O
values O
for O
rifampicin B-drug
and O
rifabutin B-drug
were O
in O
the O
range O
of O
0.1-0.8 O
mg/l O
and O
0.1-0.4 O
mg/l O
respectively O
. O

Antibiotics B-group
( O
e.g. O
, O
erythromycin B-drug
, O
trimethoprim B-drug
and O
sulfamethoxazole B-drug
, O
amoxicillin B-drug
) O
. O

If O
such O
measurements O
are O
necessary O
, O
the O
use O
of O
other O
methods O
is O
recommended O
. O

The O
following O
information O
was O
obtained O
from O
studies O
in O
normal O
volunteers O
. O

. O

Few O
systemic O
data O
have O
been O
collected O
on O
the O
metabolism O
of O
WELLBUTRIN B-brand
following O
concomitant O
administration O
with O
other O
drugs O
or O
, O
alternatively O
, O
the O
effect O
of O
concomitant O
administration O
of O
WELLBUTRIN B-brand
on O
the O
metabolism O
of O
other O
drugs O
. O

While O
the O
recognition O
of O
drug O
toxicity O
resulting O
from O
interactions O
is O
of O
importance O
to O
all O
physciains O
, O
it O
is O
especially O
so O
for O
the O
clinician O
responsible O
for O
the O
welfare O
of O
those O
in O
the O
aerospace O
environment O
. O

The O
serum O
estrogen O
concentrations O
of O
estradiol B-drug
+ O
endotoxin-treated B-drug_n
rats O
decreased O
by O
50 O
% O
, O
while O
those O
of O
the O
endotoxin-treated B-drug_n
rats O
increased O
( O
2- O
to O
5-fold O
) O
. O

however O
, O
in O
a O
study O
of O
12 O
normal O
subjects O
, O
concurrent O
administration O
of O
aspirin B-brand
decreased O
ketoprofen B-drug
protein O
binding O
and O
increased O
ketoprofen B-drug
plasma O
clearance O
from O
0.07 O
L/kg/h O
without O
aspirin B-brand
to O
0.11 O
L/kg/h O
with O
aspirin B-brand
. O

Everolimus B-drug
dose-proportionality O
and O
stability O
over O
time O
were O
assessed O
in O
the O
context O
of O
linear O
regression O
and O
ANOVA O
models O
. O

Based O
on O
in O
vitro O
studies O
in O
human O
liver O
microsomes O
, O
des-ciclesonide B-drug
appears O
to O
have O
no O
inhibitory O
or O
induction O
potential O
on O
the O
metabolism O
of O
other O
drugs O
metabolized O
by O
CYP O
450 O
enzymes O
. O

Thiazides B-group
: O
Thiazides B-group
are O
known O
to O
induce O
hypercalcemia O
by O
the O
reduction O
of O
calcium O
excretion O
in O
urine O
. O

Cssmax O
of O
the O
metabolite O
, O
ucb O
L057 O
, O
was O
approximately O
doubled O
in O
the O
presence O
of O
probenecid B-drug
while O
the O
fraction O
of O
drug O
excreted O
unchanged O
in O
the O
urine O
remained O
the O
same O
. O

Severe O
hypoglycemia O
has O
been O
reported O
in O
patients O
concomitantly O
receiving O
azole B-group
antifungal I-group
agents I-group
and O
oral O
hypoglycemic B-group
agents I-group
. O

Corticosteroids B-group
may O
increase O
the O
clearance O
of O
chronic O
high O
dose O
aspirin B-brand
. O

adjust O
salicylate B-group
dosage O
accordingly O
if O
effect O
is O
altered O
. O

Nevertheless O
, O
caution O
is O
indicated O
in O
the O
co-administration O
of O
TCAs B-group
with O
any O
of O
the O
SSRIs B-group
and O
also O
in O
switching O
from O
one O
class O
to O
the O
other O
. O

Chapter O
2 O
considers O
the O
mode O
of O
action O
, O
including O
ovulation O
prevention O
; O

Diuretics B-group
: O
Patients O
on O
diuretics B-group
, O
especially O
those O
in O
whom O
diuretic O
therapy O
was O
recently O
instituted O
, O
may O
occasionally O
experience O
an O
excessive O
reduction O
of O
blood O
pressure O
after O
initiation O
of O
therapy O
with O
Lotensin B-brand
. O

Because O
of O
the O
increased O
risk O
of O
adverse O
reactions O
in O
patients O
who O
have O
been O
taking O
benzodiazepines B-group
on O
a O
regular O
basis O
, O
it O
is O
particularly O
important O
that O
physicians O
query O
patients O
or O
their O
guardians O
carefully O
about O
benzodiazepine B-group
, O
alcohol B-drug
and O
sedative B-group
use O
as O
part O
of O
the O
history O
prior O
to O
any O
procedure O
in O
which O
the O
use O
of O
ROMAZICON B-brand
is O
planned O
. O

+15 O
% O
+5 O
% O
+15 O
% O
+4 O
% O

the O
doses O
of O
naloxone B-drug
required O
to O
antagonize O
the O
effects O
of O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
were O
more O
than O
100 O
times O
higher O
than O
those O
required O
to O
antagonize O
the O
effects O
of O
morphine B-drug
. O

Among O
aspirin B-brand
or O
NSAID B-group
users O
, O
the O
incidence O
of O
upper O
gastrointestinal O
adverse O
events O
in O
patients O
treated O
with O
ibandronate B-drug
2.5 O
mg O
daily O
( O
28.9 O
% O
) O
was O
similar O
to O
that O
in O
placebo-treated O
patients O
( O
30.7 O
% O
) O
. O

Warfarin B-drug
: O
The O
effect O
of O
celecoxib B-drug
on O
the O
anti-coagulant O
effect O
of O
warfarin B-drug
was O
studied O
in O
a O
group O
of O
healthy O
subjects O
receiving O
daily O
doses O
of O
2-5 O
mg O
of O
warfarin B-drug
. O

4 O
. O

Increased O
anticoagulation O
effects O
due O
to O
interactions O
of O
erythromycin B-drug
with O
various O
oral O
anticoagulents O
may O
be O
more O
pronounced O
in O
the O
elderly O
. O

Colchicine B-drug
may O
increase O
sensitivity O
to O
the O
CNS B-group
depressants I-group
. O

Phenytoin B-drug
increases O
the O
clearance O
of O
busulfan B-drug
by O
15 O
% O
or O
more O
, O
possibly O
due O
to O
the O
induction O
of O
glutathione-S-transferase O
. O

In O
clinical O
trials O
, O
doxazosin B-drug
mesylate I-drug
tablets O
have O
been O
administered O
to O
patients O
on O
a O
variety O
of O
concomitant O
medications O
; O

The O
evidence O
for O
a O
role O
for O
norepinephrine O
and O
dopamine O
and O
the O
effects O
of O
antihistaminics B-group
on O
them O
are O
less O
well O
established O
. O

H2 B-group
Blockers/Proton I-group
Pump I-group
Inhibitors I-group
: O
Long-term O
suppression O
of O
gastric O
acid O
secretion O
by O
H2 B-group
blockers I-group
or O
proton B-group
pump I-group
inhibitors I-group
( O
eg O
, O
famotidine B-drug
and O
omeprazole B-drug
) O
is O
likely O
to O
reduce O
dasatinib B-drug
exposure O
. O

abnormal O
vaginal O
bleeding O
; O

Inhibitors O
or O
substrates O
of O
CYP2D6 O
( O
i.e. O
, O
quinidine B-drug
, O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
[ O
SSRIs B-group
] O
) O
may O
increase O
the O
plasma O
concentration O
of O
doxepin B-drug
when O
administered O
concomitantly O
. O

No O
volunteer O
showed O
hormonal O
evidence O
of O
ovulation O
, O
but O
one O
volunteer O
reported O
intermenstrual O
bleeding O
during O
felbamate B-drug
treatment O
. O

Paralytic O
ileus O
may O
occur O
in O
patients O
taking O
tricyclic B-drug
antidepressants I-drug
in O
combination O
with O
anticholinergic-type B-drug
drugs O
. O

Repeat O
Treatment O
Studies O
evaluating O
the O
use O
of O
repeated O
courses O
of O
Zmax B-brand
have O
not O
been O
conducted O
. O

The O
extent O
to O
which O
SSRI-TCA B-group
interactions O
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-group
involved O
. O

this O
can O
cause O
headaches O
and O
other O
signs O
of O
hypertensive O
crisis O
. O

chloral B-drug
hydrate* O
; O

Chlorpropamide B-drug
: O
Chlorpropamides B-drug
plasma O
half-life O
may O
be O
prolonged O
by O
allopurinol B-drug
, O
since O
allopurinol B-drug
and O
chlorpropamide B-drug
may O
compete O
for O
excretion O
in O
the O
renal O
tubule O
. O

This O
is O
especially O
true O
in O
patients O
who O
may O
subject O
themselves O
to O
an O
overdosage O
of O
drugs O
. O

Colchicine B-drug
para-aminosalicylic I-drug
acid I-drug
and O
heavy O
alcohol B-drug
intake O
for O
longer O
than O
2 O
weeks O
may O
produce O
malabsorption O
of O
vitamin B-drug
B12 I-drug
. O

When O
administered O
concurrently O
, O
the O
following O
drugs O
may O
interact O
with O
beta-adrenergic B-group
receptor I-group
blocking I-group
agents I-group
: O
Anesthetics B-group
, O
general O
: O
exaggeration O
of O
the O
hypotension O
induced O
by O
general O
anesthetics B-group
. O

It O
has O
been O
reported O
that O
Itraconazole B-drug
enhances O
the O
anticoagulant O
effect O
of O
coumarin-like B-group
drugs O
. O

Cimetidine B-drug
at O
400 O
mg O
BID O
( O
the O
usual O
prescription O
dose O
) O
co-administered O
with O
TIKOSYN B-brand
( O
500 O
mcg O
BID O
) O
for O
7 O
days O
has O
been O
shown O
to O
increase O
dofetilide B-drug
plasma O
levels O
by O
58 O
% O
. O

. O

Integumentary O

341 O
PI O
affecting O
197 O
patients O
( O
31.5 O
% O
, O
95 O
% O
CI O
, O
+/- O
3.6 O
) O
were O
identified O
. O

Because O
bupropion B-drug
is O
extensively O
metabolized O
, O
the O
coadministration O
of O
other O
drugs O
may O
affect O
its O
clinical O
activity O
. O

Nonsteroidal B-group
Anti-Inflammatory I-group
Drugs I-group
( O
NSAIDs B-group
) O
-A O
drug O
interaction O
study O
of O
eplerenone B-drug
with O
an O
NSAID B-group
has O
not O
been O
conducted O
. O

Steroids B-group
enhance O
the O
renal O
toxicity O
of O
edetate B-drug
calcium I-drug
disodium I-drug
in O
animals O
. O
7 O
Edetate B-drug
calcium I-drug
disodium I-drug
interferes O
with O
the O
action O
of O
zinc B-drug
insulin I-drug
preparations O
by O
chelating O
the O
zinc B-drug
. O
7 O

These O
effects O
are O
usually O
reversible O
. O

Vitamin B-group
D I-group
: O
The O
coadministration O
of O
any O
of O
the O
vitamin B-group
D I-group
analogues O
should O
be O
avoided O
as O
this O
could O
create O
possible O
additive O
effects O
and O
hypercalcemia O
. O

H1 O
and O
H2 B-group
Blockers I-group
- O
Although O
not O
reported O
, O
L-histidine B-drug
, O
via O
its O
metabolism O
to O
histamine O
, O
might O
decrease B-group
the I-group
efficacy O
of O
H1 O
and O
H2 B-group
blockers I-group
. O

Serious O
toxicity O
may O
result O
if O
dextromethorphan B-drug
is O
coadministered O
with O
monoamine B-group
oxidase I-group
inhibitors I-group
( O
MAOIs B-group
) O
. O

Human O
pharmacokinetic O
data O
indicate O
that O
oral O
ketoconazole B-drug
markedly O
inhibits O
the O
metabolism O
of O
cisapride B-drug
, O
resulting O
in O
a O
mean O
eight-fold O
increase O
in O
AUC O
of O
cisapride B-drug
. O

Growth O
of O
M O
. O

Opiate B-group
agonists I-group

Maximum O
calculated O
theophylline B-drug
clearance O
ranged O
from O
2 O
1/2 O
to O
3 O
1/2 O
times O
baseline O
. O

Interactions O
may O
also O
occur O
with O
the O
following O
: O
anti-depressants/anti-anxiety B-group
drugs I-group
, O
drugs O
used O
to O
treat O
an O
overactive O
thyroid O
, O
beta-blockers B-group
( O
e.g. O
, O
propranolol B-drug
) O
, O
sparfloxacin B-drug
, O
grepafloxacin B-drug
, O
guanethidine B-drug
, O
guanadrel B-drug
, O
metrizamide B-drug
, O
cabergoline B-drug
, O
lithium B-drug
, O
narcotic B-group
pain O
medication O
( O
e.g. O
, O
codeine B-drug
) O
, O
drugs O
used O
to O
aid O
sleep O
, O
drowsiness-causing O
antihistamines B-group
( O
e.g. O
, O
diphenhydramine B-drug
) O
, O
any O
other O
drugs O
that O
may O
make O
you O
drowsy O
. O

however O
, O
there O
was O
extensive O
concomitant O
use O
of O
NSAIDs B-group
in O
clinical O
studies O
and O
no O
differential O
effect O
was O
observed O
. O

however O
, O
at O
lower O
concentrations O
only O
zinc B-drug
demonstrated O
toxicity O
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
DIABINESE B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O

Drugs O
that O
may O
decrease O
dasatinib B-drug
plasma O
concentrations O
CYP3A4 O
Inducers O
: O
Drugs O
that O
induce O
CYP3A4 O
activity O
may O
decrease O
dasatinib B-drug
plasma O
concentrations O
. O

Valproate I-drug
** O

In O
vitro O
studies O
have O
shown O
that O
precipitation O
occurs O
when O
eye O
drops O
containing O
thimerosal B-drug_n
are O
mixed O
with O
latanoprost B-drug
. O

plasma O
levels O
of O
several O
closely O
related O
tricyclic B-group
antidepressants I-group
have O
been O
reported O
to O
be O
increased O
by O
the O
concomitant O
administration O
of O
methylphenidate B-drug
or O
hepatic O
enzyme O
inhibitors O
( O
e.g. O
, O
cimetidine B-drug
, O
fluoxetine B-drug
) O
and O
decreased O
by O
the O
concomitant O
administration O
of O
hepatic O
enzyme O
inducers O
( O
e.g. O
, O
barbiturates B-group
, O
phenytoin B-drug
) O
, O
and O
such O
an O
effect O
may O
be O
anticipated O
with O
CMI B-drug
as O
well O
. O

Therefore O
, O
interactions O
could O
occur O
following O
concomitant O
administration O
of O
psychotropic B-group
drugs I-group
( O
e.g. O
, O
narcotics B-group
, O
analgesics B-group
, O
antiemetics B-group
, O
sedatives B-group
, O
tranquilizers B-group
) O
. O

Although O
no O
clinical O
drug-drug O
interaction O
studies O
have O
been O
conducted O
to O
date O
, O
on O
the O
basis O
of O
the O
in O
vitro O
studies O
, O
cytochrome O
p450 O
inhibitors O
and O
inducers O
are O
unlikely O
to O
affect O
the O
metabolism O
of O
clofarabine B-drug
. O

ACE B-group
inhibitors I-group
: O
Reports O
suggest O
that O
NSAIDs B-group
may O
diminish O
the O
antihypertensive O
effect O
of O
ACE B-group
inhibitors I-group
. O

Due O
to O
its O

This O
conference O
reviews O
recent O
developments O
in O
these O
areas O
, O
examines O
the O
effects O
of O
drug O
use O
in O
the O
elderly O
and O
implications O
for O
management O
, O
and O
discusses O
current O
information O
on O
how O
age O
may O
influence O
the O
response O
of O
cancer O
to O
therapy O
. O

We O
incorporate O
the O
principles O
of O
recovery O
and O
define O
positive O
and O
constructive O
alternatives O
in O
dealing O
with O
cocaine O
hunger O
. O

Although O
a O
causal O
mechanism O
and O
a O
cause-and-effect O
relationship O
have O
not O
been O
established O
, O
current O
evidence O
suggests O
that O
renal O
function O
should O
be O
monitored O
in O
patients O
on O
thiazide B-group
diuretics I-group
and O
allopurinol B-drug
even O
in O
the O
absence O
of O
renal O
failure O
, O
and O
dosage O
levels O
should O
be O
even O
more O
conservatively O
adjusted O
in O
those O
patients O
on O
such O
combined O
therapy O
if O
diminished O
renal O
function O
is O
detected.. O

These O
effects O
were O
not O
considered O
clinically O
important O
. O

Drugs O
that O
have O
been O
associated O
with O
peripheral O
neuropathy O
include O
antiretroviral B-drug
nucleoside I-drug
analogues I-drug
, O
chloramphenicol B-drug
, O
cisplatin B-drug
, O
dapsone B-drug
, O
disulfiram B-drug
, O
ethionamide B-drug
, O
glutethimide B-drug
, O
gold B-drug
, O
hydralazine B-drug
, O
iodoquinol B-drug
, O
isoniazid B-drug
, O
metronidazole B-drug
, O
nitrofurantoin B-drug
, O
phenytoin B-drug
, O
ribavirin B-drug
, O
and O
vincristine B-drug
. O

. O

Concurrent O
use O
of O
phenothiazines B-group
may O
antagonize O
the O
anorectic O
effect O
of O
diethylpropion B-drug
. O

It O
is O
extensively O
metabolized O
, O
predominantly O
by O
cytochrome O
P450 O
3A4 O
. O

There O
are O
other O
agents O
that O
may O
result O
in O
serious O
and/or O
life-threatening O
drug O
interactions O
. O

In O
another O
report O
, O
nine O
patients O
with O
breast O
cancer O
were O
reported O
to O
have O
decreased O
symptoms O
of O
methotrexate-related B-drug
toxicity O
when O
given O
supplemental O
L-glutamine B-drug
at O
a O
dose O
of O
0.5 O
gram/kilogram/day O
. O

Other O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
that O
inhibit O
prostaglandin O
synthesis O
have O
been O
shown O
to O
interfere O
with O
thiazide B-group
diuretics I-group
in O
some O
studies O
and O
with O
potassium-sparing B-group
diuretics I-group
. O

Both O
groups O
of O
agents O
lower O
blood O
levels O
and O
efficacy O
of O
amphetamines B-group
. O

- O
Carmustine B-drug
( O
e.g. O
, O
BiCNU B-brand
) O
or O

The O
mechanism O
of O
these O
interactions O
has O
been O
evaluated O
in O
in O
vitro O
, O
in O
situ O
, O
and O
in O
vivo O
animal O
models O
. O

Concomitant O
use O
of O
L-phenylalanine B-drug
and O
non-selective B-group
MAO I-group
inhibitors I-group
may O
cause O
hypertension O
. O

The O
safety O
of O
such O
concomitant O
use O
with O
Activase B-brand
for O
the O
management O
of O
acute O
ischemic O
stroke O
is O
unknown O
. O

Veratrum B-group
alkaloids I-group
: O
Amphetamines B-group
inhibit O
the O
hypotensive O
effect O
of O
veratrum B-group
alkaloids I-group
. O

Rarely O
salicylate B-group
toxicity O
may O
occur O
in O
patients O
who O
discontinue O
steroids B-group
after O
concurrent O
high-dose O
aspirin B-brand
therapy O
. O

Since O
amiodarone B-drug
is O
a O
substrate O
for O
CYP3A4 O
and O
CYP2C8 O
, O
drugs/substances O
that O
inhibit O
these O
isoenzymes O
may O
decrease O
the O
metabolism O
and O
increase O
serum O
concentration O
of O
amiodarone B-drug
. O

. O

the O
dose O
of O
Prostigmin B-brand
may O
have O
to O
be O
increased O
accordingly O
. O

Accelerated O
prothrombin O
time O
, O
partial O
thromboplastin O
time O
, O
and O
platelet O
aggregation O
time O
; O

Concomitant O
administration O
of O
probenecid B-drug
doubled O
the O
AUC O
for O
cefprozil B-drug
. O

Therefore O
, O
the O
potential O
exists O
for O
interaction O
between O
carbamazepine B-drug
and O
any O
agent O
that O
induces O
CYP3A4 O
. O

Digoxin B-drug
: O
Concomitant O
administration O
of O
erythromycin B-drug
and O
digoxin B-drug
has O
been O
reported O
to O
result O
in O
elevated O
digoxin B-drug
serum O
levels O
. O

The O
effect O
of O
TORADOL B-brand
on O
plasma O
lithium B-drug
has O
not O
been O
studied O
, O
but O
cases O
of O
increased O
lithium B-drug
plasma O
levels O
during O
TORADOL B-brand
therapy O
have O
been O
reported O
. O

These O
studies O
indicate O
that O
ketoconazole B-drug
or O
erythromycin B-drug
co-administration O
enhances O
fexofenadine B-drug
gastrointestinal O
absorption O
. O

Because O
prostaglandina O
play O
an O
important O
role O
in O
hemostasis O
and O
ketoprofen B-drug
has O
an O
effect O
on O
platelet O
function O
as O
well O
, O
concurent O
therapy O
with O
ketoprofen B-drug
and O
warfarin B-drug
requires O
close O
monitoring O
of O
patients O
on O
both O
drugs O
. O

Initial O
doses O
of O
adrenergic B-group
agents I-group
, O
such O
as O
dopamine B-drug
or O
epinephrine B-drug
, O
should O
be O
reduced O
and O
titrated O
to O
achieve O
the O
desired O
response O
. O

But O
it O
is O
now O
difficult O
to O
situate O
the O
exact O
place O
of O
the O
pharmacological O
indications O
of O
magnesium B-drug
. O

In O
the O
experiments O
reported O
here O
, O
we O
examined O
the O
interactions O
between O
1,25 B-drug
( I-drug
OH I-drug
) I-drug
2D3 I-drug
and O
the O
antiestrogen B-group
4-hydroxytamoxifen B-drug_n
( O
TAM B-drug_n
) O
, O
which O
also O
induces O
apoptosis O
in O
MCF-7 O
cells O
. O

Anti-HIV B-group
protease I-group
inhibitors I-group
: O
Saquinavir/ritonavir B-drug
combination O

Diethyl B-drug_n
pyrocarbonate I-drug_n
, O
at O
pH O
7.0 O
, O
was O
used O
to O
chemically O
modify O
exposed O
histidine O
residues O
on O
toxin B-drug_n
A I-drug_n
. O

in O
vitro O
data O
on O
metabolic O
interactions O
indicate O
that O
Keppra B-brand
is O
unlikely O
to O
produce O
, O
or O
be O
subject O
to O
, O
pharmacokinetic O
interactions O
. O

Estrogen B-group
increased O
levels O
of O
corticosteroid-binding O
globulin O
, O
thereby O
increasing O
the O
bound O
( O
inactive O
) O
fraction O
; O

AMEVIVE B-brand
underwent O
trans-placental O
passage O
and O
produced O
in O
utero O
exposure O
in O
the O
developing O
monkeys O
. O

No O
special O
precautions O
appear O
to O
be O
necessary O
when O
oral O
anticoagulant O
therapy O
is O
begun O
in O
a O
patient O
already O
stabilized O
on O
maintenance O
thyroid O
replacement O
therapy O
. O

Diagnostic O
, O
treatment O
and O
aftercare O
approaches O
to O
cocaine B-drug
abuse O
. O

Antidiabetic B-group
drugs I-group
: O
( O
oral O
agents O
and O
insulin B-drug
) O
- O
dosage O
adjustment O
of O
the O
antidiabetic B-group
drug I-group
may O
be O
required O
. O

Although O
studies O
designed O
to O
examine O
drug O
interactions O
have O
not O
been O
done O
, O
it O
was O
noted O
that O
corticosteroid B-group
or O
ACTH B-drug
treatment O
of O
relapses O
for O
periods O
of O
up O
to O
28 O
days O
has O
been O
administered O
to O
patients O
( O
N=180 O
) O
receiving O
Betaseron B-brand
. O

Indinavir I-drug
and O
didanosine B-drug
formulations O
containing O
buffer O
should O
be O
administered O
at O
least O
one O
hour O
apart O
on O
an O
empty O
stomach O
. O

OBJECTIVES O
: O
To O
examine O
the O
effects O
of O
acute O
hydrocortisone B-drug
pretreatment O
on O
the O
subjective O
and O
behavioral O
effects O
of O
d-amphetamine B-drug
. O

Efavirenz B-drug
has O
been O
shown O
in O
vivo O
to O
induce O
CYP3A4 O
. O

The O
beta-blocker B-group
should O
be O
withdrawn O
first O
. O

Although O
this O
interaction O
has O
not O
been O
reported O
with O
cinoxacin B-drug
, O
caution O
should O
be O
exercised O
when O
cinoxacin B-drug
is O
given O
concomitantly O
with O
caffeine-containing B-drug
products O
. O

It O
is O
probable O
that O
dexamethasone B-drug
, O
given O
as O
antiemetic O
prophylaxis O
, O
contributed O
to O
hyperglycemia O
in O
some O
patients O
. O

[ O
Drug O
treatment O
of O
erection O
disorders O
in O
patients O
with O
cardiovascular O
disease O
] O
Erectile O
dysfunction O
is O
a O
frequent O
condition O
in O
cardiovascular O
patients O
. O

Physostigmine B-drug
briefly O
reduced O
the O
amplitude O
of O
most O
components O
, O
including O
P2 O
. O

No O
specific O
studies O
in O
humans O
have O
been O
performed O
and O
caution O
is O
recommended O
. O

Coadministered O
Concentration O
Concentration O

Co-administration O
of O
lovastatin B-drug
, O
atenolol B-drug
, O
warfarin B-drug
, O
furosemide B-drug
, O
digoxin B-drug
, O
celecoxib B-drug
, O
hydrochlorothiazide B-drug
, O
ramipril B-drug
, O
valsartan B-drug
, O
metformin B-drug
and O
amlodipine B-drug
did O
not O
result O
in O
clinically O
significant O
increases O
in O
aliskiren B-drug
exposure O
. O

During O
administration O
of O
multiple O
oral O
doses O
of O
TAMBOCOR B-brand
to O
healthy O
subjects O
stabilized O
on O
a O
maintenance O
dose O
of O
digoxin B-drug
, O
a O
13 O
% O
-19 O
% O
increase O
in O
plasma O
digoxin B-drug
levels O
occurred O
at O
six O
hours O
postdose O
. O

Some O
reports O
have O
shown O
that O
the O
concomitant O
administration O
of O
thiazides B-group
with O
vitamin B-group
D I-group
causes O
hypercalcemia O
. O

This O
report O
describes O
a O
recently O
identified O
case O
of O
interference O
of O
acetylcysteine B-drug
with O
the O
urine O
test O
for O
ketones O
and O
demonstrates O
the O
importance O
of O
a O
thorough O
medication O
review O
in O
evaluating O
abnormal O
laboratory O
tests O
. O

Nondepolarizing B-group
Muscle I-group
Relaxants I-group
: O
In O
postmarketing O
experience O
there O
have O
been O
reports O
of O
a O
possible O
interaction O
between O
TORADOLIV/IM O
and O
nondepolarizing B-group
muscle I-group
relaxants I-group
that O
resulted O
in O
apnea O
. O

Phenytoin B-drug
: O
Amphetamines B-group
may O
delay O
intestinal O
absorption O
of O
phenytoin B-drug
; O

faecalis O
ATCC O
51299 O
showed O
the O
flavonoids O
alone O
significantly O
lowered O
numbers O
of O
colony O
forming O
units O
( O
CFUs O
) O
. O

Catecholamine-depleting O
drugs O
( O
eg O
, O
reserpine B-drug
) O
may O
have O
an O
additive O
effect O
when O
given O
with O
beta-blocking B-group
agents O
. O

in O
vitro O
, O
Gleevec B-brand
inhibits O
the O
cytochrome O
P450 O
isoenzyme O
CYP2D6 O
activity O
at O
similar O
concentrations O
that O
affect O
CYP3A4 O
activity O
. O

When O
the O
STADOL B-brand
NS I-brand
was O
administered O
30 O
minutes O
after O
the O
sumatriptan B-drug
nasal O
spray O
, O
the O
AUC O
of O
butorphanol B-drug
increased O
11 O
% O
and O
Cmax O
decreased O
18 O
% O
. O

Dosage O
adjustments O
of O
BROVANA B-brand
are O
not O
necessary O
when O
the O
drug O
is O
given O
concomitantly O
with O
potent O
CYP2D6 O
inhibitors O
. O

Other O
drugs O
Drug O
interactions O
have O
been O
reported O
with O
concomitant O
administration O
of O
erythromycin B-drug
and O
other O
medications O
, O
including O
cyclosporine B-drug
, O
hexobarbital B-drug
, O
carbamazepine B-drug
, O
alfentanil B-drug
, O
disopyramide B-drug
, O
phenytoin B-drug
, O
bromocriptine B-drug
, O
valproate B-drug
, O
astemizole B-drug
, O
and O
lovastatin B-drug
. O

Drug/Laboratory O
Test O
Interferences O
: O
Dicumarol B-drug
and O
indanedione B-group
anticoagulants I-group
, O
including O
anisindione B-drug
, O
or O
their O
metabolites O
may O
color O
alkaline O
urine O
red-orange O
, O
which O
may O
interfere O
with O
spectrophotometrically O
determined O
urinary O
laboratory O
tests O
. O

. O

An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCA B-group
may O
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O

Antacids B-group
: O
In O
a O
single O
dose O
study O
( O
n=6 O
) O
, O
ingestion O
of O
an O
antacid B-group
containing O
1.7-gram O
of O
magnesium B-drug
hydroxide I-drug
with O
500-mg O
of O
mefenamic B-drug
acid I-drug
increased O
the O
Cmax O
and O
AUC O
of O
mefenamic B-drug
acid I-drug
by O
125 O
% O
and O
36 O
% O
, O
respectively O
. O
A O
number O
of O
compounds O
are O
inhibitors O
of O
CYP2C9 O
including O
fluconazole B-drug
, O
lovastatin B-drug
and O
trimethoprim B-drug
. O

When O
ouabain B-drug
was O
applied O
to O
the O
muscle O
in O
the O
presence O
of O
phentolamine B-drug
, O
both O
first O
and O
second O
contractile O
responses O
to O
PTX B-drug_n
were O
abolished O
. O

Studies O
in O
rats O
have O
shown O
that O
neomycin B-drug
administration O
attenuates O
certain O
types O
of O
adrenocortical B-group
steroid I-group
dependent O
hypertension O
, O
including O
ACTH B-drug
hypertension O
. O

If O
these O
agents O
are O
to O
be O
administered O
concurrently O
, O
cyclosporine B-drug
concentrations O
should O
be O
monitored O
, O
especially O
when O
diltiazem B-drug
therapy O
is O
initiated O
, O
adjusted O
, O
or O
discontinued O
. O

We O
conclude O
that O
ADL B-drug
8-2698 I-drug
prevents O
morphine-induced B-drug
increases O
in O
gastrointestinal O
transit O
time O
by O
means O
of O
selective O
peripheral O
opioid O
anitagonism O
without O
affecting O
central O
opioid O
analgesia O
. O

Dose O
reduction O
of O
CRIXIVAN B-brand
to O
600 O
mg O
every O
8 O
hours O
should O
be O
considered O
when O
taking O
delavirdine B-drug
400 O
mg O
three O
times O
a O
day O
. O

As O
with O
other O
drugs O
that O
block O
angiotensin O
II O
or O
its O
effects O
, O
concomitant O
use O
of O
potassium-sparing B-group
diuretics I-group
( O
e.g. O
, O
spironolactone B-drug
, O
triamterene B-drug
, O
amiloride B-drug
) O
, O
potassium B-drug
supplements O
, O
or O
salt O
substitutes O
containing O
potassium O
may O
lead O
to O
increases O
in O
serum O
potassium O
. O

In O
healthy O
subjects O
, O
no O
significant O
drug-drug O
interaction O
was O
observed O
when O
Norpace B-brand
was O
coadministered O
with O
either O
propranolol B-drug
or O
diazepam B-drug
. O

Concomitant O
administration O
of O
alosetron B-drug
and O
fluvoxamine B-drug
is O
contraindicated O
. O

Interaction O
of O
GABITRIL B-brand
with O
Highly O
Protein O
Bound O
Drugs O
: O
In O
vitro O
data O
showed O
that O
tiagabine B-drug
is O
96 O
% O
bound O
to O
human O
plasma O
protein O
and O
therefore O
has O
the O
potential O
to O
interact O
with O
other O
highly O
protein O
bound O
compounds O
. O

Alternate O
treatments O
lacking O
CYP3A4 O
inducing O
activity O
should O
be O
considered O
. O

In O
many O
of O
these O
cases O
, O
buprenorphine B-drug
was O
misused O
by O
self-injection O
of O
crushed O
SUBUTEX B-brand
tablets O
. O

Sildenafil B-drug
citrate I-drug
- O
Theoretically O
, O
L-arginine B-drug
supplements O
taken O
concomitantly O
with O
sildenafil B-drug
citrate I-drug
, O
may O
potentiate O
the O
effects O
of O
the O
drug O
. O

. O

Agents O
Having O
Vasodilator O
Activity O
: O
Data O
on O
the O
effect O
of O
concomitant O
use O
of O
other O
vasodilators B-group
in O
patients O
receiving O
captopril B-drug
for O
heart O
failure O
are O
not O
available O
; O

The O
coadministration O
of O
a O
potent O
CYP3A4 O
enzyme O
inducer O
, O
although O
not O
posing O
a O
safety O
concern O
, O
thus O
could O
lead O
to O
ineffectiveness O
of O
zaleplon B-drug
. O

Lithium B-drug
serum O
concentrations O
should O
be O
monitored O
closely O
when O
initiating O
or O
changing O
therapy O
with O
BEXTRA B-brand
in O
patients O
receiving O
lithium B-drug
. O

Five O
, O
10 O
, O
20 O
, O
or O
50 O
mg/kg O
of O
ketamine B-drug
alone O
or O
20 O
, O
50 O
, O
or O
100 O
mg/kg O
of O
metabolite O
I O
alone O
produced O
less O
than O
10 O
minutes O
of O
hypnosis O
. O

Fluoxetine B-drug

Theophylline B-drug
alone O
caused O
identical O
insulin O
and O
glucagon O
release O
in O
diabetics O
and O
normals O
. O

It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
be O
used O
. O

However O
, O
neither O
phenobarbital B-drug
nor O
diazepam B-drug
appears O
to O
affect O
Dantrium B-brand
metabolism O
. O

Bile B-group
acid I-group
binding I-group
resins I-group
may O
also O
interfere O
with O
the O
absorption O
of O
oral O
phosphate B-drug
supplements O
and O
hydrocortisone B-drug
. O

Cyclosporine B-drug
: O
Because O
cyclosporine B-drug
can O
produce O
nephrotoxicity O
with O
decreases O
in O
creatinine O
clearance O
and O
rises O
in O
serum O
creatinine O
, O
and O
because O
renal O
excretion O
is O
the O
primary O
elimination O
route O
of O
fibrate B-group
drugs I-group
including O
TRICOR B-brand
, O
there O
is O
a O
risk O
that O
an O
interaction O
will O
lead O
to O
deterioration O
. O

- O
Antithyroid B-group
agents I-group
( O
medicine O
for O
overactive O
thyroid O
) O
or O

In O
the O
digitalized O
patient O
, O
slow O
alterations O
in O
serum O
levels O
after O
oral O
administration O
appeared O
well O
correlated O
with O
, O
at O
least O
, O
the O
negative O
chronotropic O
effects O
of O
the O
drug O
. O

Potential O
for O
Other O
Drugs O
to O
Affect O
ABILIFY B-brand
Aripiprazole I-brand
is O
not O
a O
substrate O
of O
CYP1A1 O
, O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2B6 O
, O
CYP2C8 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
or O
CYP2E1 O
enzymes O
. O

Coadministration O
of O
oral O
contraceptives B-group
, O
diazepam B-drug
, O
phenytoin B-drug
, O
or O
quinidine B-drug
did O
not O
seem O
to O
change O
the O
pharmacokinetic O
profile O
of O
esomeprazole B-drug
. O

DRUG/LABORATORY O
TEST O
INTERACTIONS O
1 O
. O

In O
several O
well-controlled O
studies O
, O
guanfacine B-drug
was O
administered O
together O
with O
diuretics B-group
with O
no O
drug O
interactions O
reported O
. O

Spermine B-drug
( O
0.5-2 O
mM O
) O
promoted O
the O
translocation O
of O
phosphatidate O
phosphohydrolase O
from O
the O
soluble O
to O
the O
microsomal O
fraction O
in O
a O
cell-free O
system O
derived O
from O
rat O
liver O
. O

Ethinyl B-drug
estradiol I-drug
and O
Norethindrone B-drug

Due O
to O
the O
potential O
for O
additive O
effects O
, O
caution O
and O
careful O
titration O
are O
warranted O
in O
patients O
receiving O
diltiazem B-drug
hydrochloride I-drug
concomitantly O
with O
other O
agents O
known O
to O
affect O
cardiac O
contractility O
and/or O
conduction O
. O

laryngeal O
edema O

Since O
Zarontin B-brand
( O
ethosuximide B-drug
) O
may O
interact O
with O
concurrently O
administered O
antiepileptic B-group
drugs I-group
, O
periodic O
serum O
level O
determinations O
of O
these O
drugs O
may O
be O
necessary O
( O
eg O
, O
ethosuximide B-drug
may O
elevate O
phenytoin B-drug
serum O
levels O
and O
valproic B-drug
acid I-drug
has O
been O
reported O
to O
both O
increase O
and O
decrease O
ethosuximide B-drug
levels O
) O
. O

Interactions O
with O
Mixed B-group
Agonist/Antagonist I-group
Opioid I-group
Analgesics I-group
: O
Agonist/antagonist B-group
analgesics I-group
( O
eg O
, O
pentazocine B-drug
, O
nalbuphine B-drug
, O
butorphanol B-drug
, O
dezocine B-drug
and O
buprenorphine B-drug
) O
should O
NOT O
be O
administered O
to O
a O
patient O
who O
has O
received O
or O
is O
receiving O
a O
course O
of O
therapy O
with O
a O
pure B-group
agonist I-group
opioid I-group
analgesic I-group
such O
as O
Levo-Dromoran B-brand
. O

Amphotericin B-drug
B I-drug
or O
Corticosteroids B-group
or O
Corticotropin B-drug
( O
ACTH B-drug
) O

If O
oral O
anticoagulants B-group
are O
also O
being O
given O
, O
compensatory O
increases O
in O
clotting O
factor O
synthesis O
are O
impaired O
. O

Because O
efficient O
labeling O
can O
be O
achieved O
with O
0.1 O
% O
biocytin O
with O
whole-cell O
recording O
, O
higher O
concentrations O
are O
contraindicated O
. O

Nevertheless O
, O
the O
possibility O
of O
additive O
negative O
inotropic O
effects O
of O
beta B-group
blockers I-group
and O
flecainide B-drug
should O
be O
recognized O
. O

Caution O
should O
be O
taken O
when O
ENABLEX B-brand
is O
used O
concomitantly O
with O
medications O
that O
are O
predominantly O
metabolized O
by O
CYP2D6 O
and O
which O
have O
a O
narrow O
therapeutic O
window O
, O
such O
as O
flecainide B-drug
, O
thioridazine B-drug
and O
tricyclic B-group
antidepressants I-group
( O
see O
CLINICAL O
PHARMACOLOGY O
) O
. O

These O
results O
show O
that O
lung B-group
surfactant I-group
has O
the O
potential O
of O
enhancing O
the O
rate O
and O
extent O
of O
dissolution O
of O
drugs O
administered O
to O
the O
lung O
. O

Inhibition O
of O
renal O
lithium B-drug
clearance O
leading O
to O
increases O
in O
plasma O
lithium B-drug
concentrations O
has O
also O
been O
reported O
. O

Effects O
of O
low O
temperatures O
on O
microtubules O
in O
the O
non-myelinated O
axons O
of O
post-ganglionic O
sympathetic O
nerves O
. O

However O
, O
LDL-C O
reduction O
was O
greater O
when O
atorvastatin B-drug
and O
colestipol B-drug
were O
coadministered O
than O
when O
either O
drug O
was O
given O
alone O
. O

therefore O
, O
VIRACEPT B-brand
should O
not O
be O
administered O
concurrently O
with O
terfenadine B-drug
because O
of O
the O
potential O
for O
serious O
and/or O
life-threatening O
cardiac O
arrhythmias O
. O

Results O
with O
warfarin B-drug
wshow O
no O
evidence O
of O
interaction O
with O
either O
single O
or O
repeated O
doses O
of O
Trileptal B-brand
. O

The O
magnitude O
of O
interaction O
with O
multiple O
doses O
of O
erythromycin B-drug
is O
unknown O
. O

In O
general O
, O
most O
patients O
treated O
with O
dirithromycin B-drug
who O
are O
receiving O
concomitant O
theophylline B-drug
therapy O
may O
not O
require O
empiric O
adjustment O
of O
theophylline B-drug
dosage O
or O
monitoring O
of O
theophylline B-drug
plasma O
concentrations O
. O

and O
glutamate B-drug
( O
15 O
mg/kg O
e.w O
. O
) O

Other O
drugs O
which O
may O
enhance O
the O
neuromuscular O
blocking O
action O
of O
nondepolarizing B-group
agents I-group
such O
as O
NIMBEX B-brand
include O
certain O
antibiotics B-group
( O
e. O
g. O
, O
aminoglycosides B-group
, O
tetracyclines B-group
, O
bacitracin B-drug
, O
polymyxins B-group
, O
lincomycin B-drug
, O
clindamycin B-drug
, O
colistin B-drug
, O
and O
sodium B-drug
colistemethate I-drug
) O
, O
magnesium B-group
salts O
, O
lithium B-drug
, O
local O
anesthetics B-group
, O
procainamide B-drug
, O
and O
quinidine B-drug
. O

diseases O
of O
the O
liver O
, O
gallbladder O
, O
and O
bowel O
; O

In O
in O
vivo O
studies O
, O
10- O
to O
30-mg/day O
doses O
of O
aripiprazole B-drug
had O
no O
significant O
effect O
on O
metabolism O
by O
CYP2D6 O
( O
dextromethorphan B-drug
) O
, O
CYP2C9 O
( O
warfarin B-drug
) O
, O
CYP2C19 O
( O
omeprazole B-drug
, O
warfarin B-drug
) O
, O
and O
CYP3A4 O
( O
dextromethorphan B-drug
) O
substrates O
. O

Lapatinib B-drug
did O
not O
significantly O
inhibit O
the O
following O
enzymes O
in O
human O
liver O
microsomes O
: O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
and O
CYP2D6 O
or O
UGT O
enzymes O
in O
vitro O
, O
however O
, O
the O
clinical O
significance O
is O
unknown O
. O

On O
the O
other O
hand O
, O
the O
enhanced O
secretion O
of O
colonic O
fluid O
by O
dmPGE2 B-drug_n
, O
given O
intraluminally O
, O
was O
only O
half O
of O
that O
in O
control O
rats O
, O
whereas O
the O
colonic O
transit-enhancing O
effect O
of O
dmPGE2 B-drug_n
in O
cecectomized O
rats O
was O
more O
pronounced O
than O
in O
control O
rats O
at O
15 O
but O
not O
at O
30 O
min O
after O
its O
administration O
. O

Increases O
in O
INR O
and O
prothrombin O
time O
may O
lead O
to O
abnormal O
bleeding O
and O
even O
death O
. O

A O
5-mg O
Vardenafil B-drug
dose O
should O
not O
be O
exceeded O
when O
used O
in O
combination O
with O
200 O
mg O
once O
daily O
ketoconazole B-drug
. O

Fluvoxamine B-drug
increased O
mean O
alosetron B-drug
plasma O
concentrations O
( O
AUC O
) O
approximately O
6-fold O
and O
prolonged O
the O
half-life O
by O
approximately O
3-fold O
. O

[ O
Stimulation O
by O
cerulein B-drug_n
-- O
an O
analog O
of O
the O
octapeptide O
cholecystokinin O
-- O
of O
3H-spiroperidol B-drug_n
binding O
after O
the O
long-term O
administration O
of O
neuroleptics B-group
] O
It O
has O
been O
established O
in O
experiments O
on O
white O
male O
rats O
that O
prolonged O
administration O
( O
twice O
a O
day O
for O
14 O
days O
) O
of O
haloperidol B-drug
( O
0.25 O
mg/kg O
) O
and O
pyreneperone B-drug_n
( O
0.25 O
mg/kg O
) O
resulted O
in O
the O
reduced O
interaction O
between O
3H-spiroperidol B-drug_n
and O
low O
affinity O
binding O
sites O
for O
apomorphine B-drug
in O
subcortical O
structures O
, O
whereas O
3H-spiroperidol B-drug_n
binding O
with O
high O
affinity O
binding O
sites O
for O
apomorphine B-drug
increased O
both O
in O
the O
frontal O
cortex O
and O
subcortical O
structures O
of O
the O
forebrain O
. O

Pulmonary O
granulomata O
, O
subacute O
hepatitis O
and O
other O
lesions O
resulting O
from O
intravenous O
drug O
use O
were O
common O
findings O
at O
autopsy O
. O

Blunting O
of O
the O
antihypertensive O
effect O
of O
beta-adrenoceptor B-group
blocking I-group
agents I-group
by O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
has O
been O
reported O
. O

Therefore O
, O
when O
heparin B-drug
sodium I-drug
is O
given O
with O
dicumarol B-drug
or O
warfarin B-drug
sodium I-drug
, O
a O
period O
of O
at O
least O
5 O
hours O
after O
the O
last O
intravenous O
dose O
or O
24 O
hours O
after O
the O
last O
subcutaneous O
dose O
should O
elapse O
before O
blood O
is O
drawn O
if O
a O
valid O
prothrombin O
time O
is O
to O
be O
obtained O
. O

The O
concurrent O
use O
of O
TORADOL B-brand
with O
muscle B-group
relaxants I-group
has O
not O
been O
formally O
studied O
. O

When O
increases O
in O
the O
dose O
of O
INDOCIN B-brand
are O
made O
, O
they O
should O
be O
made O
carefully O
and O
in O
small O
increments O
. O

In O
some O
patients O
, O
a O
disulfiram-like B-drug
reaction O
may O
be O
produced O
by O
the O
ingestion O
of O
alcohol B-drug
. O

+12 O
% O
+19 O
% O
-11 O
% O
-3 O
% O

Because O
both O
of O
these O
drugs O
have O
negative O
inotropic O
properties O
and O
the O
effects O
of O
coadministration O
with O
TAMBOCOR B-brand
are O
unknown O
, O
neither O
disopyramide B-drug
nor O
verapamil B-drug
should O
be O
administered O
concurrently O
with O
TAMBOCOR B-brand
unless O
, O
in O
the O
judgment O
of O
the O
physician O
, O
the O
benefits O
of O
this O
combination O
outweigh O
the O
risks O
. O

The O
20 O
% O
v/v O
solution O
of O
alcohol B-drug
was O
prepared O
in O
water O
from O
a O
stock O
solution O
of O
95 O
% O
ethanol B-drug
. O

The O
clinical O
significance O
of O
this O
interaction O
in O
preterm O
neonates O
is O
not O
known O
. O

Retrospective O
analysis O
of O
side O
effects O
in O
clinical O
trials O
showed O
that O
poor O
2D6 O
metabolizers O
had O
a O
higher O
rate O
of O
dizziness O
during O
up-titration O
, O
presumably O
resulting O
from O
vasodilating O
effects O
of O
the O
higher O
concentrations O
of O
the O
a-blocking O
R O
( O
+ O
) O
enantiomer O
. O

asthma O
drugs O
and O
antipsychotics B-group
. O

bone O
marrow O
hypoplasia O

( O
20 O
mg O
QD O
) O

Coadministration O
of O
entecavir B-drug
with O
lamivudine B-drug
, O
adefovir B-drug
dipivoxil I-drug
, O
or O
tenofovir B-drug
disoproxil I-drug
fumarate I-drug
did O
not O
result O
in O
significant O
drug O
interactions O
. O

Because O
of O
the O
possible O
additive O
effects O
of O
drugs O
that O
may O
depress O
the O
nervous O
system O
, O
ethanol B-drug
or O
triazolam B-drug
should O
be O
used O
cautiously O
in O
combination O
with O
tiagabine B-drug
. O

Aminoglutethimide B-drug
: O
Aminoglutethimide B-drug
may O
diminish O
adrenal O
suppression O
by O
corticosteroids B-group
. O

Atropine B-drug
, O
either O
alone O
or O
in O
combination O
with O
alcohol B-drug
, O
produced O
approximately O
the O
same O
degree O
of O
enhancement O
of O
component O
P2 O
. O

Animals O
studies O
on O
the O
various O
dual-memory O
theories O
have O
been O
carried O
out O
mainly O
on O
the O
basis O
of O
hippocampal O
system O
function O
. O

Sertraline B-drug

Potential O
Drug O
Interactions O
Dofetilide B-drug
is O
eliminated O
in O
the O
kidney O
by O
cationic O
secretion O
. O

was O
evaluated O
as O
a O
possible O
explanation O
for O
the O
association O
of O
deep-seated O
infection O
with O
this O
organism O
and O
abuse O
of O
these O
drugs O
. O

When O
Vardenafil B-drug
dosing O
was O
separated O
from O
terazosin B-drug
10 O
mg O
by O
6 O
hours O
, O
7 O
of O
28 O
subjects O
who O
received O
20 O
mg O
of O
Vardenafil B-drug
experienced O
a O
decrease O
in O
standing O
systolic O
blood O
pressure O
below O
85 O
mm O
Hg O
. O

However O
, O
reports O
suggest O
that O
NSAIDs B-group
may O
diminish O
the O
antihypertensive O
effect O
of O
ACE B-group
inhibitors I-group
. O

The O
neurochemical O
and O
functional O
consequences O
following O
MPTP B-drug_n
administration O
to O
the O
rat O
were O
evaluated O
and O
compared O
to O
similar O
effects O
following O
methamphetamine B-drug
administration O
. O

Caffeine B-drug
administered O
concurrently O
with O
ketoprofen B-drug
reduced O
the O
urine O
volume O
in O
4 O
healthy O
volunteers O
. O

There O
have O
been O
reports O
of O
theophylline-related B-drug
side-effects O
in O
patients O
on O
concomitant O
theophylline-quinolone B-drug
therapy O
. O

Non-steroidal B-group
anti-inflammatory I-group
drugs I-group
( O
but O
not O
aspirin B-brand
) O
: O
These O
drugs O
in O
combination O
with O
very O
high O
doses O
of O
quinolones B-group
have O
been O
shown O
to O
provoke O
convulsions O
in O
pre-clinical O
studies O
. O

In O
vitro O
human O
liver O
microsome O
studies O
and O
an O
in O
vivo O
metabolic O
probe O
study O
demonstrated O
that O
alosetron B-drug
did O
not O
inhibit O
CYP O
enzymes O
2D6 O
, O
3A4 O
, O
2C9 O
, O
or O
2C19 O
. O

In O
contrast O
to O
its O
enantiomer O
, O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
failed O
to O
increase O
FI O
responding O
significantly O
in O
either O
species O
; O

The O
extent O
to O
which O
SSRI-TCAinteractions B-group
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-group
involved O
. O

Thus O
, O
in O
addition O
to O
its O
proposed O
specific O
information O
processing O
functions O
( O
i.e. O
, O
relational O
) O
, O
the O
hippocampus O
would O
play O
a O
role O
in O
addressing O
information O
to O
the O
brain O
memory O
system O
that O
, O
in O
a O
given O
situation O
, O
has O
the O
best O
adaptive O
value O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

When O
INDOCIN B-brand
is O
given O
to O
patients O
receiving O
probenecid B-drug
, O
the O
plasma O
levels O
of O
indomethacin B-drug
are O
likely O
to O
be O
increased O
. O

Antihistamines B-group
: O
Amphetamines B-group
may O
counteract O
the O
sedative O
effect O
of O
antihistamines B-group
. O

Mixing O
of O
Insulins B-group

There O
was O
not O
a O
significant O
difference O
( O
p O
> O
0.05 O
) O
in O
AUC O
( O
48.59 O
+/- O
8.52 O
vs. O
49.9 O
+/- O
9.93 O
) O
, O
Cmax O
( O
7.73 O
+/- O
2.6 O
vs. O
6.6 O
+/- O
2.0 O
) O
, O
and O
tmax O
( O
1.1 O
+/- O
0.6 O
vs. O
1.6 O
+/- O
1.1 O
) O
for O
levofloxacin B-drug
versus O
levofloxacin/oxycodone B-drug
regimens O
. O

The O
thiazolidinediones B-group
( O
rosiglitazone B-drug
and O
pioglitazone B-drug
) O
, O
a O
new O
class O
of O
oral O
antidiabetic B-group
agents I-group
, O
are O
" O
insulin O
sensitizers O
" O

Although O
specific O
drug O
interaction O
studies O
in O
HIV-1 O
seropositive O
subjects O
have O
not O
been O
conducted O
for O
the O
classes O
of O
drugs O
listed O
in O
Table O
4 O
, O
additional O
clinical O
monitoring O
may O
be O
warranted O
when O
co-administering O
these O
drugs O
. O

In O
this O
situation O
, O
special O
patient O
care O
and O
observation O
are O
appropriate O
. O

Labetalol B-drug
HCl I-drug
has O
also O
been O
reported O
to O
produce O
a O
false O
positive O
test O
for O
amphetamine B-drug
when O
screening O
urine O
for O
the O
presence O
of O
drugs O
using O
the O
commercially O
available O
assay O
methods O
Toxi-Lab O
A O
( O
thin-layer O
chromatographic O
assay O
) O
and O
Emit-d.a.u O
. O
( O
radioenzymatic O
assay O
) O
. O

Therefore O
, O
close O
monitoring O
of O
prothrombin O
time O
is O
recommended O
and O
adjustment O
of O
the O
anticoagulant B-group
dose O
may O
be O
necessary O
when O
EULEXIN B-brand
Capsules O
are O
administered O
concomitantly O
with O
warfarin B-drug
. O

The O
data O
inTables O
1 O
and O
3 O
are O
based O
on O
the O
results O
of O
drug O
interaction O
studies O
conducted O
in O
HIV-1 O
seropositive O
subjects O
unless O
otherwise O
indicated O
. O

Phenobarbital B-drug
toxicity O
has O
been O
reported O
to O
have O
occurred O
in O
a O
patient O
on O
chronic O
phenobarbital B-drug
treatment O
following O
the O
initiation O
of O
diclofenac B-drug
therapy O
. O

Hydrochlorothiazide B-drug
: O
A O
study O
in O
normal O
healthy O
volunteers O
has O
shown O
that O
concomitant O
administration O
of O
DynaCirc B-brand
( O
isradipine B-drug
) O
and O
hydrochlorothiazide B-drug
does O
not O
result O
in O
altered O
pharmacoktnetics O
of O
either O
drug O
. O

CANCIDAS B-brand
has O
no O
effect O
on O
the O
pharmacokinetics O
of O
itraconazole B-drug
, O
amphotericin B-drug
B I-drug
, O
or O
the O
active O
metabolite O
of O
mycophenolate O
. O

Antidepressants B-group
( O
tricyclic B-group
) O
, O
atropine B-drug
or O
other O
anticholinergic B-group
agents I-group
, O
or O
digitalis B-group
glycosides I-group
: O
concurrent O
use O
with O
arbutamine B-drug
may O
produce O
additive O
inotropic O
and/or O
chronotropic O
effects O
. O

This O
interaction O
appears O
to O
be O
clinically O
significant O
. O

Since O
bacteriostatic O
drugs O
may O
interfere O
with O
the O
bactericidal O
action O
of O
penicillin B-drug
, O
it O
is O
advisable O
to O
avoid O
giving O
tetracyclines B-group
in O
conjunction O
with O
penicillin B-group
. O

The O
mean O
reduction O
of O
growth O
caused O
by O
the O
drugs O
was O
1,000-fold O
greater O
for O
49 O
Pseudomonas O
strains O
from O
normal O
subjects O
than O
for O
32 O
strains O
from O
drug O
addicts O
( O
4.2 O
vs. O
1.3 O
logs O
of O
reduction O
at O
2 O
hr O
, O
P O
less O
than O
.0005 O
) O
. O

Diazepam B-drug
: O
Diazepam B-drug
( O
Valium B-brand
) O
is O
a O
CYP O
3A4 O
and O
CYP O
2C19 O
substrate O
. O

INCREASED O
PHENYTOIN B-drug
LEVELS O
SHOULD O
BE O
TREATED O
WITH O
APPROPRIATE O
DOSAGE O
ADJUSTMENT O
. O

Therefore O
, O
if O
concomitant O
use O
of O
these O
agents O
is O
indicated O
because O
of O
demonstrated O
hypokalemia O
, O
they O
should O
be O
used O
with O
caution O
and O
with O
frequent O
monitoring O
of O
serum O
potassium O
. O

Drugs O
Metabolized O
by O
Cytochrome O
P4502D6 O
- O
In O
vitro O
studies O
did O
not O
reveal O
an O
inhibitory O
effect O
of O
escitalopram B-drug
on O
CYP2D6 O
. O

The O
concomitant O
administration O
of O
macrolide B-group
antibiotics I-group
and O
other O
hydroxymethylglutaryl B-group
coenzyme I-group
A I-group
( I-group
HMG-CoA I-group
) I-group
reductase I-group
inhibitors I-group
have O
resulted O
in O
previous O
reports O
of O
rhabdomyolysis O
. O

The O
pressor O
effects O
of O
ERGOMAR B-brand
and O
other O
vasoconstrictor B-group
drugs I-group
can O
combine O
to O
cause O
dangerous O
hypertension O
. O

A O
causal O
relationship O
between O
these O
events O
and O
the O
concomitant O
administration O
of O
lithium B-drug
and O
HALDOL B-brand
has O
not O
been O
established O
; O

Aortic O
rings O
with O
intact O
endothelium O
from O
the O
high-dose O
( O
4 O
mg/kg/day O
) O
estradiol B-drug
group O
were O
supersensitive O
to O
noradrenaline B-drug
compared O
to O
the O
vehicle O
or O
low-dose O
( O
10 O
microg/kg/day O
) O
estradiol O
groups O
( O
pD2 O
values O
= O
7.86+/-0.09 O
, O
7.30+/-0.11 O
and O
7.35+/-0.04 O
, O
respectively O
) O
. O

The O
concurrent O
use O
of O
two O
or O
more O
drugs O
with O
anticholinergic O
activity O
-- O
such O
as O
an O
antipsychotic B-group
drug I-group
( O
eg O
, O
chlorpromazine B-drug
) O
, O
an O
antiparkinsonian B-group
drug I-group
( O
eg O
, O
trihexyphenidyl B-drug
) O
, O
and/or O
a O
tricyclic B-group
antidepressant I-group
( O
eg O
, O
amitriptyline B-drug
) O
-- O
commonly O
results O
in O
excessive O
anticholinergic O
effects O
, O
including O
dry O
mouth O
and O
associated O
dental O
complications O
, O
blurred O
vision O
, O
and O
, O
in O
patients O
exposed O
to O
high O
temperature O
and O
humidity O
, O
hyperpyrexia O
. O

Although O
the O
pattern O
of O
use O
for O
oral O
allopurinol B-drug
includes O
longer O
term O
therapy O
, O
particularly O
for O
gout O
and O
renal O
calculi O
, O
the O
experience O
gained O
may O
be O
relevant O
. O

Similarly O
, O
in O
the O
1-year O
monthly O
comparison O
study O
, O
aspirin B-brand
and O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
were O
taken O
by O
39 O
% O
of O
the O
1602 O
patients O
. O

These O
factors O
, O
in O
concert O
with O
age-dependent O
alterations O
in O
immune O
function O
and O
host O
defense O
, O
may O
help O
to O
explain O
the O
increased O
risk O
of O
malignant O
disease O
in O
aged O
persons O
. O

Although O
there O
was O
a O
slight O
reduction O
in O
blood O
sugar O
concentrations O
during O
concomitant O
administration O
of O
flurbiprofen B-drug
and O
hypoglycemic B-group
agents I-group
, O
there O
were O
no O
signs O
or O
symptoms O
of O
hypoglycemia O
. O

Survival O
of O
miracidia O
was O
reduced O
by O
increasing O
metal O
concentration O
except O
at O
concentrations O
of O
10 O
microg/l O
for O
single O
metal O
toxicity O
where O
survival O
was O
increased O
above O
the O
control O
. O

- O
Antihypertensives B-group
: O
Bumetanide B-drug
may O
potentiate O
the O
effect O
of O
various O
antihypertensive B-group
drugs I-group
, O
necessitating O
a O
reduction O
in O
the O
dosage O
of O
these O
drugs O
. O

acetaminophen/theophylline B-drug
, O
lidocaine/quinidine B-drug
, O
phenobarbital/acetaminophen B-drug
, O
phenobarbital/valproic B-drug
acid I-drug
, O
quinidine/lidocaine B-drug
, O
theophylline/acetaminophen B-drug
, O
and O
valproic B-drug
acid/phenobarbital I-drug
. O

- O
Increased O
prothrombin O
and O
factors O
VII O
, O
VIII O
, O
IX O
, O
and O
X O
; O

Enalapril B-drug
IV O
has O
been O
used O
concomitantly O
with O
digitalis B-group
without O
evidence O
of O
clinically O
significant O
adverse O
reactions O
. O

Administration O
of O
CMI B-drug
has O
been O
reported O
to O
increase O
the O
plasma O
levels O
of O
phenobarbital B-drug
, O
if O
given O
concomitantly O
. O

eosinophilia O

Presumably O
, O
phenytoin B-drug
acts O
as O
a O
stimulator O
of O
coumarin B-group
metabolism O
and O
has O
been O
reported O
to O
cause O
decreased O
serum O
levels O
of O
the O
coumarin B-group
anticoagulants I-group
and O
increased O
prothrombin-proconvertin O
concentrations O
. O

Johns O
Wort O
) O
may O
significantly O
reduce O
exposure O
to O
Gleevec B-brand
. O

( O
Read O
circulars O
for O
lithium B-drug
preparations O
before O
use O
of O
such O
concomitant O
therapy O
. O
) O

The O
results O
indicate O
that O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
readily O
penetrates O
both O
the O
mucosal O
and O
serosal O
surfaces O
of O
the O
epithelial O
membrane O
. O

Clarithromycin B-drug

Aspirin/Nonsteroidal B-brand
Antiinflammatory B-group
Drugs O
( O
NSAIDs B-group
) O

thyroid B-drug
medication O
; O

Pharmacokinetic O
interaction O
studies O
with O
cetirizine B-drug
in O
adults O
were O
conducted O
with O
pseudoephedrine B-drug
, O
antipyrine B-drug
, O
ketoconazole B-drug
, O
erythromycin B-drug
and O
azithromycin B-drug
. O

When O
given O
i.p. O
, O
dmPGE2 B-drug_n
( O
0.3 O
mg/kg O
) O
induced O
a O
watery O
stool O
in O
cecectomized O
and O
control O
rats O
with O
the O
same O
efficacy O
, O
although O
these O
effects O
were O
short-lasting O
as O
compared O
to O
oral O
administration O
. O

Prior O
administration O
of O
4-methylpyrazole B-drug
( O
90 O
mg O
kg O
( O
-1 O
) O
body O
weight O
) O
was O
shown O
to O
prevent O
the O
conversion O
of O
1,3-difluoro-2-propanol B-drug_n
( O
100 O
mg O
kg O
( O
-1 O
) O
body O
weight O
) O
to O
( B-drug_n
- I-drug_n
) I-drug_n
-erythro-fluorocitrate I-drug_n
in O
vivo O
and O
to O
eliminate O
the O
fluoride O
and O
citrate O
elevations O
seen O
in O
1,3-difluoro-2-propanol-intoxicated B-drug_n
animals O
. O

Therefore O
, O
use O
of O
lamivudine B-drug
in O
combination O
with O
zalcitabine B-drug
is O
not O
recommended O

Echistatin B-drug_n
alone O
had O
no O
effect O
on O
tyrosine O
phosphorylation O
in O
T24 O
cells O
, O
but O
dose-dependently O
inhibits O
the O
effects O
of O
contortrostatin B-drug_n
when O
both O
are O
added O
simultaneously O
. O

Patients O
taking O
diuretics B-group
are O
at O
a O
greater O
risk O
of O
developing O
renal O
failure O
secondary O
to O
a O
decrease O
in O
renal O
blood O
flow O
caused O
by O
prostaglandin O
inhibition O
. O

Heparin B-drug
, O
other O
anticoagulants B-group
, O
thrombolytics B-group
, O
and O
anti B-group
platelet I-group
agents I-group
are O
associated O
with O
an O
increase O
in O
bleeding O
. O

- O
Ethotoin B-drug
( O
e.g. O
, O
Peganone B-brand
) O
or O

Further O
, O
they O
bring O
into O
question O
the O
utility O
of O
using O
PCP B-drug_n
combination O
procedures O
in O
animals O
to O
screen O
for O
antipsychotic O
potential O
. O

chloral B-drug
hydrate* O
; O

clofibrate B-drug
; O

Caution O
should O
be O
taken O
in O
concurrent O
or O
serial O
use O
of O
other O
neurotoxic O
and/ O
or O
nephrotoxic O
drugs O
because O
of O
possible O
enhancement O
of O
the O
nephrotoxicity O
and/or O
ototoxicity O
of O
neomycin B-drug
. O

Lithium B-drug
: O
Ibuprofen B-drug
produced O
an O
elevation O
of O
plasma O
lithium B-drug
levels O
and O
a O
reduction O
in O
renal O
lithium B-drug
clearance O
in O
a O
study O
of O
eleven O
normal O
volunteers O
. O

fenoprofen B-drug
; O

The O
genotypes O
of O
CYP2C9 B-drug
and O
2C19 O
, O
the O
enzymes O
responsible O
for O
phenytoin O
metabolism O
, O
were O
homozygous O
for O
the O
wild-type O
alleles O
( O
CYP2C9*1/*1 B-drug
and O
2C19*1/ O
*1 O
) O
. O

Gabapentin B-drug
had O
no O
effect O
on O
naproxen B-drug
pharmacokinetic O
parameters O
. O

Coadministration O
with O
valdecoxib B-drug
( O
40 O
mg O
BID O
for O
7 O
days O
) O
resulted O
in O
a O
significant O
increase O
in O
dextromethorphan B-drug
plasma O
levels O
suggesting O
that O
, O
at O
these O
doses O
, O
valdecoxib B-drug
is O
a O
weak O
inhibitor O
of O
2D6 O
. O

- O
Lofexidine B-drug
may O
enhance O
the O
effects O
of O
anti-hypertensive B-group
drug I-group
therapy O

Drug O
Interactions O
: O
The O
central O
anticholinergic B-group
syndrome O
can O
occur O
when O
anticholinergic O
agents O
such O
as O
AKINETON B-brand
are O
administered O
concomitantly O
with O
drugs O
that O
have O
secondary O
anticholinergic O
actions O
, O
e.g. O
, O
certain O
narcotic B-group
analgesics I-group
such O
as O
meperidine B-drug
, O
the O
phenothiazines B-group
and O
other O
antipsychotics B-group
, O
tricyclic B-group
antidepressants I-group
, O
certain O
antiarrhythmics B-group
such O
as O
the O
quinidine B-drug
salts O
, O
and O
antihistamines B-group
. O

unlike O
ibogaine B-drug_n
, O
18-MC B-drug_n
does O
not O
affect O
responding O
for O
a O
nondrug O
reinforcer O
( O
water O
) O
. O

INOmax B-brand
has O
been O
administered O
with O
tolazoline B-drug
, O
dopamine B-drug
, O
dobutamine B-drug
, O
steroids B-group
, O
surfactant B-drug
, O
and O
high-frequency O
ventilation O
. O

The O
clinical O
significance O
of O
this O
interaction O
with O
doxepin B-drug
has O
not O
been O
systematically O
evaluated O
. O

in O
vitro O
, O
Gleevec B-brand
inhibits O
acetaminophen O
O-glucuronidation O
( O
Ki O
value O
of O
58.5 O
M O
) O
at O
therapeutic O
levels O
. O

There O
were O
several O
factors O
that O
could O
have O
increased O
his O
risk O
for O
developing O
rhabdomyolysis O
, O
including O
chronic O
renal O
failure O
. O

These O
small O
changes O
are O
not O
clinically O
significant O
and O
no O
dose O
adjustment O
is O
necessary O
. O

and O
diuretics B-group
, O
such O
as O
furosemide B-drug
. O

D O
. O

NovoSeven B-brand
should O
not O
be O
mixed O
with O
infusion O
solutions O
until O
clinical O
data O
are O
available O
to O
direct O
this O
use O
. O

Therefore O
, O
the O
combined O
use O
of O
lovastatin B-drug
with O
fibrates B-group
should O
generally O
be O
avoided O
. O

Gentamycin B-drug
reduced O
twitch O
strength O
from O
40 O
+/- O
1 O
% O
( O
mean O
+/- O
sem O
) O
to O
29 O
+/- O
4 O
% O
within O
7.0 O
+/- O
1.5 O
min O
( O
P O
= O
0.02 O
) O
. O

Therefore O
, O
co-administration O
of O
bupropion B-drug
with O
drugs O
that O
are O
metabolized O
by O
CYP2D6 O
isoenzyme O
including O
certain O
antidepressants B-group
( O
e.g. O
, O
nortriptyline B-drug
, O
imipramine B-drug
, O
desipramine B-drug
, O
paroxetine B-drug
, O
fluoxetine B-drug
, O
sertraline B-drug
) O
, O
antipsychotics B-group
( O
e.g. O
, O
haloperidol B-drug
, O
risperidone B-drug
, O
thioridazine B-drug
) O
, O
beta-blockers B-group
( O
e.g. O
, O
metoprolol B-drug
) O
, O
and O
Type B-group
1C I-group
antiarrhythmics I-group
( O
e.g. O
, O
propafenone B-drug
, O
flecainide B-drug
) O
, O
should O
be O
approached O
with O
caution O
and O
should O
be O
initiated O
at O
the O
lower O
end O
of O
the O
dose O
range O
of O
the O
concomitant O
medication O
. O

The O
plasma O
and O
tumour O
total O
nitrosourea B-group
peak O
concentrations O
were O
reduced O
by O
1.5 O
and O
1.7 O
fold O
respectively O
. O

The O
clinical O
significance O
of O
this O
reduction O
is O
not O
known O
, O
hence O
zalcitabine B-drug
is O
not O
recommended O
to O
be O
ingested O
simultaneously O
with O
magnesium/aluminum-containing B-drug
antacids B-group
. O

phophatase O

Therefore O
, O
hormonal B-group
contraceptives I-group
, O
including O
oral O
, O
injectable O
, O
transdermal O
, O
and O
implantable O
forms O
, O
may O
not O
be O
reliable O
when O
TRACLEER B-brand
is O
co-administered O
. O

Calcium B-drug
Supplements O
: O
Uncontrolled O
intake O
of O
additional O
calcium-containing B-drug
preparations O
should O
be O
avoided O
. O

It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
( O
such O
as O
Clinistix O
or O
Tes-Tape O
) O
be O
used O
. O

Corticosteroids B-group
: O
A O
relationship O
of O
functional O
antagonism O
exists O
between O
vitamin B-group
D I-group
analogues I-group
, O
which O
promote O
calcium O
absorption O
, O
and O
corticosteroids B-group
, O
which O
inhibit O
calcium O
absorption O
. O

Infusion O
requirements O
of O
NIMBEX B-brand
in O
patients O
administered O
succinylcholine B-drug
prior O
to O
infusions O
of O
NIMBEX B-brand
were O
comparable O
to O
or O
slightly O
greater O
than O
when O
succinylcholine B-drug
was O
not O
administered O
. O

The O
potentiation O
resulted O
from O
a O
CNS O
pharmacodynamic O
interaction O
; O

Since O
fondaparinux B-drug
sodium I-drug
does O
not O
bind O
significantly O
to O
plasma O
proteins O
other O
than O
ATIII O
, O
no O
drug O
interactions O
by O
protein-binding O
displacement O
are O
expected O
. O

Adjustment O
of O
dosage O
of O
oral O
anticoagulants B-group
may O
be O
required O
. O

However O
, O
because O
bleeding O
has O
been O
reported O
when O
ibuprofen B-drug
and O
other O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
have O
been O
administered O
to O
patients O
on O
coumarin-type B-group
anticoagulants I-group
, O
the O
physician O
should O
be O
cautious O
when O
administering O
ibuprofen B-drug
to O
patients O
on O
anticoagulants B-group
. O

In O
vitro O
data O
suggest O
that O
itraconazole B-drug
also O
markedly O
inhibits O
the O
biotransformation O
system O
mainly O
responsible O
for O
the O
metabolism O
of O
cisapride B-drug
; O

fecal O
excretion O
, O
too O
, O
was O
increased O
by O
supplementary O
iron B-drug
; O

No O
statistically O
significant O
differences O
between O
treatment O
groups O
were O
observed O
for O
any O
of O
the O
calculated O
digoxin B-drug
pharmacokinetic O
parameters O
. O

Medications O
can O
cause O
in O
vivo O
effects O
when O
the O
concentration O
or O
activity O
of O
the O
analyte O
is O
altered O
before O
the O
analysis O
and O
therefore O
the O
assay O
result O
is O
true O
and O
accurate O
. O

tadalafil I-drug
concentration O

Neomycin B-drug
has O
no O
effect O
on O
the O
blood O
pressure O
or O
metabolic O
responses O
to O
ACTH B-group
in O
sheep O
. O

The O
concurrent O
use O
of O
anticholinergics B-group
with O
hydrocodone B-drug
may O
produce O
paralytic O
ileus O
. O

Modification O
of O
surface O
histidine O
residues O
abolishes O
the O
cytotoxic O
activity O
of O
Clostridium B-drug_n
difficile I-drug_n
toxin I-drug_n
A I-drug_n
. O

Induction O
of O
apoptosis O
in O
breast O
cancer O
cells O
in O
response O
to O
vitamin B-group
D I-group
and O
antiestrogens B-group
. O

These O
six O
volunteers O
received O
terfenadine B-drug
alone O
( O
60 O
mg O
twice O
daily O
) O
for O
8 O
days O
, O
followed O
by O
terfenadine B-drug
in O
combination O
with O
dirithromycin B-drug
( O
500 O
mg O
once O
daily O
) O
for O
10 O
days O
. O

However O
, O
there O
are O
limited O
in O
vivo O
data O
suggesting O
a O
modest O
CYP2D6 O
inhibitory O
effect O
for O
escitalopram B-drug
, O
i.e. O
, O
coadministration O
of O
escitalopram B-drug
( O
20 O
mg/day O
for O
21 O
days O
) O
with O
the O
tricyclic B-group
antidepressant I-group
desipramine B-drug
( O
single O
dose O
of O
50 O
mg O
) O
, O
a O
substrate O
for O
CYP2D6 O
, O
resulted O
in O
a O
40 O
% O
increase O
in O
Cmax O
and O
a O
100 O
% O
increase O
in O
AUC O
of O
desipramine B-drug
. O

Ketoconazole/Itraconazole B-drug
, O
Macrolides B-group
, O
Including O
Erythromycin B-drug

Transient O
and O
minor O
adverse O
events O
occurred O
with O
similar O
frequency O
on O
placebo O
and O
rofecoxib B-drug
treatments O
, O
and O
no O
treatment-related O
pattern O
was O
apparent O
. O

The O
following O
drug O
interactions O
were O
observed O
in O
some O
patients O
undergoing O
treatment O
with O
oral O
allopurinol B-drug
. O

. O

INDOCIN B-brand
and O
potassium-sparing B-group
diuretics I-group
each O
may O
be O
associated O
with O
increased O
serum O
potassium O
levels O
. O

Potassium-sparing B-group
diuretics I-group
( O
spironolactone B-drug
, O
amiloride B-drug
, O
triamterene B-drug
, O
and O
others O
) O
or O
potassium B-drug
supplements O
can O
increase O
the O
risk O
of O
hyperkalemia O
. O

Therefore O
, O
erlotinib B-drug
exposure O
may O
be O
increased O
in O
patients O
with O
hepatic O
dysfunction O
. O

alone O
. O

Pregnancy O
Pregnancy O
Category O
D O
: O
. O

Nevirapine B-drug
is O
known O
to O
be O
an O
inducer O
of O
these O
enzymes O
. O

Therefore O
, O
in O
patients O
taking O
insulin B-drug
or O
oral O
hypoglycemics B-group
, O
regular O
monitoring O
of O
blood O
glucose O
is O
recommended O
. O

It O
is O
recommended O
that O
in O
patients O
taking O
anticoagulants B-group
, O
prothrombin O
time O
be O
determined O
before O
starting O
lovastatin B-drug
and O
frequently O
enough O
during O
early O
therapy O
to O
insure O
that O
no O
significant O
alteration O
of O
prothrombin O
time O
occurs O
. O

Similarly O
, O
there O
is O
currently O
little O
adequate O
evidence O
on O
either O
the O
presence O
or O
the O
absence O
of O
serious O
adverse O
reactions O
to O
such O
doses O
of O
ascorbic B-drug
acid I-drug
, O
although O
many O
such O
reactions O
have O
been O
hypothesized O
. O

These O
agents O
include O
medications O
such O
as O
: O
anticoagulants B-group
, O
platelet B-group
inhibitors I-group
including O
acetylsalicylic B-drug
acid I-drug
, O
sali-cylates O
, O
NSAIDs B-group
( O
including O
ketorolac B-drug
tromethamine I-drug
) O
, O
dipyridamole B-drug
, O
or O
sulfinpyrazone B-drug
. O

Diminished O
urinary O
excretion O
of O
norfloxacin B-drug
has O
been O
reported O
during O
the O
concomitant O
administration O
of O
probenecid B-drug
and O
norfloxacin B-drug
. O

Retention O
was O
calculated O
by O
the O
balance O
technique O
and O
by O
the O
comparative O
slaughter O
technique O
. O

St. O
John O
s O
wort O
( O
Hypericum O
perforatum O
) O

Either O
single O
( O
170 O
mg/kg O
) O
or O
repeated O
( O
75 O
mg/kg O
per O
day O
for O
5 O
days O
) O
oral O
administration O
of O
cypermethrin B-drug
was O
found O
to O
produce O
significant O
oxidative O
stress O
in O
cerebral O
and O
hepatic O
tissues O
of O
rats O
, O
as O
was O
evident O
by O
the O
elevation O
of O
the O
level O
of O
thiobarbituric O
acid O
reactive O
substances O
( O
TBARS O
) O
in O
both O
tissues O
, O
either O
4 O
or O
24 O
h O
after O
treatment O
. O

The O
use O
of O
REGRANEX B-brand
Gel O
with O
other O
topical O
drugs O
has O
not O
been O
studied O
. O

Histidine O
modification O
had O
no O
effect O
on O
the O
glucosyl O
transferase O
enzyme O
activity O
of O
toxin B-drug_n
A I-drug_n
. O

Hypotension O
, O
AV O
conduction O
disturbances O
, O
and O
left O
ventricular O
failure O
have O
been O
reported O
in O
some O
patients O
receiving O
beta-adrenergic B-group
blocking I-group
agents I-group
when O
an O
oral O
calcium B-group
antagonist I-group
was O
added O
to O
the O
treatment O
regimen O
. O

When O
a O
diuretic B-group
is O
added O
to O
the O
therapy O
of O
a O
patient O
receiving O
PRINIVIL B-brand
, O
an O
additional O
antihypertensive O
effect O
is O
usually O
observed O
. O

METHODS O
. O

These O
recommendations O
are O
based O
on O
either O
drug O
interaction O
studies O
or O
predicted O
interactions O
due O
to O
the O
expected O
magnitude O
of O
interaction O
and O
potential O
for O
serious O
events O
or O
loss O
of O
efficacy O
. O

free O
T4 O
concentration O
is O
unaltered O
: O
impaired O
glucose O
tolerance O
; O

The O
inhibition O
of O
CYP-2C19 O
by O
OXC B-drug
and O
MHD B-drug_n
, O
however O
, O
is O
clinically O
relevant O
. O

anticholinergics B-group
or O
other O
medications O
with O
anticholinergic O
activity O
- O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
diphenidol B-drug
; O

Lopinavir/Ritonavir B-drug

Other O
factors O
may O
increase O
the O
risk O
of O
this O
drug O
interaction O
, O
including O
the O
administration O
of O
other O
medications O
that O
are O
associated O
with O
myopathy O
, O
underlying O
renal O
insufficiency O
, O
and O
administration O
of O
high O
doses O
of O
HMG-CoA B-group
reductase I-group
inhibitors I-group
. O

When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
MICRONASE B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O

Other O
Drug O
Interactions O
Oral O
Contraceptives B-group
Keppra B-brand
( O
500 O
mg O
twice O
daily O
) O
did O
not O
influence O
the O
pharmacokinetics O
of O
an O
oral O
contraceptive B-group
containing O
0.03 O
mg O
ethinyl B-drug
estradiol I-drug
and O
0.15 O
mg O
levonorgestrel B-drug
, O
or O
of O
the O
luteinizing O
hormone O
and O
progesterone O
levels O
, O
indicating O
that O
impairment O
of O
contraceptive O
efficacy O
is O
unlikely O
. O

Amitriptyline B-drug
: O
Concurrent O
administration O
of O
25 O
mg O
or O
100 O
mg O
cinacalcet B-drug
with O
50 O
mg O
amitriptyline B-drug
increased O
amitriptyline B-drug
exposure O
and O
nortriptyline B-drug_n
( O
active O
metabolite O
) O
exposure O
by O
approximately O
20 O
% O
in O
CYP2D6 O
extensive O
metabolizers O
. O

When O
patients O
being O
treated O
with O
labetalol B-drug
have O
a O
positive O
urine O
test O
for O
amphetamine B-drug
using O
these O
techniques O
confirmation O
should O
be O
made O
by O
using O
more O
specific O
methods O
such O
as O
a O
gas O
chromatographic-mass O
spectrometer O
technique O
. O

Cyclosporine B-drug
: O
Combination O
hormonal B-group
contraceptives I-group
may O
inhibit O
the O
metabolism O
of O
cyclosporine B-drug
, O
leading O
to O
increased O
plasma O
concentrations O
; O

Since O
indomethacin B-drug
and O
potassium-sparing B-group
diuretics I-group
, O
including O
MIDAMOR B-brand
, O
may O
each O
be O
associated O
with O
increased O
serum O
potassium O
levels O
, O
the O
potential O
effects O
on O
potassium O
kinetics O
and O
renal O
function O
should O
be O
considered O
when O
these O
agents O
are O
administered O
concurrently O
. O

Some O
preliminary O
data O
suggest O
that O
calcium B-group
blockers I-group
also O
increase O
generation O
of O
vasodilator O
and O
platelet O
antiaggregant O
prostacyclin O
, O
which O
could O
contribute O
to O
decrease O
in O
platelet O
function O
. O

Hypotension O
Patients O
on O
Diuretic B-group
Therapy O
: O
Patients O
on O
diuretics B-group
and O
especially O
those O
in O
whom O
diuretic B-group
therapy O
was O
recently O
instituted O
, O
as O
well O
as O
those O
on O
severe O
dietary O
salt O
restriction O
or O
dialysis O
, O
may O
occasionally O
experience O
a O
precipitous O
reduction O
of O
blood O
pressure O
usually O
within O
the O
first O
hour O
after O
receiving O
the O
initial O
dose O
of O
captopril B-drug
. O

Theophylline B-drug
: O
Ethinyl B-drug
estradiol I-drug
may O
inhibit O
the O
metabolism O
of O
theophylline B-drug
, O
leading O
to O
increased O
plasma O
concentrations O
. O

by O
the O
nonlinear O
kinetic O
characteristics O
for O
verapamil B-drug
and O
diltiazem B-drug
( O
and O
probably O
for O
nifedipine B-drug
, O
as O
well O
) O
and O
the O
derivative O
implications O
for O
decreased O
dosing O
frequency O
requirements O
; O

In O
eight O
HIV-infected O
patients O
, O
the O
steady-state O
AUC O
of O
ciprofloxacin B-drug
was O
decreased O
an O
average O
of O
26 O
% O
( O
95 O
% O
CI O
= O
14 O
% O
, O
37 O
% O
) O
when O
ciprofloxacin B-drug
was O
administered O
2 O
hours O
prior O
to O
a O
marketed O
chewable/dispersible O
tablet O
formulation O
of O
VIDEX B-brand
. O

Coadministration O
of O
gly-buride O
and O
metformin B-drug
did O
not O
result O
in O
any O
changes O
in O
either O
metformin B-drug
pharmacokinetics O
or O
pharmaco-dynamics O
. O

Patients O
who O
begin O
taking O
diclofenac B-drug
or O
who O
increase O
their O
diclofenac B-drug
dose O
or O
any O
other O
NSAID B-group
while O
taking O
digoxin B-drug
, O
methotrexate B-drug
, O
or O
cyclosporine B-drug
may O
develop O
toxicity O
characteristics O
for O
these O
drugs O
. O

Mercaptopurine/Azathioprine B-drug
: O
Allopurinol B-drug
inhibits O
the O
enzymatic O
oxidation O
of O
mercaptopurine B-drug
and O
azathioprine B-drug
to O
6-thiouric B-drug
acid I-drug
. O

There O
was O
a O
small O
increase O
in O
plasma O
concentrations O
of O
capecitabine B-drug
and O
one O
metabolite O
( O
5-DFCR B-drug_n
) O
; O

Concomitant O
oral O
administration O
of O
ketoconazole B-drug
( O
a O
known O
inhibitor O
of O
CYP3A4 O
activity O
in O
the O
liver O
and O
in O
the O
intestinal O
mucosa O
) O
caused O
an O
eight-fold O
increase O
of O
the O
systemic O
exposure O
to O
oral O
budesonide B-drug
. O

Probenecid B-drug
or O
Cimetidine B-drug
: O
Concomitant O
administration O
of O
probenecid B-drug
or O
cimetidine B-drug
decreases O
the O
elimination O
of O
zalcitabine B-drug
, O
most O
likely O
by O
inhibition O
of O
renal O
tubular O
secretion O
of O
zalcitabine B-drug
. O

There O
is O
no O
information O
on O
the O
effect O
of O
other O
highly O
plasma O
protein O
bound O
drugs O
on O
doxazosin B-drug
binding O
. O

sickle O
cell O
disease O
; O

Buprenorphine B-drug
is O
metabolized O
to O
norbuprenorphine B-drug_n
by O
cytochrome O
CYP O
3A4 O
. O

Patients O
receiving O
other O
narcotic B-group
analgesics I-group
, O
antipsychotics B-group
, O
antianxiety B-group
agents I-group
, O
or O
other O
CNS B-group
depressants I-group
( O
including O
alcohol B-drug
) O
concomitantly O
with O
hydrocodone B-drug
and O
acetaminophen B-drug
tablets O
may O
exhibit O
an O
additive O
CNS O
depression O
. O

Depending O
on O
the O
traction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8 O
fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA B-group
) O
. O

Isoproterenol B-drug
alone O
at O
a O
dose O
of O
2.7 O
mg/kg/day O
( O
approximately O
7 O
times O
the O
maximum O
recommended O
daily O
inhalation O
dose O
in O
adults O
on O
a O
mg/m2 O
basis O
) O
increased O
both O
resorptions O
and O
malformations O
. O

This O
could O
facilitate O
the O
action O
of O
fatty O
acids O
and O
enable O
cells O
to O
increase O
their O
capacity O
for O
triacylglycerol O
synthesis O
to O
match O
an O
increased O
availability O
of O
fatty O
acids O
. O

Formal O
drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
ORENCIA B-brand
. O

Benzylpenicillin B-drug
, O
ampicillin B-drug
, O
oxacillin B-drug
, O
chlortetracycline B-drug
, O
doxycycline B-drug
, O
cephalothin B-drug
, O
erythromycin B-drug
, O
and O
sulfamethoxazole B-drug
have O
no O
influence O
in O
vitro O
on O
the O
protein O
binding O
of O
diclofenac B-drug
in O
human O
serum O
. O

Cyclosporine B-drug
, O
hexobarbital B-drug
and O
phenytoin B-drug
concentrations O
. O

Anticholinergic B-group
agents I-group
: O
Although O
ipratropium B-drug
bromide I-drug
is O
minimally O
absorbed O
into O
the O
systemic O
circulation O
, O
there O
is O
some O
potential O
for O
an O
additive O
interaction O
with O
concomitantly O
used O
anticholinergic B-group
medications I-group
. O

Preliminary O
animal O
and O
human O
studies O
have O
shown O
that O
small O
quantities O
of O
systemically O
administered O
leucovorin B-drug
enter O
the O
CSF O
primarily O
as O
5-methyltetrahydro-folate O
and O
, O
in O
humans O
, O
remain O
1 O
to O
3 O
orders O
of O
magnitude O
lower O
than O
the O
usual O
methotrexate B-drug
concentrations O
following O
intrathecal O
administration O
. O

THE O
POTENTIATING O
ACTION O
OF O
HYDROXYZINE B-drug
MUST O
BE O
CONSIDERED O
WHEN O
THE O
DRUG O
IS O
USED O
IN O
CONJUNCTION O
WITH O
CENTRAL B-group
NERVOUS I-group
SYSTEM I-group
DEPRESSANTS I-group
SUCH O
AS O
NARCOTICS B-group
, O
NON-NARCOTIC B-group
ANALGESICS I-group
AND O
BARBITURATES B-group
. O

Cholestyramine B-drug
increases O
enterohepatic O
elimination O
of O
amiodarone B-drug
and O
may O
reduce O
its O
serum O
levels O
and O
t1/2 B-drug
. O

Patients O
receiving O
these O
drugs O
in O
combination O
with O
zalcitabine B-drug
should O
be O
monitored O
for O
signs O
of O
toxicity O
and O
the O
dose O
of O
zalcitabine B-drug
reduced O
if O
warranted O
. O

. O

Thiazides B-group
: O
Thiazides B-group
are O
known O
to O
induce O
hypercalcemia O
by O
the O
reduction O
of O
calcium B-drug
excretion O
in O
urine O
. O

The O
drugs O
may O
, O
however O
, O
be O
administered O
alternately O
provided O
a O
proper O
interval O
has O
elapsed O
between O
doses O
. O

Data O
suggest O
that O
coadministration O
of O
oral O
ketoconazole B-drug
and O
cisapride B-drug
can O
result O
in O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O

. O

The O
plasma O
concentration O
of O
CMI B-drug
has O
been O
reported O
to O
be O
increased O
by O
the O
concomitant O
administration O
of O
haloperidol B-drug
; O

In O
vitro O
studies O
have O
shown O
that O
naproxen B-drug
anion O
, O
because O
of O
its O
affinity O
for O
protein O
, O
may O
displace O
from O
their O
binding O
sites O
other O
drugs O
which O
are O
also O
albumin-bound O
. O

Caution O
should O
be O
exercised O
when O
these O
2 O
agents O
are O
coadministered O
. O

In O
the O
case O
of O
digoxin B-drug
, O
serum O
levels O
should O
be O
monitored O
. O

Ranitidine B-drug
150 O
mg O
twice O
daily O
did O
not O
interact O
significantly O
with O
nisoldipine B-drug
( O
AUC O
was O
decreased O
by O
15-20 O
% O
) O
. O

Therefore O
, O
in O
patients O
taking O
VIOXX B-brand
, O
antiplatelet O
therapies O
should O
not O
be O
discontinued O
and O
should O
be O
considered O
in O
patients O
with O
an O
indication O
for O
cardiovascular O
prophylaxis O
. O

Co-administration O
of O
bosentan B-drug
decreased O
the O
plasma O
concentrations O
of O
cyclosporine B-drug
A I-drug
( O
a O
CYP3A4 O
substrate O
) O
by O
approximately O
50 O
% O
. O

Diuretics B-group
: O
Diclofenac B-drug
and O
other O
NSAIDs B-group
can O
inhibit O
the O
activity O
of O
diuretics B-group
. O

Clinical O
experience O
with O
concomitant O
administration O
of O
bosentan B-drug
and O
warfarin B-drug
in O
patients O
with O
pulmonary O
arterial O
hypertension O
did O
not O
show O
clinically O
relevant O
changes O
in O
INR O
or O
warfarin B-drug
dose O
( O
baseline O
vs. O
end O
of O
the O
clinical O
studies O
) O
, O
and O
the O
need O
to O
change O
the O
warfarin B-drug
dose O
during O
the O
trials O
due O
to O
changes O
in O
INR O
or O
due O
to O
adverse O
events O
was O
similar O
among O
bosentan- B-drug
and O
placebo-treated O
patients O
. O

This O
included O
post O
myocardial O
infarction O
patients O
who O
were O
receiving O
intravenous O
or O
transdermal O
nitroglycerin B-drug
. O

Potentiation O
of O
the O
hypotensive O
effects O
of O
nitrates B-group
for O
patients O
with O
ischemic O
heart O
disease O
has O
not O
been O
evaluated O
, O
and O
concomitant O
use O
of O
Vardenafil B-drug
and O
nitrates B-group
is O
contraindicated O
. O

sulindac B-drug
; O

. O

No O
differences O
in O
safety O
or O
efficacy O
were O
observed O
between O
older O
and O
younger O
patients O
, O
but O
there O
were O
not O
sufficient O
data O
to O
exclude O
important O
differences O
. O

Increased O
thyroid-binding O
globulin O
( O
TBG O
) O
levels O
leading O
to O
increased O
circulating O
total O
thyroid O
hormone O
levels O
as O
measured O
by O
protein-bound O
iodine B-drug
( O
PBI O
) O
, O
T4 O
levels O
( O
by O
column O
or O
by O
radioimmunoassay O
) O
or O
T3 O
levels O
by O
radioimmunoassay O
. O

Bosentan B-drug
is O
also O
expected O
to O
reduce O
plasma O
concentrations O
of O
other O
oral O
hypoglycemic B-group
agents I-group
that O
are O
predominantly O
metabolized O
by O
CYP2C9 O
or O
CYP3A4 O
. O

2 O
. O

In O
vitro O
data O
suggest O
that O
itraconazole B-drug
, O
when O
compared O
to O
ketoconazole B-drug
, O
has O
a O
less O
pronounced O
effect O
on O
the O
biotransformation O
system O
responsible O
for O
the O
metabolism O
of O
astemizole B-drug
. O

These O
data O
suggest O
the O
modified O
histidine O
residues O
on O
toxin B-drug_n
A I-drug_n
are O
critical O
to O
its O
cytotoxic O
activity O
. O

Misonidazole B-drug_n
has O
a O
complex O
effect O
on O
oral O
CCNU B-drug
pharmacokinetics O
. O

Free O
T4 O
and O
free O
T3 O
concentrations O
are O
unaltered O
. O

Alcohol B-drug
: O
It O
should O
be O
borne O
in O
mind O
that O
alcohol B-drug
ingestion O
may O
increase O
the O
danger O
inherent O
in O
any O
intentional O
or O
unintentional O
SINEQUAN B-brand
overdosage O
. O

A O
similar O
effect O
would O
be O
expected O
with O
eszopiclone B-drug
. O

Plasma O
concentrations O
decreased O
by O
SUSTIVA B-brand
; O

The O
effect O
may O
be O
mediated O
by O
the O
known O
inhibition O
of O
cimetidine B-drug
on O
hepatic O
cytochrome O
P-450 O
, O
the O
enzyme O
system O
probably O
responsible O
for O
the O
first-pass O
metabolism O
of O
nifedipine B-drug
. O

No O
formal O
drug-interaction O
studies O
have O
been O
performed O
, O
and O
a O
clinically O
significant O
interaction O
with O
other O
medications O
used O
in O
the O
treatment O
of O
hypoxic O
respiratory O
failure O
can O
not O
be O
excluded O
based O
on O
the O
available O
data O
. O

unreliable O
prothrombin O
time O
determinations O
; O

Since O
etodolac B-drug
has O
a O
well-defined O
pharmacokinetic-pharmacodynamic O
relationship O
, O
measurement O
of O
pharmacokinetic O
parameters O
is O
clinically O
relevant O
. O

Core O
temperature O
was O
decreased O
in O
rats O
in O
a O
dose-dependent O
manner O
when O
ethanol B-drug
was O
administered O
to O
rats O
treated O
with O
disulfiram B-drug
8 O
hours O
before O
the O
ethanol B-drug
challenge O
. O

Other O
drug O
interactions O

These O
drugs O
include O
the O
thiazides B-group
and O
other O
diuretics B-group
, O
corticosteroids B-group
, O
phenothiazines B-group
, O
thyroid O
products O
, O
estrogens B-group
, O
oral O
contraceptives B-group
, O
phenytoin B-drug
, O
nicotinic B-drug
acid I-drug
, O
sympathomimetics B-group
, O
calcium B-group
channel I-group
blocking I-group
drugs I-group
, O
and O
isoniazid B-drug
. O

When O
you O
are O
using O
idoxuridine B-drug
, O
it O
is O
especially O
important O
that O
your O
health O
care O
professional O
know O
if O
you O
are O
using O
the O
following O
: O
Eye O
product O
containing O
boric B-drug
acid I-drug
. O

Rifabutin B-drug
did O
not O
significantly O
affect O
amprenavir B-drug
's O
pharmacokinetics O
. O

an O
oral O
200 O
mg O
dose O
achieves O
a O
highest O
level O
of O
approximately O
5 O
uM O
in O
people O
) O
; O

These O
drugs O
should O
not O
be O
given O
concomitantly O
. O

The O
mechanisms O
of O
metal O
toxicity O
to O
miracidia O
are O
briefly O
discussed O
. O

Dolasetron B-drug
does O
not O
influence O
anesthesia O
recovery O
time O
in O
patients O
. O

Co-administration O
of O
TIKOSYN B-brand
with O
verapamil B-drug
resulted O
in O
increases O
in O
dofetilide B-drug
peak O
plasma O
levels O
of O
42 O
% O
, O
although O
overall O
exposure O
to O
dofetilide B-drug
was O
not O
significantly O
increased O
. O

Theophylline B-drug
decreased O
the O
binding O
of O
acetaminophen B-drug
by O
a O
net O
change O
of O
6.8 O
% O
( O
percentage O
increase O
in O
FDF O
, O
8.8 O
% O
) O
at O
277.5 O
micromol/L O
; O

This O
small O
decrease O
in O
excretion O
of O
gabapentin B-drug
by O
cimetidine B-drug
is O
not O
expected O
to O
be O
of O
clinical O
importance O
. O

The O
average O
infusion O
rate O
requirement O
may O
be O
decreased O
by O
as O
much O
as O
30 O
% O
to O
40 O
% O
. O

This O
report O
describes O
two O
cases O
in O
which O
theophylline B-drug
clearance O
accelerated O
markedly O
with O
concomitant O
phenytoin B-drug
administration O
. O

Minimum O
inhibitory O
concentrations O
( O
MICs O
) O
and O
viable O
counts O
were O
determined O
in O
Iso-sensitest O
broth O
using O
a O
microtitre O
method O
. O

Consequently O
, O
caution O
is O
advised O
if O
the O
concomitant O
administration O
of O
REVIA B-brand
and O
other O
drugs O
is O
required O
. O

Sinus O
bradycardia O
has O
been O
reported O
with O
oral O
amiodarone B-drug
in O
combination O
with O
lidocaine B-drug
( O
CYP3A4 B-drug
substrate O
) O
given O
for O
local O
anesthesia B-drug
. O

Need O
for O
more O
inhalations O
than O
usual O
of O
short-acting B-group
, I-group
inhaled I-group
beta2-agonists I-group
. O

The O
clinical O
significance O
of O
these O
changes O
is O
unknown O
. O

Cimetidine B-drug
at O
doses O
of O
100 O
mg O
BID O
( O
OTC O
dose O
) O
resulted O
in O
a O
13 O
% O
increase O
in O
dofetilide B-drug
plasma O
levels O
( O
500 O
mcg O
single O
dose O
) O
. O

Blood O
levels O
of O
hydrodolasetron B-drug_n
increased O
24 O
% O
when O
dolasetron B-drug
was O
coadministered O
with O
cimetidine B-drug
( O
nonselective O
inhibitor O
of O
cytochrome O
P-450 O
) O
for O
7 O
days O
, O
and O
decreased O
28 O
% O
with O
coadministration O
of O
rifampin B-drug
( O
potent O
inducer O
of O
cytochrome O
P-450 O
) O
for O
7 O
days O
. O

Rifabutin B-drug
, O
another O
rifamycin B-drug
, O
is O
structurally O
similar O
to O
rifampin B-drug
and O
may O
possibly O
have O
some O
of O
the O
same O
drug O
interactions O
as O
rifampin B-drug
. O

Binding O
to O
plasma O
proteins O
is O
reduced O
by O
warfarin B-drug
and O
clotibrate O
and O
increased O
by O
tolbutamide B-drug
. O

( O
600 O
mg O
Q12h O
) O

Cisapride B-drug
is O
metabolized O
mainly O
via O
the O
cytochrome O
P450 O
3A4 O
enzyme O
. O

The O
clinical O
significance O
of O
this O
increased O
bioavailability O
and O
whether O
similar O
increases O
will O
occur O
in O
patients O
given O
oral O
H2-antagonists B-group
is O
unknown O
; O

The O
clinical O
significance O
of O
this O
interaction O
is O
not O
known O
; O

Literature O
reports O
indicate O
that O
coadministration O
of O
indomethacin B-drug
may O
reduce O
the O
natriuretic O
and O
antihypertensive O
effects O
of O
furosemide B-drug
in O
some O
patients O
by O
inhibiting O
prostaglandin O
synthesis O
. O

Drug O
regimens O
in O
patients O
with O
cardiovascular O
disease O
are O
frequently O
complex O
and O
can O
be O
significantly O
affected O
by O
alterations O
in O
renal O
function O
. O

SUBUTEX B-brand
and O
SUBOXONE B-brand
should O
be O
prescribed O
with O
caution O
to O
patients O
on O
benzodiazepines B-group
or O
other O
drugs O
that O
act O
on O
the O
central O
nervous O
system O
, O
regardless O
of O
whether O
these O
drugs O
are O
taken O
on O
the O
advice O
of O
a O
physician O
or O
are O
taken O
as O
drugs O
of O
abuse O
. O

The O
effect O
of O
digoxin B-drug
on O
Exjade B-brand
pharmacokinetics O
has O
not O
been O
studied O
. O

The O
antimicrobial O
combinations O
of O
GL B-drug_n
with O
four O
antibiotics B-group
resulted O
in O
additive O
effect O
in O
most O
instances O
, O
synergism O
in O
two O
instances O
, O
and O
antagonism O
in O
two O
instances O
. O

The O
pharmacokinetics O
of O
a O
1-mg O
dose O
of O
butorphanol B-drug
administered O
as O
STADOL B-brand
NS I-brand
were O
not O
affected O
by O
the O
coadministration O
of O
cimetidine B-drug
( O
300 O
mg O
QID O
) O
. O

In O
post-marketing O
experience O
, O
bleeding O
events O
have O
been O
reported O
, O
predominantly O
in O
the O
elderly O
, O
in O
association O
with O
increases O
in O
prothrombin O
time O
in O
patients O
receiving O
VIOXX B-brand
concurrently O
with O
warfarin B-drug
. O

Interactions O
between O
treatments O
with O
coumaphos B-drug_n
, O
bishydroxycoumarin B-drug
( O
an O
anticoagulant B-group
) O
, O
trichlorfon B-drug_n
( O
an O
organophosphorous B-group
compound I-group
) O
, O
and O
phenobarbital B-drug
sodium I-drug
( O
an O
inducer O
of O
microsomal O
enzymes O
) O
were O
investigated O
in O
sheep O
. O

Clinical O
comments O
about O
possible O
dosage O
modifications O
based O
on O
these O
pharmacokinetic O
changes O
are O
listed O
in O
Table O
3 O
. O

In O
contrast O
, O
in O
isolated O
single O
pancreatic O
acinar O
cells O
, O
RR B-drug_n
had O
no O
effect O
on O
InsP B-drug_n
( I-drug_n
3 I-drug_n
) I-drug_n
-induced O
responses O
. O

Other O
No O
clinically O
important O
pharmacokinetic O
interactions O
occurred O
when O
Lotensin B-brand
was O
administered O
concomitantly O
with O
hydrochlorothiazide B-drug
, O
chlorthalidone B-drug
, O
furosemide B-drug
, O
digoxin B-drug
, O
propranolol B-drug
, O
atenolol B-drug
, O
naproxen B-drug
, O
or O
cimetidine B-drug
. O

These O
differences O
were O
reflected O
in O
the O
roughly O
twofold O
greater O
antitumour O
activity O
for O
the O
oral O
route O
. O

ISUPREL B-brand
should O
be O
used O
with O
caution O
, O
if O
at O
all O
, O
when O
potent O
inhalational O
anesthetics B-group
such O
as O
halothane B-drug
are O
employed O
because O
of O
potential O
to O
sensitize O
the O
myocardium O
to O
effects O
of O
sympathomimetic B-group
amines I-group
. O

Drugs O
Metabolized O
by O
P450 O
2D6 O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
caucasian O
population O
( O
about O
7 O
to O
10 O
% O
of O
caucasians O
are O
so O
called O
poor O
metabolizers O
) O
; O

Conversely O
, O
the O
coumarin B-group
anticoagulants I-group
have O
been O
reported O
to O
increase O
the O
serum O
levels O
and O
prolong O
the O
serum O
half-life O
of O
phenytoin B-drug
by O
inhibiting O
its O
metabolism O
. O

Antinociception O
was O
measured O
by O
the O
hot-plate O
method O
. O

The O
possibility O
of O
worsened O
glucose O
control O
in O
patients O
using O
these O
agents O
should O
be O
considered O
. O

Catecholamine-depleting B-group
drugs I-group
, O
such O
as O
reserpine B-drug
, O
may O
have O
an O
additive O
effect O
when O
given O
with O
beta-blocking B-group
agents I-group
. O

Antacids B-group
or O
H B-group
2 I-group
-receptor I-group
antagonists I-group
: O
The O
effect O
of O
increased O
gastric O
pH O
on O
the O
bioavailability O
of O
ceftibuten B-drug
was O
evaluated O
in O
18 O
healthy O
adult O
volunteers O
. O

In O
vitro O
and O
in O
vivo O
studies O
have O
shown O
that O
esomeprazole B-drug
is O
not O
likely O
to O
inhibit O
CYPs O
1A2 O
, O
2A6 O
, O
2C9 O
, O
2D6 O
, O
2E1 O
and O
3A4 O
. O

The O
use O
of O
antacids B-group
should O
be O
considered O
in O
place O
of O
H2 B-group
blockers I-group
or O
proton B-group
pump I-group
inhibitors I-group
in O
patients O
receiving O
SPRYCEL B-brand
therapy O
. O

No O
significant O
drug O
interactions O
have O
been O
reported O
in O
studies O
of O
candesartan B-drug
cilexetil I-drug
given O
with O
other O
drugs O
such O
as O
glyburide B-drug
, O
nifedipine B-drug
, O
digoxin B-drug
, O
warfarin B-drug
, O
hydrochlorothiazide B-drug
, O
and O
oral O
contraceptives B-group
in O
healthy O
volunteers O
, O
or O
given O
with O
enalapril B-drug
to O
patients O
with O
heart O
failure O
( O
NYHA O
class O
II O
and O
III O
) O
. O

Potential O
pharmacokinetic O
interactions O
were O
assessed O
in O
clinical O
pharmacokinetic O
studies O
( O
phenytoin B-drug
, O
valproate B-drug
, O
oral O
contraceptive B-group
, O
digoxin B-drug
, O
warfarin B-drug
, O
probenecid B-drug
) O
and O
through O
pharmacokinetic O
screening O
in O
the O
placebo-controlled O
clinical O
studies O
in O
epilepsy O
patients O
. O

N=13 O
) O
. O

Concomitant O
use O
of O
bupropion B-drug
with O
other O
drugs O
metabolized O
by O
CYP2D6 O
has O
not O
been O
formally O
studied O
. O

Warfarin B-drug
: O
The O
effects O
of O
warfarin B-drug
and O
NSAIDs B-group
on O
GI O
bleeding O
are O
synergistic O
, O
such O
that O
users O
of O
both O
drugs O
together O
have O
a O
risk O
of O
serious O
GI O
bleeding O
higher O
than O
that O
of O
users O
of O
either O
drug O
alone O
. O

Systemic O
exposure O
to O
acetaminophen B-drug
is O
expected O
to O
be O
increased O
when O
coadministered O
with O
Gleevec B-brand
. O

If O
such O
drugs O
are O
used O
they O
should O
be O
administered O
with O
an O
interval O
of O
at O
least O
5 O
minutes O
between O
applications O
. O

Others O
reported O
: O
Neuropsychiatric O
: O
Confusion O
( O
1-11 O
% O
) O
, O
headache O
( O
4-8 O
% O
) O
, O
insomnia O
( O
2-7 O
% O
) O
; O

Effects O
of O
sympathomimetics B-group
are O
increased O
with O
MAO B-group
inhibitors I-group
and O
beta B-group
adrenergic I-group
blockers I-group
. O

Other O
Cardiovascular O
Agents O
: O
Enalapril B-drug
and O
enalapril B-drug
IV O
have O
been O
used O
concomitantly O
with O
beta B-group
adrenergic-blocking I-group
agents I-group
, O
methyldopa B-drug
, O
nitrates B-group
, O
calcium-blocking B-group
agents I-group
, O
hydralazine B-drug
, O
prazosin B-drug
and O
digoxin B-drug
without O
evidence O
of O
clinically O
significant O
adverse O
interactions O
. O

The O
co-administration O
of O
Natrecor B-brand
with O
IV O
vasodilators B-group
such O
as O
nitroglycerin B-drug
, O
nitroprusside B-drug
, O
milrinone B-drug
, O
or O
IV O
ACE B-group
inhibitors I-group
has O
not O
been O
evaluated O
( O
these O
drugs O
were O
not O
co-administered O
with O
Natrecor B-brand
in O
clinical O
trials O
) O
. O

Ketoconazole B-drug

The O
contribution O
of O
each O
of O
the O
treatments O
to O
this O
adverse O
reaction O
is O
unknown O
but O
the O
possibility O
of O
a O
drug O
interaction O
can O
not O
be O
excluded O
. O

v. O
Patients O
should O
be O
cautioned O
regarding O
potential O
adverse O
cardiovascular O
effects O
, O
such O
as O
palpitations O
or O
chest O
pain O
. O

Research O
has O
shown O
that O
herbal O
remedy O
use O
may O
be O
associated O
with O
acute O
renal O
failure O
. O

Because O
oral O
anticoagulants B-group
may O
interfere O
with O
the O
hepatic O
metabolism O
of O
phenytoin B-drug
, O
toxic O
levels O
of O
the O
anticonvulsant B-group
may O
occur O
when O
an O
oral O
anticoagulant B-group
and O
phenytoin B-drug
are O
administered O
concurrently O
. O

Irinotecan B-drug
concentrations O
were O
similar O
in O
patients O
receiving O
bolus-IFL O
alone O
and O
in O
combination O
with O
AVASTIN B-brand
. O

Possible O
drug O
interactions O
of O
HUMORSOL B-brand
with O
succinylcholine B-drug
or O
with O
other O
anticholinesterase B-group
agents I-group
. O

The O
interaction O
of O
Activase B-brand
with O
other O
cardioactive O
or O
cerebroactive O
drugs O
has O
not O
been O
studied O
. O

Concurrent O
use O
of O
tetracyclines B-group
with O
oral O
contraceptives B-group
may O
render O
oral O
contraceptives B-group
less O
effective O
. O

600-1800 O

Insulin B-drug
: O
A O
clinical O
study O
in O
6 O
insulin-dependent O
diabetic O
patients O
demonstrated O
no O
effect O
of O
EXTRANEAL B-brand
on O
insulin B-drug
absorption O
from O
the O
peritoneal O
cavity O
or O
on O
insulins B-drug
ability O
to O
control O
blood O
glucose O
when O
insulin B-drug
was O
administered O
intraperitoneally O
with O
EXTRANEAL B-brand
. O

indinavir I-drug
concentration O

Imipramine B-drug
( O
5 O
mg/kg O
) O
, O
moclobemide B-drug
( O
30 O
mg/kg O
) O
, O
clonazepam B-drug
( O
0.25 O
mg/kg O
) O
, O
fluoxetine B-drug
( O
20 O
mg/kg O
) O
sertraline B-drug
( O
30 O
mg/kg O
) O
or O
vehicle O
was O
administered O
. O

The O
LST O
mice O
did O
not O
show O
any O
changes O
in O
the O
Kd O
and O
Bmax O
in O
either O
the O
STR O
or O
the O
NAC O
. O

When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
MICRONASE B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
loss O
of O
control O
. O

There O
is O
evidence O
that O
the O
use O
of O
halofantrine B-drug
after O
Mefloquineuine O
causes O
a O
significant O
lengthening O
of O
the O
QTc O
interval O
. O

Systemic O
clonidine B-drug
may O
inhibit O
the O
production O
of O
catecholamines O
in O
response O
to O
insulin-induced O
hypoglycemia O
and O
mask O
the O
signs O
and O
symptoms O
of O
hypoglycemia O
. O

therefore O
, O
plasma O
concentrations O
of O
phenytoin B-drug
should O
also O
be O
monitored O
when O
it O
is O
given O
concurrently O
with O
Itraconazole B-drug
. O

While O
18-MC B-drug_n
and O
ibogaine B-drug_n
have O
similar O
affinities O
for O
kappa O
opioid O
and O
possibly O
nicotinic O
receptors O
, O
18-MC B-drug_n
has O
much O
lower O
affinities O
than O
ibogaine B-drug_n
for O
NMDA O
and O
sigma-2 O
receptors O
, O
sodium O
channels O
, O
and O
the O
5-HT O
transporter O
. O

The O
specific O
objectives O
of O
this O
study O
were O
to O
elucidate O
metal O
toxicity O
to O
hatching O
, O
survival O
and O
avoidance O
behaviour O
of O
Schistosoma O
mansoni O
miracidia O
. O

Although O
the O
relevance O
of O
these O
reports O
and O
any O
mechanism O
of O
coagulation O
alterations O
is O
unclear O
, O
patients O
on O
warfarin B-drug
should O
have O
their O
prothrombin O
time O
monitored O
. O

( O
Thiazide B-group
diuretics I-group
may O
raise O
the O
level O
of O
blood O
uric O
acid O
; O

A O
conservative O
approach O
to O
dosing O
felodipine B-drug
should O
be O
taken O
. O

the O
disulfiram B-drug
should O
be O
discontinued O
if O
such O
signs O
appear O
. O

This O
may O
increase O
or O
enhance O
the O
occurrence O
of O
osteomalacia O
in O
some O
patients O
receiving O
chronic O
phenytoin B-drug
therapy O
. O

Glucose B-drug
and O
insulin B-drug
exert O
additive O
ocular O
and O
renal O
vasodilator O
effects O
on O
healthy O
humans O
. O

The O
rate O
of O
metabolism O
and O
the O
leukopenic O
activity O
of O
cyclophosphamide B-drug
reportedly O
are O
increased O
by O
chronic O
administration O
of O
high O
doses O
of O
phenobarbital B-drug
. O

Exjade B-brand
should O
not O
be O
combined O
with O
other O
iron O
chelator O
therapies O
, O
as O
safety O
of O
such O
combinations O
has O
not O
been O
established O
. O

the O
remainder O
were O
of O
uncertain O
cause O
. O

In O
occasional O
susceptible O
patients O
or O
in O
those O
receiving O
anticholinergic B-group
drugs I-group
( O
including O
antiparkinsonism O
agents O
) O
in O
addition O
, O
the O
atropine-like O
effects O
may O
become O
more O
pronounced O
( O
e.g. O
, O
paralytic O
ileus O
) O
. O

Thioridazine B-drug
: O
Coadministration O
of O
single O
doses O
of O
Sonata B-brand
20 O
mg O
and O
thioridazine B-drug
50 O
mg O
produced O
additive O
effects O
on O
decreased O
alertness O
and O
impaired O
psychomotor O
performance O
for O
2 O
to O
4 O
hours O
after O
administration O
. O

Pharmacology O
and O
pharmacotherapy O
of O
cardiovascular O
drugs O
in O
patients O
with O
chronic O
renal O
disease O
. O

No O
drug O
interactions O
have O
been O
identified O
. O

Motility O
agents O

No O
Important O
Interactions O
To O
Date O
Levosimendan B-drug
does O
not O
have O
clinically O
important O
pharmacokinetic O
interactions O
with O
captopril B-drug
, O
beta-blockers B-group
, O
felodipine B-drug
, O
digoxin B-drug
, O
warfarin B-drug
, O
isosorbide B-drug
mononitrate I-drug
, O
carvedilol B-drug
, O
ethanol B-drug
or O
itraconazole B-drug
. O

Selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
( O
e.g. O
, O
fluoxetine B-drug
, O
fluvoxamine B-drug
, O
paroxetine B-drug
, O
sertraline B-drug
) O
have O
been O
reported O
, O
rarely O
, O
to O
cause O
weakness O
, O
hyperreflexia O
, O
and O
incoordination O
when O
coadministered O
with O
5-HTv O
agonists O
. O

1 O
hour O
after O
starting O
the O
oxycodone B-drug
or O
levofloxacin B-drug
500 O
mg O
p.o O
. O

Vitamin B-group
A I-group
and O
oral O
retinoids B-group
: O
Concomitant O
administration O
of O
vitamin B-group
A I-group
and/or O
other O
oral O
retinoids B-group
with O
acitretin B-drug
must O
be O
avoided O
because O
of O
the O
risk O
of O
hypervitaminosis O
A O
. O

Drug/Laboratory O
Test O
Interactions O
: O
Amphetamines B-group
can O
cause O
a O
significant O
elevation O
in O
plasma O
corticosteroid O
levels O
. O

In O
addition O
, O
higher-than O
expected O
steady-state O
serum O
concentrations O
of O
tricyclic B-group
antidepressants I-group
have O
been O
observed O
when O
therapy O
is O
initiated O
in O
patients O
already O
taking O
cimetidine B-drug
. O

However O
, O
higher O
plasma O
concentrations O
of O
AMICAR B-brand
may O
occur O
in O
patients O
with O
severe O
renal O
failure O
. O

During O
concomitant O
therapy O
with O
ibuprofen B-drug
, O
the O
patient O
should O
be O
observed O
closely O
for O
signs O
of O
renal O
failure O
, O
as O
well O
as O
to O
assure O
diuretic B-group
efficacy O
. O

Antifungal B-group
Agents I-group

Cisapride B-drug
should O
not O
be O
used O
concomitantly O
with O
other O
drugs O
known O
to O
prolong O
the O
QT O
interval O
: O
certain O
antiarrhythmics B-group
, O
including O
those O
of O
Class O
IA O
( O
such O
as O
quinidine B-drug
and O
procainamide B-drug
) O
and O
Class O
III O
( O
such O
as O
sotalol B-drug
) O
; O

therefore O
, O
coadministration O
of O
Aprepitant B-drug
with O
drugs O
that O
strongly O
induce O
CYP3A4 O
activity O
( O
e.g. O
, O
rifampin B-drug
, O
carbamazepine B-drug
, O
phenytoin B-drug
) O
may O
result O
in O
reduced O
plasma O
concentrations O
of O
aprepitant B-drug
that O
may O
result O
in O
decreased O
efficacy O
of O
Aprepitant B-drug
. O

Warfarin B-drug
: O
Anticoagulant O
activity O
should O
be O
monitored O
, O
particularly O
in O
the O
first O
few O
days O
after O
initiating O
or O
changing O
VIOXX B-brand
therapy O
in O
patients O
receiving O
warfarin B-drug
or O
similar O
agents O
, O
since O
these O
patients O
are O
at O
an O
increased O
risk O
of O
bleeding O
complications O
. O

Although O
beta-adrenergic B-group
blockers I-group
or O
calcium B-group
channel I-group
blockers I-group
and O
digoxin B-drug
may O
be O
useful O
in O
combination O
to O
control O
atrial O
fibrillation O
, O
their O
additive O
effects O
on O
AV O
node O
conduction O
can O
result O
in O
advanced O
or O
complete O
heart O
block O
. O

subjects O
. O

No O
specific O
information O
available O

It O
is O
proposed O
that O
the O
phosphohydrolase O
becomes O
metabolically O
active O
when O
it O
combines O
with O
membranes O
and O
that O
polyamines O
might O
help O
to O
regulate O
this O
interaction O
. O

These O
results O
suggest O
that O
both O
dexamethasone B-drug
and O
retinyl B-drug
acetate I-drug
, O
and O
possibly O
other O
glucocorticoids B-group
and O
retinoids B-group
, O
may O
regulate O
the O
proliferation O
of O
prostate O
epithelium O
by O
a O
dose-dependent O
modification O
of O
the O
activity O
of O
insulin B-drug
and O
EGF B-drug_n
. O

Neurochemical O
and O
functional O
consequences O
following O
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine B-drug_n
( O
MPTP B-drug_n
) O
and O
methamphetamine B-drug
. O

There O
are O
few O
data O
regarding O
the O
coadministration O
of O
radiation O
therapy O
and O
epirubicin B-drug
. O

Cimetidine B-drug
increased O
the O
AUC O
of O
epirubicin B-drug
by O
50 O
% O
. O

TRACRIUM B-brand
should O
not O
be O
administered O
until O
a O
patient O
has O
recovered O
from O
succinylcholine-induced B-drug
neuromuscular O
block O
. O

We O
conclude O
that O
the O
prophylactic O
and O
antidotal O
properties O
of O
4-methylpyrazole B-drug
seen O
in O
animals O
treated O
with O
1,3-difluoro-2-propanol B-drug_n
derive O
from O
its O
capacity O
to O
inhibit O
the O
NAD+-dependent O
oxidation O
responsible O
for O
converting O
1,3-difluoro-2-propanol B-drug_n
to O
1,3-difluoroacetone B-drug_n
in O
the O
committed O
step O
of O
the O
toxic O
pathway O
. O

No O
drugs O
are O
known O
to O
interfere O
with O
the O
conversion O
of O
fosphenytoin B-drug
to O
phenytoin B-drug
. O

Patients O
receiving O
concomitant O
lovastatin B-drug
and O
erythromycin B-drug
should O
be O
carefully O
monitored O
; O

Combination O
Therapy O
: O
Any O
form O
of O
therapy O
which O
adds O
to O
the O
stress O
of O
the O
patient O
, O
interferes O
with O
nutrition O
or O
depresses O
bone O
marrow O
function O
will O
increase O
the O
toxicity O
of O
Floxuridine B-drug
. O

The O
1-year O
risk O
of O
relapse O
( O
rehospitalisation O
) O
was O
significantly O
lower O
with O
olanzapine B-drug
than O
with O
haloperidol B-drug
treatment O
. O

Vitamin B-group
A I-group
: O
Because O
of O
the O
relationship O
of O
Accutane B-brand
to O
vitamin B-group
A I-group
, O
patients O
should O
be O
advised O
against O
taking O
vitamin B-group
supplements I-group
containing O
vitamin B-group
A I-group
to O
avoid O
additive O
toxic O
effects O

similar O
events O
have O
been O
reported O
in O
patients O
taking O
other O
psychotropic B-group
drugs I-group
or O
even O
Clozapine B-drug
by O
itself O
. O

In O
EM O
individuals O
treated O
with O
paroxetine B-drug
or O
fluoxetine B-drug
, O
the O
AUC O
of O
atomoxetine B-drug
is O
approximately O
6- O
to O
8-fold O
and O
Css O
, O
max O
is O
about O
3- O
to O
4-fold O
greater O
than O
atomoxetine B-drug
alone O
. O

The O
risk O
of O
using O
bromocriptine B-drug
mesylate I-drug
in O
combination O
with O
other O
drugs O
has O
not O
been O
systematically O
evaluated O
, O
but O
alcohol B-drug
may O
potentiate O
the O
side O
effects O
of O
bromocriptine B-drug
mesylate I-drug
. O

Fatalities O
have O
been O
reported O
. O

However O
, O
retinyl B-drug
acetate I-drug
stimulated O
, O
but O
did O
not O
significantly O
inhibit O
, O
proliferation O
in O
the O
presence O
of O
insulin B-drug
. O

In O
a O
study O
in O
which O
the O
2 O
mg O
clonazepam B-drug
orally O
disintegrating O
tablet O
was O
administered O
with O
and O
without O
propantheline B-drug
( O
an O
anticholinergic B-group
agent I-group
with O
multiple O
effects O
on O
the O
GI O
tract O
) O
to O
healthy O
volunteers O
, O
the O
AUC O
of O
clonazepam B-drug
was O
10 O
% O
lower O
and O
the O
Cmax O
of O
clonazepam B-drug
was O
20 O
% O
lower O
when O
the O
orally O
disintegrating O
tablet O
was O
given O
with O
propantheline B-drug
compared O
to O
when O
it O
was O
given O
alone O
. O

Agents O
Increasing O
Serum O
Potassium O
: O
Enalapril B-drug
and O
enalapril B-drug
IV O
attenuate O
potassium O
loss O
caused O
by O
thiazide-type B-group
diuretics I-group
. O

4 O
. O

Protease B-group
inhibitors I-group
: O
Amprenavir B-drug
, O
lopinavir B-drug
, O
nelfinavir B-drug
, O
and O
ritonavir B-drug
have O
been O
shown O
to O
decrease O
plasma O
levels O
of O
combination B-group
hormonal I-group
contraceptives I-group
; O

The O
effect O
of O
a O
higher O
ketoconazole B-drug
dose O
( O
400 O
mg/day O
) O
has O
not O
been O
studied O
. O

Although O
clinical O
studies O
have O
not O
been O
performed O
, O
based O
on O
the O
involvement O
of O
the O
cytochrome O
P-450 O
3A O
family O
in O
clonazepam B-drug
metabolism O
, O
inhibitors O
of O
this O
enzyme O
system O
, O
notably O
oral O
antifungal B-group
agents I-group
, O
should O
be O
used O
cautiously O
in O
patients O
receiving O
clonazepam B-drug
. O

Carbamazepine B-drug
, O
clonazepam B-drug
, O
ethosuximide B-drug

As O
a O
result O
, O
when O
giving O
these O
drugs O
concomitantly O
, O
plasma O
warfarin B-drug
levels O
may O
change O
with O
the O
potential O
for O
increases O
in O
coagulation O
time O
. O

Ritonavir B-drug
: O
Coadministration O
of O
ritonavir B-drug
with O
VIRACEPT B-brand
resulted O
in O
a O
152 O
% O
increase O
in O
nelfinavir B-drug
plasma O
AUC O
and O
very O
little O
change O
in O
ritonavir B-drug
plasma O
A.C O
. O

These O
usually O
clear O
within O
a O
week O
, O
leaving O
only O
the O
" O
drug O
hunger O
" O

- O
Although O
not O
a O
true O
drug O
interaction O
, O
tricyclic B-group
antidepressants I-group
may O
precipitate O
seizures O
in O
susceptible O
patients O
and O
Cerebyx B-brand
dosage O
may O
need O
to O
be O
adjusted O

Selective B-group
Serotonin I-group
Reuptake I-group
Inhibitors I-group
( O
SSRIs B-group
) O
: O
SSRIs B-group
( O
e.g. O
, O
fluoxetine B-drug
, O
fluvoxamine B-drug
, O
paroxetine B-drug
, O
sertraline B-drug
) O
have O
been O
rarely O
reported O
to O
cause O
weakness O
, O
hyperreflexia O
, O
and O
incoordination O
when O
coadministered O
with O
5-HT1 B-group
agonists I-group
. O

Lamivudine B-drug
is O
predominantly O
eliminated O
in O
the O
urine O
by O
active O
organic O
cationic O
secretion O
. O

Because O
prostaglandins O
play O
an O
important O
role O
in O
hemostasis O
, O
and O
NSAIDs B-group
affect O
platelet O
function O
as O
well O
, O
concurrent O
therapy O
with O
all O
NSAIDs B-group
, O
including O
diclofenac B-drug
, O
and O
warfarin B-drug
requires O
close O
monitoring O
of O
patients O
to O
be O
certain O
that O
no O
change O
in O
their O
anticoagulant B-group
dosage O
is O
required O
. O

Cytosine B-drug
arabinoside I-drug
, O
a O
cytostatic B-group
agent I-group
, O
has O
been O
reported O
to O
inactivate O
the O
antifungal O
activity O
of O
flucytosine B-drug
by O
competitive O
inhibition O
. O

Administration O
of O
eszopiclone B-drug
3 O
mg O
to O
a O
patient O
taking O
another O
drug O
that O
is O
highly O
protein-bound O
would O
not O
be O
expected O
to O
cause O
an O
alteration O
in O
the O
free O
concentration O
of O
either O
drug O
. O

Pyrazolone B-group
Derivatives I-group
( O
phenylbutazone B-drug
, O
oxyphenbutazone B-drug
, O
and O
possibly O
dipyrone B-drug
) O
: O
Concomitant O
administration O
with O
aspirin B-drug
may O
increase O
the O
risk O
of O
gastrointestinal O
ulceration O
. O

18-MC B-drug_n
, O
a O
novel O
iboga O
alkaloid O
congener O
, O
is O
being O
developed O
as O
a O
potential O
treatment O
for O
multiple O
forms O
of O
drug O
abuse O
. O

Drugs O
With O
A O
Narrow O
Therapeutic O
Index O
Digoxin B-drug
A O
single O
dose O
of O
eszopiclone B-drug
3 O
mg O
did O
not O
affect O
the O
pharmacokinetics O
of O
digoxin B-drug
measured O
at O
steady O
state O
following O
dosing O
of O
0.5 O
mg O
twice O
daily O
for O
one O
day O
and O
0.25 O
mg O
daily O
for O
the O
next O
6 O
days O
. O

Mineral B-drug_n
Oil-Concomitant O
intake O
of O
mineral B-drug_n
oil I-drug_n
and O
vitamin B-group
K I-group
may O
reduce O
the O
absorption O
of O
vitamin B-group
K I-group
. O

Lithium B-drug
carbonate I-drug
: O
The O
anorectic O
and O
stimulatory O
effects O
of O
amphetamines B-group
may O
be O
inhibited O
by O
lithium B-drug
carbonate I-drug
. O

400-2800 O

Studies O
with O
famotidine B-drug
in O
man O
, O
in O
animal O
models O
, O
and O
in O
vitro O
have O
shown O
no O
significant O
interference O
with O
the O
disposition O
of O
compounds O
metabolized O
by O
the O
hepatic O
microsomal O
enzymes O
, O
e.g. O
, O
cytochrome O
P450 O
system O
. O

Agents O
with O
Increased O
Levels O
in O
the O
Presence O
of O
Carbamazepine B-drug
: O
EQUETROTM B-brand
increases O
the O
plasma O
levels O
of O
the O
following O
agents O
: O
Clomipramine B-drug
HCl I-drug
, O
Phenytoin B-drug
( O
6 O
) O
, O
and O
primidone B-drug
Thus O
, O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
on O
one O
of O
the O
agents O
in O
this O
category O
, O
and O
then O
begins O
a O
course O
of O
the O
treatment O
with O
EQUETROTM B-brand
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
decrease O
for O
the O
concomitant O
agent O
may O
be O
necessary O
. O

These O
doses O
were O
6 O
to O
11 O
times O
( O
mouse O
) O
and O
8 O
to O
16 O
times O
( O
rat O
) O
the O
human O
AUC O
( O
0-24 O
) O
based O
on O
the O
maximum O
recommended O
human O
dose O
of O
80 O
mg/day O
. O

In O
some O
patients O
the O
combined O
use O
of O
indomethacin B-drug
and O
diflunisal B-drug
has O
been O
associated O
with O
fatal O
gastrointestinal O
hemorrhage O
. O

FLUOTHANE B-brand
may O
augment O
the O
hypotension O
caused O
by O
the O
ganglionic-blocking O
effect O
of O
tubocurarine B-drug
. O

Specific O
studies O
with O
ibandronate B-drug
have O
not O
been O
performed O
. O

Acetazolamide B-drug
may O
elevate O
cyclosporine B-drug
levels O
. O

Similarly O
, O
of O
over O
1600 O
patients O
enrolled O
in O
a O
study O
comparing O
once-monthly O
with O
daily O
dosing O
regimens O
of O
ibandronate B-drug
, O
14 O
% O
of O
patients O
used O
anti-peptic O
agents O
. O

In O
vitro O
interaction O
of O
prostaglandin B-drug
F2alpha I-drug
and O
oxytocin B-drug
in O
placental O
vessels O
. O

These O
effects O
may O
be O
due O
to O
a O
relatively O
specific O
blockade O
of O
diverse O
potassium O
channel O
types O
. O

250-500 O

Patients O
taking O
both O
flurbiprofen B-drug
and O
a O
beta-blocker B-group
should O
be O
monitored O
to O
ensure O
that O
a O
satisfactory O
hypotensive O
effect O
is O
achieved O
. O

When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
DIABINESE B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
loss O
of O
control O
. O

In O
patients O
receiving O
mercaptopurine B-drug
( O
Purinethol B-brand
) O
or O
azathioprine B-drug
( O
Imuran B-brand
) O
, O
the O
concomitant O
administration O
of O
300-600 O
mg O
of O
allopurinol B-drug
per O
day O
will O
require O
a O
reduction O
in O
dose O
to O
approximately O
one-third O
to O
one-fourth O
of O
the O
usual O
dose O
of O
mercaptopurine B-drug
or O
azathioprine B-drug
. O

In O
a O
study O
of O
schizophrenic O
patients O
who O
received O
clozapine B-drug
under O
steady O
state O
conditions O
, O
fluvoxamine B-drug
or O
paroxetine B-drug
was O
added O
in O
16 O
and O
14 O
patients O
, O
respectively O
. O

Longitudinal O
assessment O
of O
everolimus B-drug
in O
de O
novo O
renal O
transplant O
recipients O
over O
the O
first O
post-transplant O
year O
: O
pharmacokinetics O
, O
exposure-response O
relationships O
, O
and O
influence O
on O
cyclosporine B-drug
. O

Nevertheless O
, O
plasma O
lithium B-drug
levels O
should O
be O
monitored O
with O
appropriate O
adjustment O
to O
the O
lithium B-drug
dose O
in O
accordance O
with O
standard O
clinical O
practice O
. O

Because O
the O
small O
magnitude O
and O
the O
direction O
of O
the O
effect O
on O
theophylline B-drug
clearance O
, O
this O
interaction O
is O
unlikely O
to O
be O
clinical O
concern O
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
MICRONASE B-brand
, O
the O
patient O
should O
be O
closely O
observed O
for O
loss O
of O
control O
. O

No O
drug-drug O
interaction O
studies O
in O
human O
subjects O
have O
been O
conducted O
. O

Depending O
on O
the O
fraction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8-fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA B-group
) O
. O

With O
combined O
use O
, O
clinicians O
should O
be O
aware O
, O
when O
phenytoin B-drug
is O
added O
, O
of O
the O
potential O
for O
reexacerbation O
of O
pulmonary O
symptomatology O
due O
to O
lowered O
serum O
theophylline B-drug
concentrations O
. O

There O
is O
one O
reported O
case O
of O
a O
patient O
with O
acute O
delirium O
associated O
with O
the O
simultaneous O
use O
of O
fluphenazine B-drug
and O
oral O
clonidine B-drug
. O

Sublingual O
nitroglycerin B-drug
may O
be O
taken O
if O
necessary O
for O
the O
control O
of O
acute O
angina O
attacks O
during O
Bepridil B-drug
therapy O
. O

Ketoconazole B-drug
( O
200 O
mg O
q12h O
) O
+307 O
% O
+73 O
% O

Studies O
with O
other O
oral O
or O
implant O
contraceptives B-group
have O
not O
been O
conducted O
. O

Effect O
of O
coadministered O
drugs O
and O
ethanol B-drug
on O
the O
binding O
of O
therapeutic O
drugs O
to O
human O
serum O
in O
vitro O
. O

A O
possible O
drug O
interaction O
of O
FOSCAVIR B-brand
and O
intravenous O
pentamidine B-drug
has O
been O
described O
. O

Caution O
should O
also O
be O
taken O
in O
concurrent O
or O
serial O
use O
of O
other O
aminoglycosides B-group
and O
polymyxins B-group
because O
they O
may O
enhance O
neomycin O
s O
nephrotoxicity O
and/or O
ototoxicity O
and O
potentiate O
neomycin B-drug
sulfate I-drug
neuromuscular O
blocking O
effects O
. O

In O
nine O
otherwise O
healthy O
subjects O
with O
epilepsy O
ingesting O
carbamazepine B-drug
, O
the O
steady-state O
trough O
( O
Cmin O
) O
carbamazepine B-drug
concentration O
was O
8 O
2 O
micrograms/mL O
. O

The O
mean O
AUC O
values O
of O
EE O
were O
decreased O
by O
48 O
% O
[ O
90 O
% O
CI O
: O
22-65 O
] O
in O
one O
study O
and O
52 O
% O
[ O
90 O
% O
CI O
: O
38-52 O
] O
in O
another O
study O
[ O
1,2 O
] O
. O

Barbiturates B-group
, O
phenytoin B-drug
, O
or O
rifampin B-drug
increased O
metabolic O
clearance O
of O
fludrocortisone B-drug
acetate I-drug
because O
of O
the O
induction O
of O
hepatic O
enzymes O
. O

There O
have O
been O
rare O
reports O
of O
reddish O
stools O
in O
patients O
who O
have O
received O
cefdinir B-drug
in O
Japan O
. O

Beta-blockers B-group
, O
clonidine B-drug
, O
lithium B-drug
salts O
, O
and O
alcohol B-drug
may O
either O
potentiate O
or O
weaken O
the O
blood-glucose-lowering O
effect O
of O
insulin B-drug
. O

Aspirin B-brand
: O
When O
Lodine B-brand
is O
administered O
with O
aspirin B-brand
, O
its O
protein O
binding O
is O
reduced O
, O
although O
the O
clearance O
of O
free O
etodolac B-drug
is O
not O
altered O
. O

The O
behavioral O
effects O
of O
these O
two O
drugs O
differ O
, O
and O
they O
do O
not O
act O
on O
the O
same O
target O
sites O
in O
the O
brain O
, O
although O
they O
may O
share O
, O
or O
partly O
share O
, O
certain O
properties O
. O

The O
extent O
of O
plasma O
protein O
binding O
of O
atovaquone B-drug
in O
human O
plasma O
is O
not O
affected O
by O
the O
presence O
of O
therapeutic O
concentrations O
of O
phenytoin B-drug
( O
15 O
mcg/ O
mL O
) O
, O
nor O
is O
the O
binding O
of O
phenytoin B-drug
affected O
by O
the O
presence O
of O
atovaquone B-drug
. O

Inhibitors O
of O
renal O
cationic O
secretion O
are O
contraindicated O
with O
TIKOSYN B-brand
. O

Nonsteroidal B-group
anti-inflammatory I-group
agents I-group
( O
NSAIDS B-group
) O
: O
Concomitant O
use O
of O
aspirin B-brand
( O
or O
other O
nonsteroidal B-group
antiinflammatory I-group
agents I-group
) O
and O
corticosteroids B-group
increases O
the O
risk O
of O
gastrointestinal O
side O
effects O
. O

Consider O
doubling O
the O
rifabutin B-drug
dose O
in O
regimens O
where O
rifabutin B-drug
is O
given O
2 O
or O
3 O
times O
a O
week O
. O

Diflunisal B-drug
decreased O
the O
hyperuricemic O
effect O
of O
hydrochlorothiazide B-drug
. O

Patients O
who O
are O
concomitantly O
receiving O
VELCADE B-brand
and O
drugs O
that O
are O
inhibitors O
or O
inducers O
of O
cytochrome O
P450 O
3A4 O
should O
be O
closely O
monitored O
for O
either O
toxicities O
or O
reduced O
efficacy O
. O

Bosentan B-drug
is O
an O
inducer O
of O
CYP3A4 O
and O
CYP2C9 O
. O

therefore O
, O
the O
efficacy O
of O
oral O
contraceptives B-group
during O
administration O
of O
Aprepitant B-drug
may O
be O
reduced O
. O

The O
effects O
of O
concomitant O
phenytoin B-drug
administration O
on O
the O
steady-state O
pharmacokinetics O
of O
quetiapine B-drug
. O

It O
is O
unknown O
whether O
the O
concomitant O
administration O
of O
proton B-group
pump I-group
inhibitors I-group
affects O
duloxetine B-drug
absorption O
. O

Routine O
administration O
of O
vaccines B-group
or O
toxoids O
should O
be O
deferred O
until O
corticosteroid B-group
therapy O
is O
discontinued O
if O
possible O
. O

While O
it O
is O
not O
known O
whether O
this O
interaction O
occurs O
with O
fibrates B-group
other O
than O
gemfibrozil B-drug
, O
myopathy O
and O
rhabdomyolysis O
have O
occasionally O
been O
associated O
with O
the O
use O
of O
fibrates B-group
alone O
, O
including O
clofibrate B-drug
. O

Clarithromycin B-drug

The O
minimal O
inhibitory O
concentration O
as O
well O
as O
minimal O
bactericidal O
concentration O
of O
KRM-1648 B-drug_n
against O
M O
. O

In O
vitro O
studies O
indicate O
that O
the O
binding O
is O
not O
easily O
removed O
. O

There O
are O
rare O
reports O
, O
however O
, O
from O
marketing O
experiences O
, O
of O
changes O
in O
effects O
of O
insulin B-drug
or O
oral O
hypoglycemic B-group
agents I-group
in O
the O
presence O
of O
diclofenac B-drug
that O
necessitated O
changes O
in O
the O
doses O
of O
such O
agents O
. O

Consequently O
, O
interactions O
with O
other O
drugs O
which O
are O
highly O
protein O
bound O
( O
e.g. O
, O
anticoagulants B-group
) O
would O
not O
be O
expected O
. O

No O
significant O
drug-drug O
pharmacokinetic O
interactions O
have O
been O
found O
in O
interaction O
studies O
with O
hydrochlorothiazide B-drug
, O
digoxin B-drug
, O
warfarin B-drug
, O
cimetidine B-drug
and O
phenobarbital B-drug
. O

Calcium B-drug
Supplements O
: O
Uncontrolled O
intake O
of O
additional O
calcium-containing B-drug
preparations O
should O
be O
avoided O
. O

DOSTINEX B-brand
should O
not O
be O
administered O
concurrently O
with O
D2-antagonists O
, O
such O
as O
phenothiazines B-group
, O
butyrophenones B-group
, O
thioxanthines B-group
, O
or O
metoclopramide B-drug
. O

Interference O
with O
the O
absorption O
of O
oral O
phosphate B-drug_n
supplements O
has O
been O
observed O
with O
another O
positively-charged O
bile O
acid O
sequestrant O
. O

Warfarin B-drug
: O
In O
a O
short-term O
controlled O
study O
in O
14 O
normal O
volunteers O
, O
ketoprofen B-drug
did O
not O
significantly O
interfere O
with O
the O
effect O
of O
warfarin B-drug
on O
prothrombin O
time O
. O

Co-administration O
: O
Concomitant O
use O
of O
Argatroban B-drug
with O
antiplatelet B-group
agents I-group
, O
thrombolytics B-group
, O
and O
other O
anticoagulants B-group
may O
increase O
the O
risk O
of O
bleeding O
. O

Corresponding O
values O
for O
free O
valproate B-drug
Cmin O
concentrations O
were O
7 O
3 O
, O
9 O
4 O
, O
and O
11 O
6 O
micrograms/mL O
for O
0 O
, O
1200 O
, O
and O
2400 O
mg/day O
Felbatol B-brand
, O
respectively O
. O

Indinavir B-drug
is O
an O
inhibitor O
of O
the O
cytochrome O
P450 O
isoform O
CYP3A4 O
. O

Currently O
, O
there O
are O
no O
safety O
and O
efficacy O
data O
available O
from O
the O
use O
of O
this O
combination O
. O

structural O
heart O
disease O
is O
a O
known O
risk O
factor O
for O
arrhythmia O
. O

Ergot B-group
alkaloids I-group

Magnesium/Aluminum-containing B-drug
Antacid B-group
Products I-group
: O
Absorption O
of O
zalcitabine B-drug
is O
moderately O
reduced O
( O
approximately O
25 O
% O
) O
when O
coadministered O
with O
magnesium/aluminum-containing B-drug
antacid B-group
products I-group
. O

This O
increase O
is O
greatest O
in O
the O
evening O
. O

Pressor O
amines O
( O
e.g. O
, O
norepinephrine B-drug
) O
: O
possible O
decreased O
response O
to O
pressor O
amines O
but O
not O
sufficient O
to O
preclude O
their O
use O
. O

Antihistamines B-group
( O
e.g. O
, O
chlorpheniramine B-group
) O
. O

Ranitidine B-drug
produced O
smaller O
, O
non-significant O
increases O
. O

Increased O
plasma O
concentrations O
of O
terfenadine B-drug
, O
astemizole B-drug
, O
and O
cisapride B-drug
cause O
QT O
prolongation O
and O
have O
been O
associated O
with O
torsades O
de O
pointes-type O
ventricular O
tachycardia O
, O
sometimes O
fatal O
. O

Aspirin B-brand
: O
Animal O
studies O
wshow O
that O
aspirin B-brand
given O
with O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
, O
including O
ibuprofen B-drug
, O
yields O
a O
net O
decrease O
in O
anti-inflammatory O
activity O
with O
lowered O
blood O
levels O
of O
the O
non-aspirin O
drug O
. O

Furthermore O
, O
rifampin B-drug
, O
phenytoin B-drug
, O
phenobarbital B-drug
, O
and O
other O
inducers O
of O
cytochrome O
P450 O
3A4 O
may O
cause O
a O
reduction O
in O
plasma O
bexarotene B-drug
concentrations O
. O

Reduced O
levels O
( O
up O
to O
20 O
% O
) O
of O
total O
glutathione O
( O
total O
GSH O
) O
, O
and O
elevation O
of O
conjugated O
dienes O
( O
approximately O
60 O
% O
in O
liver O
by O
single O
dose O
at O
4 O
h O
) O
also O
indicated O
the O
presence O
of O
an O
oxidative O
insult O
. O

General O
In O
vitro O
studies O
in O
human O
liver O
microsomes O
demonstrated O
no O
evidence O
of O
cytochrome O
P450-mediated O
drug O
interactions O
that O
are O
likely O
to O
be O
of O
clinical O
relevance O
. O

Correlative O
clinical O
studies O
have O
not O
been O
performed O
. O

This O
interaction O
, O
which O
has O
not O
been O
investigated O
using O
higher O
doses O
of O
fluvoxamine B-drug
, O
may O
be O
more O
pronounced O
if O
a O
300 O
mg O
daily O
dose O
is O
co-administered O
, O
particularly O
since O
fluvoxamine B-drug
exhibits O
non-linear O
pharmacokinetics O
over O
the O
dosage O
range O
100-300 O
mg O
. O
If O
alprazolam B-drug
is O
co-administered O
with O
Fluvoxamine B-drug
Tablets O
, O
the O
initial O
alprazolam B-drug
dosage O
should O
be O
at O
least O
halved O
and O
titration O
to O
the O
lowest O
effective O
dose O
is O
recommended O
. O

Both O
of O
these O
strategies O
will O
become O
more O
feasible O
as O
specific O
molecular O
differences O
between O
tumor O
and O
normal O
cells O
are O
being O
rapidly O
identified O
and O
new O
combination O
therapies O
that O
take O
advantage O
of O
these O
differences O
are O
being O
designed O
and O
tested O
. O

Hypothermia O
as O
an O
index O
of O
the O
disulfiram-ethanol B-drug
reaction O
in O
the O
rat O
. O

Furosemide B-drug
: O
Clinical O
studies O
, O
as O
well O
as O
post-marketing O
observations O
, O
have O
shown O
that O
NSAIDs B-group
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-drug
and O
thiazides B-group
in O
some O
patients O
. O

In O
dogs O
, O
cimetidine B-drug
unchanged O
the O
secretion O
of O
cardiotrast B-drug
, O
a O
test O
agent O
for O
anionic O
transport O
. O

This O
effect O
of O
aspirin B-brand
( O
which O
also O
lowers O
serum O
concentrations O
of O
other O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
given O
with O
it O
) O
has O
been O
demonstrated O
in O
patients O
with O
rheumatoid O
arthritis O
( O
n= O
15 O
) O
as O
well O
as O
normal O
volunteers O
( O
n= O
16 O
) O
. O

In O
extremely O
acidic O
conditions O
, O
Duloxetine B-drug
, O
unprotected O
by O
the O
enteric O
coating O
, O
may O
undergo O
hydrolysis O
to O
form O
naphthol O
. O

Amprenavir B-drug
inhibits O
CYP3A4 O
. O

Anticoagulants B-group
: O
There O
have O
been O
reports O
of O
increased O
anticoagulant O
effects O
when O
erythromycin B-drug
and O
oral O
anticoagulants B-group
were O
used O
concomitantly O
. O

Oral O
neomycin B-drug
sulfate I-drug
may O
enhance O
the O
effect O
of O
coumarin B-group
in O
anticoagulants B-group
by O
decreasing O
vitamin O
K O
availability O
. O

The O
physician O
should O
be O
alert O
for O
possible O
combined O
drug O
actions O
, O
desirable O
or O
undesirable O
, O
involving O
cyclophosphamide B-drug
even O
though O
cyclophosphamide B-drug
has O
been O
used O
successfully O
concurrently O
with O
other O
drugs O
, O
including O
other O
cytotoxic O
drugs O
. O

Among O
fifteen O
species O
of O
bacteria O
tested O
, O
the O
antimicrobial O
activity O
of O
GL B-drug_n
was O
the O
most O
potent O
against O
Micrococcus O
luteus O
( O
MIC O
, O
0.75 O
mg/ml O
) O
. O

Aprepitant I-drug
is O
a O
substrate O
for O
CYP3A4 O
; O

This O
may O
lead O
to O
reduced O
clearance O
of O
caffeine B-drug
and O
a O
prolongation O
of O
its O
plasma O
half-life O
. O

Aripiprazole B-drug
also O
does O
not O
undergo O
direct O
glucuronidation O
. O

Alcohol B-drug
, O
in O
particular O
, O
has O
been O
found O
to O
exhibit O
additive O
effects O
of O
this O
variety O
. O

Vitamin B-drug
D3 I-drug
administration O
to O
rachitic O
chicks O
was O
effective O
in O
significantly O
elevating O
duodenal O
arsenate B-drug_n
absorption O
, O
acting O
primarily O
to O
enhance O
serosal O
transport O
. O

TBg O
may O
also O
be O
increased O
during O
infectious O
hepatitis O
. O

. O

The O
plasma O
concentrations O
of O
bosentan B-drug
were O
also O
decreased O
by O
approximately O
30 O
% O
. O

Drugs O
that O
induce O
hepatic O
enzymes O
such O
as O
phenobarbital B-drug
, O
phenytoin B-drug
and O
rifampin B-drug
may O
increase O
the O
clearance O
of O
corticosteroids B-group
and O
may O
require O
increases O
in O
corticosteroid B-group
dose O
to O
achieve O
the O
desired O
response O
. O

Amiodarone B-drug
: O
Amiodarone B-drug
therapy O
alone O
can O
cause O
hypothyroidism O
or O
hyperthyroidism O
. O

Higher O
concentrations O
of O
dexamethasone B-drug
( O
10 O
( O
-8 O
) O
- O
10 O
( O
-6 O
) O
M O
) O
or O
retinyl B-drug
acetate I-drug
( O
3 O
X O
10 O
( O
-8 O
) O
- O
10 O
( O
-7 O
) O
M O
) O
enhance O
the O
mitogenic O
activity O
of O
EGF B-drug_n
. O

Certain O
drugs O
tend O
to O
produce O
hyperglycemia O
and O
may O
lead O
to O
loss O
of O
control O
. O

Recent O
studies O
and O
consensus O
reports O
have O
expanded O
our O
understanding O
of O
its O
efficacy O
, O
safety O
, O
contraindications O
, O
and O
drug O
interactions O
. O

Drugs O
That O
Inhibit O
CYP3A4 O
( O
Ketoconazole B-drug
) O
CYP3A4 O
is O
a O
major O
metabolic O
pathway O
for O
elimination O
of O
eszopiclone B-drug
. O

A O
pharmacokinetic O
study O
evaluating O
the O
administration O
of O
a O
single O
dose O
of O
INSPRA B-brand
100 O
mg O
with O
ketoconazole B-drug
200 O
mg O
BID O
, O
a O
potent O
inhibitor O
of O
the O
CYP3A4 O
pathway O
, O
showed O
a O
1.7-fold O
increase O
in O
Cmax O
of O
eplerenone B-drug
and O
a O
5.4-fold O
increase O
in O
AUC O
of O
eplerenone B-drug
. O

Caution O
should O
be O
exercised O
and O
dose O
reduction O
of O
the O
concomitant O
substrate O
drug O
should O
be O
considered O
when O
dosing O
lapatinib B-drug
concurrently O
with O
medications O
with O
narrow O
therapeutic O
windows O
that O
are O
substrates O
of O
CYP3A4 O
or O
CYP2C8 O
. O

As O
with O
other O
agents B-group
with I-group
b-blocking I-group
properties I-group
, O
if O
COREG B-brand
is O
to O
be O
administered O
orally O
with O
calcium B-group
channel I-group
blockers I-group
of O
the O
verapamil B-drug
or O
diltiazem B-drug
type O
, O
it O
is O
recommended O
that O
ECG O
and O
blood O
pressure O
be O
monitored O
. O

No O
formal O
assessments O
of O
drug-drug O
interactions O
between O
Vidaza B-brand
and O
other O
agents O
have O
been O
conducted O

Pregnancies O
have O
been O
reported O
by O
users O
of O
combined B-group
hormonal I-group
contraceptives I-group
who O
also O
used O
some O
form O
of O
St. O
Johns O
Wort O
. O

Phenobarbital B-drug

Specific O
drug O
interaction O
studies O
have O
not O
been O
performed O
with O
SUSTIVA B-brand
and O
NRTIs B-group
other O
than O
lamivudine B-drug
and O
zidovudine B-drug
. O

Concomitant O
administration O
of O
Norpace B-brand
and O
quinidine B-drug
resulted O
in O
slight O
increases O
in O
plasma O
disopyramide B-drug
levels O
and O
slight O
decreases O
in O
plasma O
quinidine B-drug
levels O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
rhabdomyolysis O
resulting O
from O
concomitant O
use O
of O
clarithromycin B-drug
and O
simvastatin B-drug
. O

Drugs O
with O
a O
Narrow O
Therapeutic O
Index O
Digoxin B-drug
: O
Sonata B-brand
( O
10 O
mg O
) O
did O
not O
affect O
the O
pharmacokinetic O
or O
pharmacodynamic O
profile O
of O
digoxin B-drug
( O
0.375 O
mg O
q24h O
for O
8 O
days O
) O
. O

Coadministration O
with O
compounds O
that O
are O
potent O
inducers O
of O
CYP3A4 O
( O
eg O
, O
phenobarbital B-drug
, O
phenytoin B-drug
, O
dexamethasone B-drug
, O
carbamazepine B-drug
) O
may O
result O
in O
decreased O
plasma O
levels O
of O
saquinavir B-drug
. O

Warfarin B-drug
: O
Quinolones B-group
, O
including O
enoxacin B-drug
, O
decrease O
the O
clearance O
of O
R-warfarin B-drug
, O
the O
less O
active O
isomer O
of O
racemic O
warfarin B-drug
. O

Drug/Laboratory O
Test O
Interactions O
Phenytoin B-drug
may O
decrease O
serum O
concentrations O
of O
14 O
. O

Combination O
hormonal B-group
contraceptives I-group
may O
also O
decrease O
the O
plasma O
concentration O
of O
acetaminophen B-drug
. O

Digoxin B-drug
: O
When O
multiple O
doses O
of O
atorvastatin B-drug
and O
digoxin B-drug
were O
coadministered O
, O
steady-state O
plasma O
digoxin B-drug
concentrations O
increased O
by O
approximately O
20 O
% O
. O

Oxcarbazepine B-drug
was O
evaluated O
in O
human O
liver O
microsomes O
to O
determine O
its O
capacity O
to O
inhibit O
the O
major O
cytochrome O
P450 O
enzymes O
responsible O
for O
the O
metabolism O
of O
other O
drugs O
. O

In O
studies O
with O
finasteride B-drug
, O
no O
clinically O
meaningful O
changes O
in O
luteinizing O
hormone O
( O
LH O
) O
, O
follicle-stimulating O
hormone O
( O
FSH O
) O
or O
prolactin O
were O
detected O
. O

Phenytoin B-drug

Amiodarone B-drug
caused O
a O
three- O
to O
fivefold O
increase O
in O
serum O
reverse O
triiodothyronine O
levels O
, O
but O
changes O
in O
thyroid O
function O
were O
not O
quantitatively O
related O
to O
the O
changes O
in O
digoxin B-drug
pharmacokinetics O
. O

The O
clinical O
significance O
of O
this O
finding O
is O
unknown O
; O

Additive O
CNS O
depression O
may O
occur O
when O
antihistamines B-group
are O
administered O
concomitantly O
with O
other O
CNS B-group
depressants I-group
including O
barbiturates B-group
, O
tranquilizers B-group
, O
and O
alcohol B-drug
. O

This O
article O
looks O
at O
five O
commonly O
used O
immunosuppressive B-group
drugs I-group
in O
turn O
( O
corticosteroids B-group
, O
cyclosporin B-drug
, O
azathioprine B-drug
, O
methotrexate B-drug
, O
cyclophosphamide B-drug
) O
, O
discussing O
the O
main O
, O
non-infection O
, O
unwanted O
effects O
, O
ways O
to O
avoid O
them O
and O
what O
to O
do O
if O
problems O
arise O
. O

Nevertheless O
, O
caution O
is O
indicated O
in O
the O
co-administration O
of O
TCAs B-group
with O
any O
of O
the O
SSRIs B-group
and O
also O
in O
switching O
from O
one O
class O
to O
the O
other O
. O

No O
pharmacokinetic-based O
drug-drug O
interaction O
studies O
have O
been O
conducted O
with O
SYNAREL B-brand
. O

Prescribers O
are O
advised O
to O
consult O
the O
package O
insert O
of O
medication O
administered O
concomitantly O
with O
hormonal B-group
contraceptives I-group
, O
since O
some O
medications O
may O
decrease O
the O
effectiveness O
of O
these O
birth O
control O
products O
. O

Co-administration O
of O
anastrozole B-drug
and O
tamoxifen B-drug
resulted O
in O
a O
reduction O
of O
anastrozole B-drug
plasma O
levels O
by O
27 O
% O
compared O
with O
those O
achieved O
with O
anastrozole B-drug
alone O
. O

The O
mechanism O
of O
this O
pharmacodynamic O
interaction O
is O
not O
known O
. O

Patients O
receiving O
high O
doses O
of O
salicylates B-group
concomitantly O
with O
furosemide B-drug
, O
as O
in O
rheumatic O
disease O
, O
may O
experience O
salicylate B-group
toxicity O
at O
lower O
doses O
because O
of O
competitive O
renal O
excretory O
sites O
. O

When O
lansoprazole B-drug
was O
administered O
concomitantly O
with O
theophylline B-drug
( O
CYP1A2 O
, O
CYP3A O
) O
, O
a O
minor O
increase O
( O
10 O
% O
) O
in O
the O
clearance O
of O
theophylline B-drug
was O
seen O
. O

Caution O
is O
advised O
in O
using O
Duloxetine B-drug
in O
patients O
with O
conditions O
that O
may O
slow O
gastric O
emptying O
( O
e.g. O
, O
some O
diabetics O
) O
. O

Diuretic B-group
agents I-group
reduce O
the O
renal O
clearance O
of O
lithium B-drug
and O
add O
a O
high O
risk O
of O
lithium B-drug
toxicity O
. O

MAO B-group
inhibitors I-group
prolong O
and O
intensify O
the O
anticholinergic O
effects O
of O
antihistamines B-group
. O

These O
cells O
express O
the O
vitamin O
D O
receptor O
and O
exhibit O
doubling O
times O
comparable O
to O
the O
parental O
MCF-7 O
cells O
, O
even O
when O
grown O
in O
100 O
mM O
1,25 B-drug
( I-drug
OH I-drug
) I-drug
2D3 I-drug
. O

Some O
reports O
have O
shown O
that O
the O
concomitant O
administration O
of O
thiazides B-group
with O
vitamin B-group
D I-group
causes O
hypercalcemia O
. O

The O
concomitant O
administration O
of O
uricosuric B-group
agents I-group
and O
allopurinol B-drug
has O
been O
associated O
with O
a O
decrease O
in O
the O
excretion O
of O
oxypurines O
( O
hypoxanthine O
and O
xanthine O
) O
and O
an O
increase O
in O
urinary O
uric O
acid O
excretion O
compared O
with O
that O
observed O
with O
allopurinol B-drug
alone O
. O

TAMBOCOR B-brand
has O
been O
used O
in O
a O
large O
number O
of O
patients O
receiving O
diuretics B-group
without O
apparent O
interaction O
. O

Drugs O
That O
Inhibit O
Aldehyde O
Oxidase O
The O
aldehyde O
oxidase O
enzyme O
system O
is O
less O
well O
studied O
than O
the O
cytochrome O
P450 O
enzyme O
system O
. O

A O
study O
in O
eight O
healthy O
volunteers O
has O
shown O
a O
50 O
% O
increase O
in O
mean O
peak O
nimodipine B-drug
plasma O
concentrations O
and O
a O
90 O
% O
increase O
in O
mean O
area O
under O
the O
curve O
, O
after O
a O
one O
week O
course O
of O
cimetidine B-drug
at O
1,000 O
mg/day O
and O
nimodipine B-drug
at O
90 O
mg/day O
. O

We O
have O
selected O
a O
subclone O
of O
MCF-7 O
cells O
resistant O
to O
1,25 B-drug
( I-drug
OH I-drug
) I-drug
2D3 I-drug
( O
MCF-7D3Res O
) O
. O

Antagonism O
between O
lincomycin B-drug
and O
erythromycin B-drug
in O
vitro O
has O
been O
demonstrated O
. O

The O
data O
suggest O
that O
the O
histidine O
residues O
may O
be O
crucial O
to O
the O
receptor-binding O
activity O
of O
toxin B-drug_n
A I-drug_n
. O

The O
following O
precautions O
should O
be O
kept O
in O
mind O
in O
the O
treatment O
of O
anticholinesterase O
poisoning O
although O
they O
do O
not O
bear O
directly O
on O
the O
use O
of O
atropine B-drug
and O
pralidoxime B-drug
. O

Drug/Laboratory O
Test O
Interactions O
None O
known O
. O

Other O
Chemotherapy O
Agents O
In O
a O
separate O
study O
, O
concomitant O
administration O
of O
lapatinib B-drug
with O
capecitabine B-drug
did O
not O
meaningfully O
alter O
the O
pharmacokinetics O
of O
either O
agent O
( O
or O
the O
metabolites O
of O
capecitabine B-drug
) O
. O

Labetalol B-drug
HCl I-drug
blunts O
the O
reflex O
tachycardia O
produced O
by O
nitroglycerin B-drug
without O
preventing O
its O
hypotensive O
effect O
. O

It O
is O
advisable O
to O
check O
coagulation O
time O
within O
the O
first O
few O
days O
after O
the O
start O
and O
discontinuation O
of O
cisapride B-drug
therapy O
, O
with O
an O
appropriate O
adjustment O
of O
the O
anticoagulant B-group
dose O
, O
if O
necessary O
. O

This O
is O
especially O
important O
in O
patients O
who O
may O
use O
alcohol B-drug
excessively O
. O

It O
is O
likely O
that O
use O
of O
epirubicin B-drug
with O
radiotherapy O
may O
sensitize O
tissues O
to O
the O
cytotoxic O
actions O
of O
irradiation O
. O

Carbamazepine B-drug
overdose O
recognized O
by O
a O
tricyclic B-group
antidepressant I-group
assay O
. O

The O
concomitant O
use O
of O
vasopressors B-group
, O
vasoconstricting O
agents O
( O
such O
as O
ergonovine B-drug
) O
and O
some O
oxytocic B-group
drugs I-group
may O
result O
in O
severe O
hypertension O
. O

Concurrent O
use O
with O
general O
anesthetics B-group
may O
result O
in O
arrhythmias O
. O

Thrombolytic B-group
agents I-group
: O
The O
safety O
and O
effectiveness O
of O
Argatroban B-drug
with O
thrombolytic B-group
agents I-group
have O
not O
been O
established O
. O

Non-steroidal B-group
Anti-inflammatory I-group
Agents I-group
: O
In O
some O
patients O
with O
compromised O
renal O
function O
who O
are O
being O
treated O
with O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
, O
the O
co-administration O
of O
enalapril B-drug
may O
result O
in O
a O
further O
deterioration O
of O
renal O
function O
. O

This O
indicates O
that O
tiagabine B-drug
does O
not O
cause O
induction O
or O
inhibition O
of O
the O
hepatic O
microsomal O
enzyme O
systems O
responsible O
for O
the O
metabolism O
of O
antipyrine B-drug
. O

indinavir I-drug
concentration O

Cimetidine B-drug
: O
Co-administration O
with O
high O
doses O
of O
cimetidine B-drug
[ O
800 O
mg O
twice O
daily O
] O
increased O
the O
Cmax O
of O
rofecoxib B-drug
by O
21 O
% O
, O
the O
AUC0-120hr O
by O
23 O
% O
and O
the O
t1/2 O
by O
15 O
% O
. O

Other O
drug O
interactions O
Cimetidine B-drug
, O
erythromycin B-drug
and O
dextropropoxyphene B-drug
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
MHD B-drug_n
. O

Standard O
monitoring O
of O
methotrexate-related B-drug
toxicity O
should O
be O
continued O
if O
VIOXX B-brand
and O
methotrexate B-drug
are O
administered O
concomitantly O
. O

Risk O
of O
Anaphylactic O
Reaction O
While O
taking O
beta-blockers B-group
, O
patients O
with O
a O
history O
of O
severe O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
be O
more O
reactive O
to O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
, O
or O
therapeutic O
. O

In O
healthy O
volunteers O
, O
treatment O
with O
finasteride B-drug
did O
not O
alter O
the O
response O
of O
LH O
and O
FSH O
to O
gonadotropin-releasing O
hormone O
indicating O
that O
the O
hypothalamic-pituitary-testicular O
axis O
was O
not O
affected O
. O

Rifabutin I-drug

The O
prior O
administration O
of O
succinylcholine B-drug
does O
not O
enhance O
the O
duration O
, O
but O
quickens O
the O
onset O
and O
may O
increase O
the O
depth O
, O
of O
neuromuscular O
block O
induced O
by O
TRACRIUM B-brand
. O

ranitidine* B-drug
; O

The O
appropriate O
interval O
between O
administration O
of O
these O
agents O
and O
dexfenfluramine B-drug
has O
not O
been O
established O
. O

The O
half-life O
increased O
from O
4.0 O
to O
4.8 O
hours O
. O

There O
is O
no O
pharmacokinetic O
interaction O
between O
zaleplon B-drug
and O
diphenhydramine B-drug
following O
the O
administration O
of O
a O
single O
dose O
( O
10 O
mg O
and O
50 O
mg O
, O
respectively O
) O
of O
each O
drug O
. O

saquinavir I-drug
concentration O

The O
adverse O
experience O
profile O
seen O
with O
KEMSTROTM B-brand
was O
similar O
to O
that O
seen O
with O
baclofen B-drug
tablets O
. O

Agents O
that O
are O
CYP3A4 O
inhibitors O
that O
have O
been O
found O
, O
or O
are O
expected O
, O
to O
increase O
plasma O
levels O
of O
EQUETROTM B-brand
are O
the O
following O
: O
Acetazolamide B-drug
, O
azole B-group
antifungals I-group
, O
cimetidine B-drug
, O
clarithromycin B-drug
( O
1 O
) O
, O
dalfopristin B-drug
, O
danazol B-drug
, O
delavirdine B-drug
, O
diltiazem B-drug
, O
erythromycin B-drug
( O
1 O
) O
, O
fluoxetine B-drug
, O
fluvoxamine B-drug
, O
grapefruit O
juice O
, O
isoniazid B-drug
, O
itraconazole B-drug
, O
ketoconazole B-drug
, O
loratadine B-drug
, O
nefazodone B-drug
, O
niacinamide B-drug
, O
nicotinamide B-drug
, O
protease B-group
inhibitors I-group
, O
propoxyphene B-drug
, O
quinine B-drug
, O
quinupristin B-drug
, O
troleandomycin B-drug
, O
valproate B-drug
( O
1 O
) O
, O
verapamil B-drug
, O
zileuton B-drug
. O

In O
three O
separate O
controlled O
, O
parallel O
group O
clinical O
pharmacology O
studies O
, O
desloratadine B-drug
at O
the O
clinical O
dose O
of O
5 O
mg O
has O
been O
coadministered O
with O
azithromycin B-drug
500 O
mg O
followed O
by O
250 O
mg O
once O
daily O
for O
4 O
days O
( O
n=18 O
) O
or O
with O
fluoxetine B-drug
20 O
mg O
once O
daily O
for O
7 O
days O
after O
a O
23 O
day O
pretreatment O
period O
with O
fluoxetine B-drug
( O
n=18 O
) O
or O
with O
cimetidine B-drug
600 O
mg O
every O
12 O
hours O
for O
14 O
days O
( O
n=18 O
) O
under O
steady O
state O
conditions O
to O
normal O
healthy O
male O
and O
female O
volunteers O
. O

Concomitant O
use O
of O
digoxin B-drug
and O
sympathomimetics B-group
increases O
the O
risk O
of O
cardiac O
arrhythmias O
. O

Olanzapine B-drug
is O
associated O
with O
significantly O
fewer O
extrapyramidal O
symptoms O
than O
haloperidol B-drug
and O
risperidone B-drug
. O

lithium B-drug
; O

Drugs O
which O
impair O
glomerular O
filtration O
may O
prolong O
the O
biological O
half-life O
of O
flucytosine B-drug
. O

Meperidine B-drug
: O
Amphetamines B-group
potentiate O
the O
analgesic O
effect O
of O
meperidine B-drug
. O

- O
Dantrolene B-drug
( O
e.g. O
, O
Dantrium B-brand
) O
or O

Drug-Laboratory O
Test O
Interactions O
There O
are O
no O
reported O
drug-laboratory O
test O
interactions O
. O

Lodine B-brand
treatment O
is O
associated O
with O
a O
small O
decrease O
in O
serum O
uric O
acid O
levels O
. O

Immediate O
and O
Extended O
Release O
Tablets O
The O
hypoglycemic O
action O
of O
sulfonylureas B-group
may O
be O
potentiated O
by O
certain O
drugs O
including O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
, O
some O
azoles B-group
and O
other O
drugs O
that O
are O
highly O
protein O
bound O
, O
salicylates B-group
, O
sulfonamides B-group
, O
chloramphenicol B-drug
, O
probenecid B-drug
, O
coumarins B-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
and O
beta B-group
adrenergic I-group
blocking I-group
agents I-group
. O

CYP3A4 O
inducers O
: O
CYP3A4 O
inducers O
may O
decrease O
the O
levels/effects O
of O
ethinyl B-drug
estradiol I-drug
. O

Aprepitant I-drug
, O
when O
given O
as O
a O
regimen O
of O
125 O
mg O
on O
Day O
1 O
and O
80 O
mg/day O
on O
Days O
2 O
and O
3 O
, O
increased O
the O
AUC O
of O
methylprednisolone B-drug
, O
a O
CYP3A4 O
substrate O
, O
by O
1.34-fold O
on O
Day O
1 O
and O
by O
2.5-fold O
on O
Day O
3 O
, O
when O
methylprednisolone B-drug
was O
coadministered O
intravenously O
as O
125 O
mg O
on O
Day O
1 O
and O
orally O
as O
40 O
mg O
on O
Days O
2 O
and O
3 O
. O

Catecholamine-depleting O
drugs O
( O
e.g. O
, O
reserpine B-drug
) O
: O
additive O
effect O
; O

Doxazosin B-drug
mesylate I-drug
tablets O
have O
been O
used O
with O
the O
following O
drugs O
or O
drug O
classes O
: O
1 O
. O

Because O
there O
is O
a O
theoretical O
basis O
that O
these O
effects O
may O
be O
additive O
, O
use O
of O
ergotamine-containing B-drug
or O
ergot-type B-group
medications I-group
( O
like O
dihydroergotamine B-drug
or O
methysergide B-drug
) O
and O
AXERT B-brand
within O
24 O
hours O
of O
each O
other O
should O
be O
avoided O
. O

Miracidia O
demonstrated O
a O
rapid O
avoidance O
behaviour O
when O
briefly O
exposed O
to O
heavy O
metals O
. O

Carbamazepine B-drug
: O
In O
healthy O
subjects O
receiving O
the O
CYP3A4 O
inducer O
, O
carbamazepine B-drug
, O
at O
100 O
mg O
twice O
daily O
for O
3 O
days O
and O
200 O
mg O
twice O
daily O
for O
17 O
days O
, O
systemic O
exposure O
( O
AUC O
) O
to O
lapatinib B-drug
was O
decreased O
approximately O
72 O
% O
. O

The O
aim O
of O
this O
paper O
was O
to O
study O
the O
interaction O
between O
neurotensin B-drug_n
and O
both O
enkephalins B-drug_n
or O
its O
synthetic O
analogue O
D-Ala2-metenkephalinamide B-drug_n
, O
or O
tuftsin B-drug_n
, O
on O
the O
antinonciceptive O
effect O
of O
these O
peptides O
in O
mice O
after O
intracisternal O
injection O
. O

Coadministration O
of O
this O
oral O
contraceptive B-group
did O
not O
influence O
the O
pharmacokinetics O
of O
levetiracetam B-drug
. O

The O
magnitude O
of O
interaction O
within O
the O
recommended O
dose O
ranges O
of O
either O
drug O
is O
not O
known O
. O

Treatment O
of O
toxin B-drug_n
A I-drug_n
with O
[ O
( O
14 O
) O
C O
] O
-diethyl B-drug_n
pyrocarbonate I-drug_n
revealed O
concentration O
dependent O
labelling O
of O
histidine O
residues O
on O
the O
toxin O
molecules O
. O

Cross-reactions O
with O
non-Aspergillus O
polysaccharides O
and O
polyfuranoses O
with O
the O
Bio-Rad O
Laboratories O
Platelia O
Aspergillus O
EIA O
test O
have O
been O
reported O
. O

Drug/Laboratory O
Test O
Interactions O
: O
A O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
with O
copper O
reduction O
tests O
( O
Benedict O
s O
or O
Fehling O
s O
solution O
or O
with O
Clinitest O
tablets O
) O
but O
not O
with O
enzyme-based O
tests O
for O
glycosuria O
. O

Grapefruit O
juice O
should O
not O
be O
taken O
during O
treatment O
with O
oral O
amiodarone O
. O

monitor O
cyclosporine B-drug
levels O
. O

Table O
3 O
Established O
Drug O
Interactions O
: O
Alteration O
in O
Dose O
or O
Regimen O
May O
Be O
Recommended O
Based O
on O
Drug O
Interaction O
Studies O

Anagrelide B-drug
is O
an O
inhibitor O
of O
cyclic O
AMP O
PDE O
III O
. O

Cyclosporine B-drug
: O
Concomitant O
administration O
of O
nicardipine B-drug
and O
cyclosporine B-drug
levels O
. O

This O
interaction O
may O
result O
in O
myopathy O
and O
rhabdomyolysis O
, O
particularly O
in O
patients O
with O
renal O
insufficiency O
or O
those O
who O
are O
concurrently O
taking O
medications O
associated O
with O
myopathy O
. O

FLUOTHANE B-brand
augments O
the O
action O
of O
non-depolarising B-group
muscle I-group
relaxants O
and O
the O
muscle O
relaxant O
effects O
of O
aminoglycosides B-group
. O

Twelve O
strains O
of O
Staphylococcus O
aureus O
( O
a O
frequent O
cause O
of O
infection O
in O
heroin B-drug_n
, O
but O
not O
in O
pentazocine B-drug
and O
tripelennamine B-drug
, O
addicts O
) O
were O
completely O
inhibited O
by O
the O
drug O
combination O
. O

Recovery O
programs O
should O
be O
flexible O
and O
involve O
individual O
and O
family O
education O
on O
recovery O
and O
the O
nature O
of O
addictive O
disease O
. O

- O
Skeletal B-group
muscle I-group
relaxants I-group
, O
nondepolarizing O
( O
e.g. O
, O
tubocurarine B-drug
) O
: O
Possible O
increased O
responsiveness O
to O
the O
muscle B-group
relaxant I-group

Continued O
admistration O
of O
the O
drug O
is O
required O
to O
maintain O
barpress O
response O
in O
this O
strain O
of O
dogs O
. O

A O
dose O
increase O
of O
lopinavir/ritonavir B-drug
to O
533/133 O
mg O
twice O
daily O
with O
food O
isrecommended O
in O
combination O
with O
nevirapine B-drug
. O

Nevertheless O
, O
caution O
should O
be O
used O
in O
patients O
receiving O
concomitant O
treatment O
with O
other O
drugs O
that O
are O
either O
inhibitors O
or O
inducers O
of O
these O
enzymes O
. O

Permanent O
nerve O
damage O
could O
theoretically O
occur O
if O
vitamin O
B12 O
deficiency O
is O
not O
treated O
. O

- O
Carbamazepine B-drug
( O
e.g. O
, O
Tegretol B-brand
) O
or O

Anagrelide B-drug
is O
metabolized O
at O
least O
in O
part O
by O
CYP1A2 O
. O

If O
the O
usual O
amounts O
of O
nondepolarizing O
relaxants O
are O
given O
, O
the O
time O
for O
recovery O
from O
neuromuscular O
blockade O
will O
be O
longer O
in O
the O
presence O
of O
Enflurane B-drug
than O
when O
halothane B-drug
or O
nitrous B-drug
oxide I-drug
with O
a O
balanced O
technique O
are O
used O
. O

Although O
not O
studied O
systematically O
in O
clinical O
trials O
, O
no O
drug O
interactions O
were O
observed O
when O
vecuronium B-drug
, O
pancuronium B-drug
, O
or O
atracurium B-drug
were O
administered O
following O
varying O
degrees O
of O
recovery O
from O
single O
doses O
or O
infusions O
of O
NIMBEX B-brand
. O

Free O
T3 O
resin O
uptake O
is O
decreased O
, O
reflecting O
the O
elevated O
TBG O
; O

In O
both O
periods O
, O
blood O
and O
urine O
were O
sampled O
at O
regular O
intervals O
. O

Interest O
in O
administering O
compounds O
in O
combination O
lies O
both O
in O
enhancing O
efficacious O
effects O
and O
in O
limiting O
adverse O
effects O
. O

May O
interact O
with O
addictive O
medications O
, O
especially O
central B-group
nervous I-group
system I-group
( I-group
CNS I-group
) I-group
depressants I-group
with O
habituating O
potential O
( O
prolonged O
concurrent O
use O
may O
increase O
the O
risk O
of O
habituation O
) O
, O
alcohol B-drug
or O
CNS O
depression O
producing O
medications O
( O
concurrent O
use O
may O
increase O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
ethinamate B-drug
) O
. O

There O
were O
no O
significant O
differences O
among O
the O
pD2 O
values O
for O
noradrenaline B-drug
in O
aortic O
rings O
without O
endothelium O
. O

Consequently O
, O
concomitant O
administration O
of O
Aprepitant B-drug
with O
strong O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
ketoconazole B-drug
, O
itraconazole B-drug
, O
nefazodone B-drug
, O
troleandomycin B-drug
, O
clarithromycin B-drug
, O
ritonavir B-drug
, O
nelfinavir B-drug
) O
should O
be O
approached O
with O
caution O
. O

Additional O
animals O
in O
both O
dose O
groups O
developed O
B-cell O
hyperplasia O
of O
the O
spleen O
and O
lymph O
nodes O
. O

When O
the O
CYP2D6 O
inhibitor O
is O
withdrawn O
from O
the O
combination O
therapy O
, O
aripiprazole B-drug
dose O
should O
then O
be O
increased O
. O

( O
Indomethacin B-drug
) O
diuretics B-group
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-group
is O
obtained O
. O

Preliminary O
studies O
indicate O
that O
the O
concomitant O
use O
of O
dobutamine B-drug
and O
nitroprusside B-drug
results O
in O
a O
higher O
cardiac O
output O
and O
, O
usually O
, O
a O
lower O
pulmonary O
wedge O
pressure O
than O
when O
either O
drug O
is O
used O
alone O
. O

In O
order O
to O
use O
the O
pharmacological O
properties O
of O
induced O
therapeutic O
hypermagnesaemia O
, O
high O
oral O
doses O
of O
magnesium B-drug
( O
> O
10 O
mg/kg/day O
) O
are O
advisable O
for O
chronic O
indications O
and O
the O
parenteral O
route O
is O
suitable O
for O
acute O
indications O
. O

insulin B-drug
requirements O
may O
be O
increased O
, O
decreased O
, O
or O
unchanged O
. O
) O

The O
CYP3A4 O
isoenzyme O
is O
present O
in O
both O
the O
liver O
and O
intestines O
. O

No O
information O
available O

DIDREX B-brand
should O
not O
be O
used O
concomitantly O
with O
other O
CNS B-group
stimulants I-group
. O

however O
, O
as O
with O
other O
NSAIDs B-group
, O
concomitant O
administration O
of O
Lodine B-brand
and O
aspirin B-brand
is O
not O
generally O
recommended O
because O
of O
the O
potential O
of O
increased O
adverse O
effects O
. O

Therefore O
, O
when O
hydroflumethiazide B-drug
and O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-group
is O
obtained O
. O
) O

In O
such O
cases O
, O
therefore O
, O
more O
frequent O
dosing O
may O
be O
required O
to O
achieve O
or O
maintain O
the O
desired O
hypotensive O
response O
. O

Gabapentin B-drug
is O
not O
appreciably O
metabolized O
nor O
does O
it O
interfere O
with O
the O
metabolism O
of O
commonly O
coadministered O
antiepileptic B-group
drugs I-group
. O

Drugs O
that O
Inhibit O
or O
Induce O
Cytochrome O
P450 O
3A4 O
Enzymes O
Lapatinib B-drug
undergoes O
extensive O
metabolism O
by O
CYP3A4 O
, O
and O
concomitant O
administration O
of O
strong O
inhibitors O
or O
inducers O
of O
CYP3A4 O
alter O
lapatinib B-drug
concentrations O
significantly O
. O

When O
initiating O
a O
multi-day O
course O
of O
grepafloxacin B-drug
in O
a O
patient O
maintained O
on O
theophylline B-drug
, O
the O
theophylline B-drug
maintenance O
dose O
should O
be O
halved O
for O
the O
period O
of O
concurrent O
use O
of O
grepafloxacin B-drug
and O
monitoring O
of O
serum O
theophylline B-drug
concentrations O
should O
be O
initiated O
as O
a O
guide O
to O
further O
dosage O
adjustments O
. O

ZEBETA B-brand
should O
be O
used O
with O
care O
when O
myocardial B-group
depressants I-group
or O
inhibitors O
of O
AV O
conduction O
, O
such O
as O
certain O
calcium B-group
antagonists I-group
( O
particularly O
of O
the O
phenylalkylamine B-group
[ O
verapamil B-drug
] O
and O
benzothiazepine B-group
[ O
diltiazem B-drug
] O
classes O
) O
, O
or O
antiarrhythmic B-group
agents I-group
, O
such O
as O
disopyramide B-drug
, O
are O
used O
concurrently O
. O

Elevated O
cyclosporine B-drug
serum O
levels O
have O
been O
reported O
with O
the O
concomitant O
use O
of O
quinolones B-group
and O
cyclosporine B-drug
. O

Cytotoxic B-group
Agents I-group
: O
Enhanced O
bone O
marrow O
suppression O
by O
cyclophosphamide B-drug
and O
other O
cytotoxic B-group
agents I-group
has O
been O
reported O
among O
patients O
with O
neoplastic O
disease O
, O
except O
leukemia O
, O
in O
the O
presence O
of O
allopurinol B-drug
. O

100-150 O

Once O
a O
stable O
prothrombin O
time O
has O
been O
documented O
, O
prothrombin O
times O
can O
be O
monitored O
at O
the O
intervals O
usually O
recommended O
for O
patients O
on O
coumarin B-group
anticoagulants I-group
. O

It O
is O
recommended O
that O
serum O
lithium B-drug
levels O
be O
monitored O
frequently O
if O
enalapril B-drug
is O
administered O
concomitantly O
with O
lithium B-drug
. O

- O
Non-steroidal B-group
Anti-inflammatory I-group
Drugs I-group
: O
In O
some O
patients O
, O
the O
administration O
of O
a O
non-steroidal B-group
anti-inflammatory I-group
agent I-group
can O
reduce O
the O
diuretic O
, O
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop O
, O
potassium-sparing O
and O
thiazide B-drug
diuretics I-drug
. O

The O
reluctance O
to O
treat O
aggressively O
is O
understandable O
because O
the O
geriatric O
population O
is O
susceptible O
to O
adverse O
drug O
reactions O
. O

Leukocyte B-drug_n
transfusions I-drug_n
: O
acute O
pulmonary O
toxicity O
has O
been O
reported O
in O
patients O
receiving O
intravenous O
amphotericin B-drug
B I-drug
and O
leukocyte B-drug_n
transfusions I-drug_n
. O

The O
effect O
of O
corticosteroids B-group
on O
oral O
anticoagulants B-group
is O
variable O
. O

The O
levorotatory O
isomer O
had O
opioid-antagonist O
and O
non-opioid O
agonist O
effects O
in O
pigeons O
and O
mixed O
opioid O
agonist-antagonist O
effects O
in O
monkeys O
. O

The O
interaction O
is O
a O
consequence O
of O
blocking O
hepatic O
metabolism O
of O
vardenafil B-drug
by O
ritonavir B-drug
, O
a O
highly O
potent O
CYP3A4 O
inhibitor O
, O
which O
also O
inhibits O
CYP2C9 O
. O

Samples O
for O
plasma O
and O
urine O
immunoreactive O
digoxin B-drug
concentrations O
were O
collected O
through O
120 O
hours O
following O
the O
digoxin B-drug
dose O
. O

. O

The O
pharmacokinetics O
of O
irbesartan B-drug
were O
not O
affected O
by O
coadministration O
of O
nifedipine B-drug
or O
hydrochlorothiazide B-drug

griseofulvin B-drug
; O

Praziquantel B-drug
: O
In O
the O
fed O
state O
, O
praziquantel B-drug
( O
40 O
mg/kg O
) O
increased O
mean O
maximum O
plasma O
concentration O
and O
area O
under O
the O
curve O
of O
albendazole B-drug
sulfoxide I-drug
by O
about O
50 O
% O
in O
healthy O
subjects O
( O
n=10 O
) O
compared O
with O
a O
separate O
group O
of O
subjects O
( O
n=6 O
) O
given O
albendazole B-drug
alone O
. O

Such O
individuals O
are O
referred O
to O
as O
poor O
metabolizers O
of O
drugs O
such O
as O
debrisoquin B-drug
, O
dextromethorphan B-drug
, O
and O
the O
tricyclic B-group
antidepressants I-group
. O

When O
these O
products O
are O
administered O
concomitantly O
, O
prothrombin O
time O
or O
other O
suitable O
coagulation O
tests O
should O
be O
monitored O
. O

- O
Anticoagulants B-group
: O
Interaction O
studies O
in O
humans O
have O
shown O
bumetanide B-drug
to O
have O
no O
effect O
on O
warfarin B-drug
metabolism O
or O
on O
plasma O
prothrombin O
activity O
. O

Both O
studies O
used O
12 O
subjects O
. O

Lithium B-drug
: O
Nonsteroidal B-group
anti-inflammatory I-group
agents I-group
have O
been O
reported O
to O
increase O
steadystate O
plasma O
lithium B-drug
levels O
. O

After O
etofibrate B-drug
treatment O
, O
there O
was O
decrease O
of O
total O
cholesterol O
and O
triglyceride O
plasma O
levels O
and O
a O
trend O
to O
increase O
high-density O
lipoprotein O
cholesterol O
plasma O
levels O
. O

nc1,2 O
30 O
% O
decrease O
[ O
CI O
: O
3 O
% O
decrease O
, O
48 O
% O
decrease O
] O

Patients O
receiving O
hydantoins B-group
, O
sulfonamides B-group
, O
or O
sulfonylureas B-group
should O
be O
observed O
for O
increased O
activity O
of O
these O
drugs O
and O
, O
therefore O
, O
signs O
of O
toxicity O
from O
these O
drugs O
. O

In O
vitro O
drug O
metabolism O
studies O
indicate O
that O
Starlix B-brand
is O
predominantly O
metabolized O
by O
the O
cytochrome O
P450 O
isozyme O
CYP2C9 O
( O
70 O
% O
) O
and O
to O
a O
lesser O
extent O
CYP3A4 O
( O
30 O
% O
) O
. O

zaleplon B-drug
did O
not O
affect O
the O
pharmacokinetics O
of O
ethanol B-drug
. O

Dofetilide B-drug
is O
not O
an O
inhibitor O
of O
CYP3A4 O
nor O
of O
other O
cytochrome O
P450 O
isoenzymes O
( O
e.g. O
, O
CYP2C9 O
, O
CYP2D6 O
) O
and O
is O
not O
expected O
to O
increase O
levels O
of O
drugs O
metabolized O
by O
CYP3A4 O
. O

Reductions O
in O
serum O
endogenous O
vitamin O
D O
concentrations O
have O
been O
observed O
following O
the O
administration O
of O
300 O
mg/day O
to O
1200 O
mg/day O
ketoconazole B-drug
for O
a O
week O
to O
healthy O
men O
. O

n-Octyl O
and O
n-cetyl O
gallate O
also O
showed O
good O
inhibition O
, O
while O
gallic O
acid O
itself O
was O
not O
so O
active O
, O
suggesting O
that O
the O
presence O
of O
hydrophobic O
side O
chain O
is O
important O
for O
the O
suppressive O
effect O
. O

These O
agents O
should O
not O
be O
used O
in O
patients O
treated O
with O
Itraconazole B-drug
. O

18-Methoxycoronaridine B-drug_n
( O
18-MC B-drug_n
) O
and O
ibogaine B-drug_n
: O
comparison O
of O
antiaddictive O
efficacy O
, O
toxicity O
, O
and O
mechanisms O
of O
action O
. O

Conjugation O
at O
NaCMC B-drug_n
with O
cysteine B-drug
moieties O
significantly O
improves O
the O
intestinal O
permeation O
of O
the O
hydrophilic O
molecule O
NaFlu B-drug
and O
the O
model O
peptide O
drugs O
bacitracin B-drug
and O
insulin B-drug
in O
vitro O
, O
therefore O
this O
conjugated O
system O
maybe O
useful O
for O
peroral O
administration O
of O
peptide O
drugs O
in O
the O
future O
. O

Reproductive O
toxicology O
studies O
have O
been O
performed O
in O
cynomolgus O
monkeys O
at O
doses O
up O
to O
5 O
mg/kg/week O
( O
about O
62 O
times O
the O
human O
dose O
based O
on O
body O
weight O
) O
and O
have O
revealed O
no O
evidence O
of O
impaired O
fertility O
or O
harm O
to O
the O
fetus O
due O
to O
AMEVIVE B-brand
. O

Since O
both O
alcohol B-drug
and O
organoleads O
are O
present O
in O
the O
environment O
and O
seem O
to O
influence O
limbic O
integration O
, O
the O
interaction O
of O
these O
two O
compounds O
was O
assessed O
in O
the O
present O
experiment O
. O

Interactions O
between O
theraputic O
agents O
have O
been O
recognized O
as O
increasingly O
important O
causes O
of O
drug O
at O
their O
usual O
recommended O
dose O
may O
, O
under O
certain O
conditions O
, O
produce O
toxicity O
of O
life-endangering O
proportions O
. O

We O
examined O
the O
effect O
of O
exogenous O
estradiol B-drug
on O
the O
changes O
in O
serum O
steroid O
hormone O
levels O
induced O
by O
a O
nonlethal O
dose O
of O
Escherichia O
coli O
endotoxin B-drug_n
in O
male O
rats O
and O
the O
deaths O
due O
to O
nonlethal O
and O
lethal O
doses O
of O
endotoxin B-drug_n
. O

Therefore O
, O
it O
should O
be O
used O
with O
caution O
in O
patients O
receiving O
such O
agents O
. O

Meperidine B-drug
: O
Amphetamines B-group
potentiate O
the O
analgesic O
effect O
of O
meperidine B-drug
. O

A O
direct O
causal O
relationship O
has O
not O
been O
established O
, O
but O
physicians O
should O
consider O
the O
possibility O
that O
diclofenac B-drug
may O
alter O
a O
diabetic O
patient O
s O
response O
to O
insulin B-drug
or O
oral O
hypoglycemic B-group
agents I-group
. O

Both O
ibogaine B-drug_n
and O
18-MC B-drug_n
decrease O
extracellular O
levels O
of O
dopamine O
in O
the O
nucleus O
accumbens O
, O
but O
only O
ibogaine B-drug_n
increases O
extracellular O
levels O
of O
serotonin O
in O
the O
nucleus O
accumbens O
. O

Before O
prescribing O
a O
symptomatic O
( O
pharmaceutical O
) O
treatment O
for O
patients O
with O
an O
erection O
disorder O
, O
attention O
should O
be O
given O
tot O
the O
sexological O
, O
psychological O
and O
medical O
backgrounds O
of O
the O
disorder O
. O

In O
a O
study O
in O
36 O
patients O
with O
mild O
to O
moderate O
hypertension O
where O
the O
antihypertensive O
effects O
of O
PRINIVIL B-brand
alone O
were O
compared O
to O
PRINIVIL B-brand
given O
concomitantly O
with O
indomethacin B-drug
, O
the O
use O
of O
indomethacin B-drug
was O
associated O
with O
a O
reduced O
antihypertensive O
effect O
, O
although O
the O
difference O
between O
the O
two O
regimens O
was O
not O
significant O
. O

In O
this O
study O
we O
investigated O
the O
effect O
of O
ginsenosides B-drug_n
on O
high O
threshold O
voltage-dependent O
Ca O
( O
2+ O
) O
channel O
subtypes O
using O
their O
selective B-group
Ca I-group
( I-group
2+ I-group
) I-group
channel I-group
blockers I-group
nimodipine B-drug
( O
L-type O
) O
, O
omega-conotoxin B-drug_n
GVIA I-drug_n
( O
N-type O
) O
, O
or O
omega-agatoxin B-drug_n
IVA I-drug_n
( O
P-type O
) O
in O
bovine O
chromaffin O
cells O
. O

Dose O
reduction O
or O
interruption O
of O
TARCEVA B-brand
should O
be O
considered O
if O
changes O
in O
liver O
function O
are O
severe O
. O

Trimethoprim B-drug
Alone O
or O
in O
Combination O
with O
Sulfamethoxazole B-drug
: O
Concomitant O
use O
of O
trimethoprim B-drug
alone O
or O
in O
combination O
with O
sulfamethoxazole B-drug
is O
contraindicated O
. O

This O
paper O
critically O
reviews O
the O
suitability O
of O
the O
urinary O
thioether O
assay O
as O
a O
method O
for O
the O
detection O
of O
exposure O
to O
electrophilic O
agents O
or O
their O
precursors O
. O

clinical O
implications O
are O
unclear O
. O

Nabilone B-drug
has O
been O
shown O
to O
have O
an O
additive O
CNS O
depressant O
effect O
when O
given O
with O
either O
diazepam B-drug
, O
secobarbitone B-brand
sodium I-brand
, O
alcohol B-drug
or O
codeine B-drug
. O

The O
interaction O
may O
be O
a O
result O
of O
inhibition O
of O
both O
CYP2C9 B-drug
and O
2C19 O
by O
fluvoxamine B-drug
. O

Other O
nephrotoxic O
medications O
: O
agents O
such O
as O
aminoglycosides B-group
, O
cyclosporine B-drug
, O
and O
pentamidine B-drug
may O
enhance O
the O
potential O
for O
drug-induced O
renal O
toxicity O
, O
and O
should O
be O
used O
concomitantly O
only O
with O
great O
caution O
. O

Methotrexate B-drug
: O
An O
increased O
risk O
of O
hepatitis O
has O
been O
reported O
to O
result O
from O
combined O
use O
of O
methotrexate B-drug
and O
etretinate B-drug
. O

certain O
antipsychotic B-group
medications I-group
( O
such O
as O
sertindole B-drug
) O
; O

Phenytoin B-drug
, O
phenobarbital B-drug
and O
carbamazepine B-drug
are O
ge O
nerally O
classified O
as O
enzyme O
inducers O
; O

Sertraline B-drug
neutralized O
the O
increase O
of O
glycemia O
induced O
by O
oral O
glucose B-drug
overload O
. O

Drug/ O
Laboratory O
Test O
Interactions O
Certain O
endocrine O
and O
liver O
function O
tests O
may O
be O
affected O
by O
estrogen-containing B-group
oral O
contraceptives B-group
. O

- O
Divalproex B-drug
( O
e.g. O
, O
Depakote B-brand
) O
or O

This O
is O
especially O
important O
for O
drugs O
associated O
with O
serious O
toxicity O
, O
such O
as O
other O
antiarrhythmics B-group
. O

In O
a O
study O
in O
hypertensive O
patients O
, O
addition O
of O
isradipine B-drug
to O
existing O
hydrochlorothiazide B-drug
therapy O
did O
not O
result O
in O
any O
unexpected O
adverse O
effects O
, O
and O
isradipine B-drug
had O
an O
additional O
antihypertensive O
effect O
. O

Acarbose B-drug
did O
not O
interfere O
with O
the O
absorption O
or O
disposition O
of O
the O
sulfonylurea B-drug
glyburide I-drug
in O
diabetic O
patients O
. O

These O
effects O
are O
usually O
reversible O
. O

Inhibitors O
Of O
Endogenous O
Prostaglandin O
Synthesis O
It O
has O
been O
reported O
that O
indomethacin B-drug
may O
reduce O
the O
antihypertensive O
effect O
of O
captopril B-drug
, O
especially O
in O
cases O
of O
low O
renin O
hypertension O
. O

Pregnancy O
( O
Category O
B O
) O

Therefore O
, O
diflunisal B-drug
and O
INDOCIN B-brand
should O
not O
be O
used O
concomitantly O
. O

Therefore O
, O
unless O
otherwise O
specified O
, O
appropriate O
dosage O
adjustments O
may O
be O
necessary O
. O

Drug-Drug O
Interactions O
Between O
Keppra B-brand
And O
Other O
Antiepileptic B-group
Drugs I-group
( O
AEDs B-group
) O
Phenytoin B-drug
Keppra B-brand
( O
3000 O
mg O
daily O
) O
had O
no O
effect O
on O
the O
pharmacokinetic O
disposition O
of O
phenytoin B-drug
in O
patients O
with O
refractory O
epilepsy O
. O

The O
benefits O
of O
Mefloquine B-drug
therapy O
should O
be O
weighed O
against O
the O
possibility O
of O
adverse O
effects O
in O
patients O
with O
cardiac O
disease O
. O

Each O
treatment O
period O
was O
separated O
by O
14 O
to O
21 O
days O
. O

Zimelidine B-drug_n
etomidate B-drug
antagonism O

In O
these O
cases O
, O
your O
doctor O
may O
want O
to O
change O
the O
dose O
, O
or O
other O
precautions O
may O
be O
necessary O
. O

Other O
significant O
inhibitors O
of O
CYP2D6 O
, O
such O
as O
fluoxetine B-drug
or O
paroxetine B-drug
, O
would O
be O
expected O
to O
have O
similar O
effects O
and O
, O
therefore O
, O
should O
be O
accompanied O
by O
similar O
dose O
reductions O
. O

Patients O
with O
major O
psychotic O
disorders O
, O
treated O
with O
neuroleptics B-group
, O
should O
be O
treated O
with O
dopamine B-group
agonists I-group
only O
if O
the O
potential O
benefits O
outweigh O
the O
risks O
. O

Nine O
additional O
patients O
who O
had O
initial O
positive O
tests O
were O
negative O
on O
repeat O
testing O
. O

Antiepileptic B-group
Drugs I-group
: O
Sporadic O
cases O
of O
seizures O
have O
been O
reported O
during O
concomitant O
use O
of O
TORADOL B-brand
and O
antiepileptic B-group
drugs I-group
( O
phenytoin B-drug
, O
carbamazepine B-drug
) O
. O

Concomitant O
Drug O

- O
Plicamycin B-drug
( O
e.g. O
, O
Mithracin B-brand
) O
or O

Digoxin B-drug
: O
When O
Starlix B-brand
120 O
mg O
before O
meals O
was O
administered O
in O
combination O
with O
a O
single O
1-mg O
dose O
of O
digoxin B-drug
to O
healthy O
volunteers O
, O
there O
were O
no O
clinically O
relevant O
changes O
in O
the O
pharmacokinetics O
of O
either O
agent O
. O

Additional O
interactions O

Therefore O
, O
inhibitors O
of O
these O
enzymes O
are O
expected O
to O
reduce O
vardenafil B-drug
clearance O
. O

Ketoconazole B-drug
: O
In O
healthy O
subjects O
receiving O
ketoconazole B-drug
, O
a O
CYP3A4 O
inhibitor O
, O
at O
200 O
mg O
twice O
daily O
for O
7 O
days O
, O
systemic O
exposure O
( O
AUC O
) O
to O
lapatinib B-drug
was O
increased O
to O
approximately O
3.6-fold O
of O
control O
and O
half-life O
increased O
to O
1.7-fold O
of O
control O
. O

Guidelines O
are O
provided O
to O
assist O
the O
clinician O
in O
his O
logical O
approach O
to O
the O
identification O
of O
drug O
interactions O
when O
serious O
drug O
toxicity O
is O
encountered O
in O
a O
pateint O
. O

Because O
of O
foscarnets B-drug
tendency O
to O
cause O
renal O
impairment O
, O
the O
use O
of O
FOSCAVIR B-brand
should O
be O
avoided O
in O
combination O
with O
potentially O
nephrotoxic O
drugs O
such O
as O
aminoglycosides B-group
, O
amphotericin B-drug
B I-drug
and O
intravenous O
pentamidine B-drug
unless O
the O
potential O
benefits O
outweigh O
the O
risks O
to O
the O
patient O
. O

Epinephrine B-drug
may O
antagonize O
the O
neuron O
blockade O
produced O
by O
guanethidine B-drug
resulting O
in O
decreased O
antihypertensive O
effect O
and O
requiring O
increased O
dosage O
of O
the O
latter O
. O

Because O
CYP O
3A4 O
inhibitors O
may O
increase O
plasma O
concentrations O
of O
buprenorphine B-drug
, O
patients O
already O
on O
CYP O
3A4 O
inhibitors O
such O
as O
azole B-group
antifungals I-group
( O
e.g O
. O

With O
each O
successive O
generation O
more O
people O
are O
becoming O
more O
severely O
depressed O
at O
a O
younger O
age O
. O

saquinavir I-drug
concentration O

Marked O
symptomatic O
orthostatic O
hypotension O
has O
been O
reported O
when O
calcium B-group
channel I-group
blockers I-group
and O
organic B-group
nitrates I-group
were O
used O
in O
combination O
. O

Thus O
no O
dosing O
adjustments O
are O
necessary O
during O
concomitant O
use O
with O
these O
agents O
. O

Concomitant O
administration O
of O
Sonata B-brand
( O
10 O
mg O
) O
and O
cimetidine B-drug
( O
800 O
mg O
) O
produced O
an O
85 O
% O
increase O
in O
the O
mean O
Cmax O
and O
AUC O
of O
zaleplon B-drug
. O

This O
antagonistic O
effect O
of O
probenecid B-drug
on O
bumetanide B-drug
natriuresis O
is O
not O
due O
to O
a O
direct O
action O
on O
sodium O
excretion O
but O
is O
probably O
secondary O
to O
its O
inhibitory O
effect O
on O
renal O
tubular O
secretion O
of O
bumetanide B-drug
. O

For O
information O
on O
the O
pharmacokinetics O
of O
Gemzar B-brand
and O
cisplatin B-drug
in O
combination O
, O
see O
Drug O
Interactions O
under O
CLINICAL O
PHARMACOLOGY O
section O
. O

Caffeine-related B-drug
adverse O
effects O
have O
occurred O
in O
patients O
consuming O
caffeine B-drug
while O
on O
therapy O
with O
enoxacin B-drug
. O

Cholestyramine B-drug
: O
Cholestyramine B-drug
may O
increase O
the O
clearance O
of O
corticosteroids B-group
. O

Among O
these O
patients O
, O
the O
incidence O
of O
upper O
gastrointestinal O
adverse O
experiences O
in O
the O
patients O
treated O
with O
Ibandronate B-drug
150 O
mg O
once O
monthly O
was O
similar O
to O
that O
in O
patients O
treated O
with O
Ibandronate B-drug
2.5 O
mg O
once O
daily O
. O

Ampicillin B-drug
: O
In O
a O
study O
of O
healthy O
volunteers O
, O
chloroquine B-drug
significantly O
reduced O
the O
bioavailability O
of O
ampicillin B-drug
. O

Metal O
mixtures O
had O
no O
effect O
on O
egg B-drug
hatching O
. O

Because O
of O
its O
primary O
CNS O
effect O
, O
caution O
should O
be O
used O
when O
EQUETROTM B-brand
is O
taken O
with O
other O
centrally B-group
acting I-group
drugs I-group
and O
alcohol B-drug
. O

Reports O
suggest O
that O
NSAIDs B-group
may O
diminish O
the O
antihypertensive O
effect O
of O
ACE B-group
inhibitors I-group
, O
including O
lisinopril B-drug
. O

Thus O
agents O
likely O
to O
be O
concomitantly O
administered O
with O
Chirocaine B-brand
that O
are O
metabolized O
by O
this O
isoenzyme O
family O
may O
potentially O
interact O
with O
Chirocaine B-brand
. O

These O
individuals O
may O
have O
higher O
than O
expected O
plasma O
concentrations O
of O
tricyclic B-group
antidepressants I-group
when O
given O
usual O
doses O
. O

In O
order O
to O
approximate O
the O
steady O
state O
level O
, O
serum O
digoxin B-drug
levels O
should O
be O
drawn O
either O
before O
or O
at O
least O
six O
hours O
following O
the O
administration O
of O
an O
oral O
tablet O
. O

The O
use O
of O
herbal O
remedies O
is O
becoming O
increasingly O
popular O
in O
the O
United O
States O
. O

Drugs O
that O
may O
decrease O
imatinib B-drug
plasma O
concentrations O
: O
Substances O
that O
are O
inducers O
of O
CYP3A4 O
activity O
may O
increase O
metabolism O
and O
decrease O
imatinib B-drug
plasma O
concentrations O
. O

This O
inhibition O
can O
result O
in O
unexpectedly O
high O
plasma O
levels O
of O
other O
drugs B-drug
which O
are O
metabolized O
by O
those O
CYP450 O
enzymes O
. O

In O
a O
study O
in O
diabetics O
with O
microalbuminuria O
INSPRA B-brand
200 O
mg O
combined O
with O
the O
ACE B-group
inhibitor I-group
enalapril B-drug
10 O
mg O
increased O
the O
frequency O
of O
hyperkalemia O
( O
serum O
potassium O
5.5 O
mEq/L O
) O
from O
17 O
% O
on O
enalapril B-drug
alone O
to O
38 O
% O
. O

Tumor O
phenotype O
and O
susceptibility O
to O
progression O
as O
an O
expression O
of O
subpopulations O
of O
initiated O
murine O
cells O
. O

Rifampin B-drug
and O
warfarin B-drug
: O
a O
drug O
interaction O
. O

When O
catecholamines B-group
are O
administered O
, O
dilute O
solutions O
should O
be O
used O
and O
blood O
pressure O
should O
be O
monitored O
closely O
. O

Iodine B-drug
or O
iodine B-drug
excess O
may O
decrease O
the O
effect O
of O
Carbimazole B-drug
, O
and O
an O
iodine B-drug
deficiency O
can O
increase O
the O
effect O
of O
Carbimazole B-drug
. O

Elevated O
serum O
levels O
of O
cyclosporine B-drug
have O
been O
reported O
with O
the O
concomitant O
use O
of O
some O
quinolones B-group
and O
cyclosporine B-drug
. O

See O
WARNINGS O
, O
Myopathy/Rhabdomyolysis O
. O

Acetazolamide B-drug
increases O
lithium B-drug
excretion O
and O
the O
lithium B-drug
may O
be O
decreased O
. O

Drugs O
that O
may O
increase O
dasatinib B-drug
plasma O
concentrations O
CYP3A4 O
Inhibitors O
: O
Dasatinib B-drug
is O
a O
CYP3A4 O
substrate O
. O

No O
significant O
interaction O
has O
been O
found O
with O
broad-spectrum O
antibiotics B-group
. O

Magnesium B-drug
: O
Magnesium-containing B-drug
preparations O
( O
eg O
, O
antacids B-group
) O
may O
cause O
hypermagnesemia O
and O
should O
therefore O
not O
be O
taken O
during O
therapy O
with O
vitamin B-group
D I-group
by O
patients O
on O
chronic O
renal O
dialysis O
. O

Currently O
, O
there O
are O
no O
safety O
and O
efficacy O
data O
available O
from O
the O
use O
of O
this O
combination O
. O

Differential O
regulation O
of O
tyrosine O
phosphorylation O
in O
tumor O
cells O
by O
contortrostatin B-drug_n
, O
a O
homodimeric O
disintegrin O
, O
and O
monomeric O
disintegrins O
echistatin B-drug_n
and O
flavoridin B-drug_n
. O

Usually O
, O
this O
has O
been O
observed O
in O
patients O
with O
a O
history O
of O
diabetes O
mellitus O
or O
evidence O
of O
glucose O
intolerance O
prior O
to O
administration O
of O
CAMPTOSAR B-brand
. O

. O

Salt O
substitutes O
containing O
potassium B-drug
should O
also O
be O
used O
with O
caution O
. O

In O
TAMBOCOR B-brand
clinical O
trials O
, O
patients O
who O
were O
receiving O
beta B-group
blockers I-group
concurrently O
did O
not O
experience O
an O
increased O
incidence O
of O
side O
effects O
. O

Benzodiazepines B-group
: O
Combination O
hormonal B-group
contraceptives I-group
may O
decrease O
the O
clearance O
of O
some O
benzodiazepines B-group
( O
alprazolam B-drug
, O
chlordiazepoxide B-drug
, O
diazepam B-drug
) O
and O
increase O
the O
clearance O
of O
others O
( O
lorazepam B-drug
, O
oxazepam B-drug
, O
temazepam B-drug
) O
. O

All O
animals O
in O
the O
study O
were O
positive O
for O
an O
endemic O
primate O
gammaherpes O
virus O
also O
known O
as O
lymphocryptovirus O
( O
LCV O
) O
. O

Cyclosporine B-drug
- O
L-arginine B-drug
may O
counteract O
the O
antinaturetic O
effect O
of O
cyclosporin B-drug
. O

Although O
, O
it O
is O
unknown O
whether O
this O
could O
result O
in O
clinically O
significant O
effects O
, O
caution O
is O
advised O
when O
administering O
Cerebyx B-brand
with O
other O
drugs O
that O
significantly O
bind O
to O
serum O
albumin O
. O

Coingestion O
of O
acetaminophen B-drug
with O
theophylline B-drug
, O
phenobarbital B-drug
with O
acetaminophen B-drug
, O
and O
valproic B-drug
acid I-drug
with O
phenobarbital B-drug
at O
high O
to O
toxic O
concentrations O
decreases O
the O
binding O
of O
the O
target O
drug O
. O

Alosetron B-drug
does O
not O
appear O
to O
induce O
the O
major O
cytochrome O
P450 O
( O
CYP O
) O
drug O
metabolizing O
enzyme O
3A O
. O

3 O
. O

antacids B-group
; O

N=12 O
) O
are O
identical O
whether O
the O
drugs O
are O
administered O
alone O
or O
together O
. O

Erythromycin B-drug
( O
500 O
mg O
t.i.d O
) O
produced O
a O
4-fold O
increase O
in O
vardenafil B-drug
AUC O
and O
a O
3-fold O
increase O
in O
Cmax O
when O
co-administered O
with O
Vardenafil B-drug
5 O
mg O
in O
healthy O
volunteers O
. O

HMG-CoA B-group
Reductase I-group
Inhibitor I-group
: O
atorvastatin B-drug

These O
results O
would O
seem O
to O
dictate O
against O
the O
clinical O
use O
of O
methotrexate B-drug
with O
ELSPAR B-brand
, O
or O
during O
the O
period O
following O
ELSPAR B-brand
therapy O
when O
plasma O
asparagine O
levels O
are O
below O
normal O
. O

Gastrointestinal O
transit O
time O
( O
lactulose O
hydrogen O
breath O
test O
) O
was O
measured O
in O
14 O
volunteers O
with O
oral O
and O
intravenous O
placebo O
, O
oral O
placebo O
and O
intravenous O
morphine B-drug
( O
0.05 O
mg O
x O
kg O
( O
-1 O
) O
) O
, O
and O
oral O
ADL B-drug
8-2698 I-drug
( O
4 O
mg O
) O
and O
intravenous O
morphine B-drug
( O
0.05 O
mg O
x O
kg O
( O
-1 O
) O
) O
in O
a O
double O
blind O
, O
cross-over O
study O
. O

Also O
, O
bleeding O
and/or O
increased O
prothrombin O
time O
have O
been O
reported O
in O
a O
few O
patients O
taking O
coumarin B-group
anticoagulants O
concomitantly O
with O
lovastatin B-drug
. O

The O
acceleration O
of O
gastric O
emptying O
by O
cisapride B-drug
could O
affect O
the O
rate O
of O
absorption O
of O
other O
drugs O
. O

In O
a O
study O
of O
15 O
male O
subjects O
( O
ages O
19 O
to O
35 O
years O
) O
who O
were O
extensive O
metabolizers O
of O
the O
CYP2D6 O
isoenzyme O
, O
daily O
doses O
of O
bupropion B-drug
given O
as O
150 O
mg O
twice O
daily O
followed O
by O
a O
single O
dose O
of O
50 O
mg O
desipramine B-drug
increased O
the O
Cmax O
, O
AUC O
, O
and O
t1/2 O
of O
desipramine B-drug
by O
an O
average O
of O
approximately O
2- O
, O
5- O
and O
2-fold O
, O
respectively O
. O

Quinolones B-group
, O
including O
cinoxacin B-drug
, O
may O
enhance O
the O
effects O
of O
oral O
anticoagulants B-group
, O
such O
as O
warfarin B-drug
or O
its O
derivatives O
. O

The O
selection O
of O
drugs O
and O
their O
dosages O
may O
be O
improved O
, O
and O
the O
number O
of O
adverse O
effects O
reduced O
by O
pharmacogenetic O
investigations O
. O

Chlorthalidone B-drug
and O
related O
drugs O
may O
increase O
the O
responsiveness O
to O
tubocurarine B-drug
. O

Although O
a O
3-day O
regimen O
of O
Aprepitant B-drug
given O
concomitantly O
with O
oral O
contraceptives B-group
has O
not O
been O
studied O
, O
alternative O
or O
back-up O
methods O
of O
contraception O
should O
be O
used O
. O

Caffeine B-drug
: O
Two O
hundred O
mg O
of O
caffeine B-drug
( O
equivalent O
to O
1 O
to O
3 O
cups O
of O
American O
coffee O
) O
was O
administered O
to O
16 O
normal O
, O
healthy O
volunteers O
who O
had O
achieved O
steady-state O
blood O
concentrations O
of O
lomefloxacin B-drug
after O
being O
dosed O
at O
400 O
mg O
qd O
. O

Their O
concurrent O
use O
should O
be O
avoided O
. O

Metoclopramide B-drug
: O
When O
coadministered O
with O
MONUROL B-brand
, O
metoclopramide B-drug
, O
a O
drug O
which O
increases O
gastrointestinal O
motility O
, O
lowers O
the O
serum O
concentration O
and O
urinary O
excretion O
of O
fosfomycin B-drug
. O

Dosage O
of O
the O
anticoagulant B-group
may O
require O
reduction O
in O
order O
to O
maintain O
satisfactory O
therapeutic O
hypoprothrombinemia O
. O

Among O
the O
proteins O
that O
undergo O
tyrosine O
phosphorylation O
in O
response O
to O
contortrostatin B-drug_n
treatment O
is O
CAS O
, O
a O
130 O
kDa O
adapter O
protein O
involved O
in O
integrin O
signaling O
. O

Careful O
observation O
is O
required O
. O

The O
presence O
of O
food O
in O
the O
stomach O
does O
not O
alter O
the O
bioavailability O
of O
PRINIVIL B-brand
. O

Epidural O
clonidine B-drug
may O
prolong O
the O
duration O
of O
pharmacologic O
effects O
of O
epidural O
local O
anesthetics B-group
, O
including O
both O
sensory O
and O
motor O
blockade O
. O

Esomeprazole B-drug
is O
extensively O
metabolized O
in O
the O
liver O
by O
CYP2C19 O
and O
CYP3A4 O
. O

also O
induced O
diarrhea O
, O
but O
did O
not O
produce O
a O
watery O
stool O
in O
cecectomized O
rats O
. O

( O
Concurrent O
use O
with O
thiazide B-group
diuretics I-group
is O
not O
recommended O
, O
as O
they O
may O
provoke O
lithium B-drug
toxicity O
because O
of O
reduced O
renal O
clearance O
. O
) O

Coadministration O
of O
astemizole B-drug
with O
ketoconazole B-drug
tablets O
is O
therefore O
contraindicated O
. O

Based O
on O
the O
literature O
reports O
, O
the O
same O
effects O
may O
be O
extrapolated O
to O
other O
fruit O
juices O
such O
as O
apple O
juice O
. O

Drugs O
possessing O
beta-blocking O
properties O
can O
blunt O
the O
bronchodilator O
effect O
of O
beta-receptor B-group
agonist I-group
drugs I-group
in O
patients O
with O
bronchospasm O
; O

Ritonavir B-drug

- O
Dapsone B-drug
or O

A O
study O
in O
six O
healthy O
volunteers O
has O
shown O
a O
significant O
increase O
in O
peak O
diltiazem B-drug
plasma O
levels O
( O
58 O
% O
) O
and O
AUC O
( O
53 O
% O
) O
after O
a O
1-week O
course O
of O
cimetidine B-drug
1200 O
mg/day O
and O
a O
single O
dose O
of O
diltiazem B-drug
60mg O
. O

The O
pathophysiologic O
consequences O
could O
be O
an O
increased O
synaptic O
concentration O
of O
norepinephrine B-drug
predisposing O
to O
adenylyl O
cyclase O
desensitization O
. O

However O
, O
a O
significantly O
higher O
proportion O
of O
neurons O
fired O
spontaneous O
action O
potentials O
with O
either O
0.05-0.2 O
or O
1 O
% O
biocytin O
compared O
to O
no O
biocytin O
. O

The O
Factrel B-brand
test O
should O
be O
conducted O
in O
the O
absence O
of O
other O
drugs O
which O
directly O
affect O
the O
pituitary O
secretion O
of O
the O
gonadotropins O
. O

Cimetidine O
Co-administration O
of O
felodipine B-drug
with O
cimetidine B-drug
( O
a O
non-specific O
CYP-450 O
inhibitor O
) O
resulted O
in O
an O
increase O
of O
approximately O
50 O
% O
in O
the O
AUC O
and O
the O
Cmax O
, O
of O
felodipine B-drug
. O

triclofos B-drug
sodium I-drug
; O

Metal O
mixture O
toxicity O
investigation O
was O
undertaken O
with O
equal O
concentrations O
of O
the O
metals O
. O

A O
pharmacokinetic O
interaction O
between O
diltiazem B-drug
and O
cyclosporine B-drug
has O
been O
observed O
during O
studies O
involving O
renal O
and O
cardiac O
transplant O
patients O
. O

Reversal O
of O
the O
block O
with O
edrophonium B-drug
and O
subsequent O
recovery O
of O
the O
horses O
from O
anaesthesia O
were O
uneventful O
. O

Mean O
number O
of O
drugs O
per O
MAC O
was O
4 O
( O
95 O
% O
CI O
, O
+/- O
0.2 O
) O
. O

The O
mean O
minimum O
lithium B-drug
concentration O
increased O
15 O
% O
and O
the O
renal O
clearance O
was O
decreased O
by O
approximately O
20 O
% O
. O

Patients O
undergoing O
systemic O
anticholinesterase O
treatment O
should O
be O
warned O
of O
the O
possible O
additive O
effects O
of O
Phospholine B-drug
Iodide I-drug
. O

The O
presence O
of O
the O
radiopharmaceutical B-group
in O
the O
kidneys O
, O
along O
with O
an O
increase O
in O
renal O
retention O
, O
tend O
to O
produce O
scintigraphic O
results O
that O
falsely O
identify O
characteristics O
related O
to O
diseases O
such O
as O
renal O
vascular O
, O
or O
urinary O
tract O
obstruction O
, O
and O
even O
renal O
cancer O
. O

When O
given O
concurrently O
the O
following O
drugs O
may O
interact O
with O
thiazide B-group
diuretics I-group
. O

Concomitant O
use O
with O
other O
oxytocic B-group
agents I-group
is O
not O
recommended O
. O

Anticonvulsants B-group
: O
Phenytoin B-drug
Phenobarbital I-drug
Carbamazepine I-drug

decreased O
pharmacologic O
effect O
of O
aspirin B-brand
. O

The O
inhibiting O
effects O
of O
anticholinergic B-group
drugs I-group
on O
gastric O
hydrochloric O
acid O
secretion O
are O
antagonized O
by O
agents O
used O
to O
treat O
achlorhydria O
and O
those O
used O
to O
test O
gastric O
secretion O
. O

The O
possibility O
of O
interactions O
with O
other O
drugs O
administered O
concurrently O
should O
be O
considered O
, O
particularly O
when O
their O
main O
route O
of O
elimination O
is O
active O
renal O
secretion O
via O
the O
organic O
cationic O
transport O
system O
( O
e.g. O
, O
trimethoprim B-drug
) O
. O

The O
following O
information O
was O
obtained O
from O
the O
literature O
. O

Co-administration O
of O
warfarin B-drug
and O
cerivastatin B-drug
did O
not O
alter O
the O
pharmacokinetics O
of O
cerivastatin B-drug
sodium I-drug
. O

However O
, O
the O
antagonism O
of O
the O
theophylline-induced B-drug
anxiogenic O
effects O
by O
CGS21680 B-drug_n
was O
only O
observed O
in O
the O
time O
spent O
in O
the O
light O
zone O
, O
and O
DPCPX-induced B-drug_n
anxiogenic O
effects O
were O
neither O
reversed O
by O
CGS B-drug
21680 I-drug
nor O
by O
CPA B-drug_n
. O

No O
clinical O
or O
drug O
interaction O
study O
was O
conducted O
with O
dolasetron B-drug
. O

Although O
other O
hormonal B-group
contraceptives I-group
are O
highly O
effective O
, O
there O
have O
been O
reports O
of O
pregnancy O
from O
women O
who O
have O
used O
combined B-group
oral I-group
contraceptives I-group
, O
as O
well O
as O
topical/injectable/implantable/insertable O
hormonal O
birth O
control O
products O
. O

Anticoagulants B-group
: O
Warfarin B-drug

METHODS O
: O
The O
study O
was O
carried O
out O
as O
an O
open O
, O
randomized O
, O
crossover O
design O
with O
14 O
healthy O
participants O
. O

7 O
. O

However O
, O
in O
a O
single O
in O
vivo O
rodent O
study O
denileukin B-drug
diftitox I-drug
had O
no O
effect O
on O
P450 O
levels O
. O

If O
hypotension O
occurs O
, O
the O
patient O
should O
be O
placed O
in O
a O
supine O
position O
and O
, O
if O
necessary O
, O
receive O
an O
intravenous O
infusion O
of O
normal O
saline O
. O

There O
have O
been O
no O
formal O
studies O
of O
the O
interaction O
of O
LEVULAN B-brand
KERASTICK I-brand
for O
Topical O
Solution O
with O
any O
other O
drugs O
, O
and O
no O
drug-specific O
interactions O
were O
noted O
during O
any O
of O
the O
controlled O
clinical O
trials O
. O

In O
addition O
, O
the O
use O
of O
herbal O
remedies O
may O
be O
detrimental O
for O
the O
patient O
with O
compromised O
renal O
function O
. O

This O
may O
result O
in O
increased O
risk O
of O
theophylline-related B-drug
adverse O
reactions O
. O

The O
pharmacokinetics O
of O
estazolam B-drug
( O
Cmax O
and O
AUC O
) O
were O
not O
affected O
during O
multiple-dose O
fluoxetine B-drug
, O
suggesting O
no O
clinically O
significant O
pharmacokinetic O
interaction O
. O

Even O
so O
dextromethorphan B-drug
plasma O
concentrations O
in O
the O
presence O
of O
high O
doses O
of O
valdecoxib B-drug
were O
almost O
5-fold O
lower O
than O
those O
seen O
in O
CYP O
2D6 O
poor O
metabolizers O
suggesting O
that O
dose O
adjustment O
is O
not O
necessary O
. O

CNS O
Acting O
Drugs O
: O
Given O
the O
primary O
CNS O
effects O
of O
Duloxetine B-drug
, O
it O
should O
be O
used O
with O
caution O
when O
it O
is O
taken O
in O
combination O
with O
or O
substituted O
for O
other O
centrally O
acting O
drugs O
, O
including O
those O
with O
a O
similar O
mechanism O
of O
action O
. O

Slow O
chylomicron O
intravascular O
catabolism O
has O
been O
associated O
with O
coronary O
artery O
disease O
and O
screening O
for O
drugs O
that O
can O
speed-up O
this O
process O
can O
be O
important O
. O

Pretreatment O
of O
healthy O
volunteers O
with O
multiple O
doses O
of O
rifampin B-drug
followed O
by O
a O
single O
dose O
of O
Gleevec B-brand
, O
increased O
Gleevec B-brand
oral-dose O
clearance O
by O
3.8-fold O
, O
which O
significantly O
( O
p O
0.05 O
) O
decreased O
mean O
cmax O
and O
AUC O
( O
0-8 O
) O
. O

sertraline I-drug
concentration O

Coadministration O
of O
almotriptan B-drug
and O
the O
potent O
CYP3A4 O
inhibitor O
ketoconazole B-drug
( O
400 O
mg O
q.d O
. O
for O
3 O
days O
) O
resulted O
in O
an O
approximately O
60 O
% O
increase O
in O
the O
area O
under O
the O
plasma O
concentration-time O
curve O
and O
maximal O
plasma O
concentrations O
of O
almotriptan B-drug
. O

Delavirdine B-drug

Because O
pregnancy O
could O
not O
be O
maintained O
in O
the O
rabbit O
following O
doses O
of O
fulvestrant B-drug
of O
1 O
mg/kg/day O
and O
above O
, O
this O
study O
was O
inadequate O
to O
fully O
define O
the O
possible O
adverse O
effects O
on O
fetal O
development O
at O
clinically O
relevant O
exposures O
. O

HMG-CoA B-group
reductase I-group
inhibitors I-group
: O
The O
combined O
use O
of O
TRICOR B-brand
and O
HMG-CoA B-group
reductase I-group
inhibitors I-group
should O
be O
avoided O
unless O
the O
benefit O
of O
further O
alterations O
in O
lipid O
levels O
is O
likely O
to O
outweigh O
the O
increased O
risk O
of O
this O
drug O
combination O
. O

Coadministration O
of O
diltiazem B-drug
with O
rifampin B-drug
or O
any O
known O
CYP3A4 O
inducer O
should O
be O
avoided O
when O
possible O
, O
and O
alternative O
therapy O
considered O
. O

Acellular O
, O
live O
and O
live-attenuated B-group
vaccines I-group
should O
not O
be O
administered O
during O
RAPTIVA B-brand
treatment O
. O

Drugs O
Highly O
Bound O
to O
Plasma O
Protein O
Zaleplon B-drug
is O
not O
highly O
bound O
to O
plasma O
proteins O
( O
fraction O
bound O
60 O
% O
15 O
% O
) O
; O

The O
administration O
of O
local O
anesthetic B-group
solutions I-group
containing O
epinephrine B-drug
or O
norepinephrine B-drug
to O
patients O
receiving O
monoamine B-group
oxidase I-group
inhibitors I-group
or O
tricyclic B-group
antidepressants I-group
may O
produce O
severe O
, O
prolonged O
hypertension O
. O

Skeletal B-group
muscle I-group
relaxants I-group
: O
amphotericin B-drug
B-induced O
hypokalemia O
may O
enhance O
the O
curariform O
effect O
of O
skeletal B-group
muscle I-group
relaxants I-group
( O
e.g. O
, O
tubocurarine B-drug
) O
. O

[ O
2 O
epidemics O
of O
arsenical O
encephalopathy O
in O
the O
treatment O
of O
trypanosomiasis O
, O
Uganda O
, O
1992-1993 O
] O
Since O
1988 O
, O
the O
french O
non-governmental O
organisation O
M O
decins O
Sans O
Fronti O
res O
is O
running O
a O
control O
program O
of O
human O
african O
trypanosomiasis O
in O
the O
district O
of O
Moyo O
, O
North-Uganda O
. O

There O
have O
been O
reports O
of O
increased O
anticoagulant O
effects O
when O
erythromycin B-drug
and O
oral O
anticoagulants B-group
were O
used O
concomitantly O
. O

Verapamil B-drug
also O
significantly O
decreased O
the O
incidence O
of O
lymphatic O
invasion O
of O
adenocarcinomas O
, O
which O
was O
enhanced O
by O
bombesin B-drug_n
. O

However O
, O
high O
doses O
of O
leucovorin B-drug
may O
reduce O
the O
efficacy O
of O
intrathecally O
administered O
methotrexate B-drug
. O

Other O
factors O
, O
such O
as O
tolerance O
and O
sensitization O
to O
the O
drugs O
' O
actions O
and O
the O
development O
of O
withdrawal O
symptoms O
, O
may O
also O
contribute O
to O
dependence O
. O

epilepsy O
; O

Cisplatin B-drug
was O
administered O
over O
the O
last O
two O
hours O
of O
the O
thiosulfate B-drug
infusion O
. O

Determinants O
of O
cellular O
sensitivity O
to O
topoisomerase-targeting B-group
antitumor I-group
drugs I-group
. O

Care O
should O
be O
given O
when O
administering O
this O
drug O
to O
patients O
with O
symptoms O
of O
myasthenic O
weakness O
who O
are O
also O
on O
anticholinesterase B-group
drugs I-group
. O

The O
concomitant O
administration O
of O
Exjade B-brand
and O
vitamin B-drug
C I-drug
has O
not O
been O
formally O
studied O
. O

it O
was O
independent O
of O
the O
influence O
of O
the O
nueronal O
cell O
body O
and O
of O
protein O
synthesis O
within O
the O
axon O
. O

An O
altered O
biodistribution O
may O
provide O
misleading O
information O
that O
can O
either O
mask O
or O
mimic O
certain O
disease O
symptoms O
. O

Such O
data O
are O
discussed O
herein O
, O
with O
emphasis O
on O
those O
aspects O
that O
impact O
on O
the O
clinical O
use O
of O
the O
calcium-entry B-group
antagonists I-group
. O

Anticoagulants B-group
: O
Ten O
patients O
who O
were O
stabilized O
on O
oral O
anticoagulants B-group
were O
given O
guanfacine B-drug
, O
1-2 O
mg/day O
, O
for O
4 O
weeks O
. O

Concurrent O
use O
with O
probenecid B-drug
or O
other O
drugs O
significantly O
eliminated O
by O
active O
renal O
tubular O
secretion O
may O
result O
in O
increased O
plasma O
concentrations O
of O
penciclovir B-drug
. O

Fenbufen B-drug
is O
not O
approved O
in O
the O
United O
States O
at O
this O
time O
. O

TAXOL B-brand
contains O
dehydrated O
alcohol O
USP O
, O
396 O
mg/mL O
; O

Another O
oral O
azole B-group
antifungal I-group
, O
ketoconazole B-drug
, O
inhibits O
the O
metabolism O
of O
astemizole B-drug
, O
resulting O
in O
elevated O
plasma O
concentrations O
of O
astemizole B-drug
and O
its O
active O
metabolite O
desmethylastermizole B-drug_n
which O
may O
prolong O
QT O
intervals O
. O

Lansoprazole B-drug
has O
also O
been O
shown O
to O
have O
no O
clinically O
significant O
interaction O
with O
amoxicillin B-drug
. O

Potential O
drug O
interactions O
between O
Keppra B-brand
and O
other O
AEDs B-group
( O
carbamazepine B-drug
, O
gabapentin B-drug
, O
lamotrigine B-drug
, O
phenobarbital B-drug
, O
phenytoin B-drug
, O
primidone B-drug
and O
valproate B-drug
) O
were O
also O
assessed O
by O
evaluating O
the O
serum O
concentrations O
of O
levetiracetam B-drug
and O
these O
AEDs B-group
during O
placebo-controlled O
clinical O
studies O
. O

These O
data O
suggest O
that O
ginsenosides B-drug_n
are O
negatively O
coupled O
to O
three O
types O
of O
calcium O
channels O
in O
bovine O
chromaffin O
cell O
, O
including O
an O
omega-conotoxin B-drug_n
GVIA-sensitive O
( O
N-type O
) O
channel O
, O
an O
omega-agatoxin B-drug_n
IVA-sensitive O
( O
P-type O
) O
channel O
and O
nimodipine/omega-conotoxin B-drug
GVIA/omega-agatoxin B-drug_n
VIA-resistant O
( O
presumptive O
Q-type O
) O
channel O
. O

Drug O
Interactions O
with O
Beta-Blockers B-group
: O
Concomitant O
use O
of O
fenoldopam B-drug
with O
beta-blockers B-group
should O
be O
avoided O
. O

Morphine B-drug
prolonged O
gastrointestinal O
transit O
time O
from O
69 O
to O
103 O
minutes O
( O
P O
= O
.005 O
) O
; O
this O
was O
prevented O
by O
ADL B-drug
8-2698 I-drug
( O
P O
= O
.004 O
) O
. O

Oral O
Contraceptives B-group
: O
Coadministration O
of O
atorvastatin B-drug
and O
an O
oral O
contraceptive B-group
increased O
AUC O
values O
for O
norethindrone B-drug
and O
ethinyl B-drug
estradiol I-drug
by O
approximately O
30 O
% O
and O
20 O
% O
. O

Caution O
should O
be O
used O
if O
INDOCIN B-brand
is O
administered O
simultaneously O
with O
methotrexate B-drug
. O

exfoliative O
dermatitis O

Therefore O
, O
it O
would O
be O
expected O
that O
a O
dosing O
schedule O
of O
cerivastatin B-drug
sodium I-drug
given O
at O
bedtime O
and O
cholestyramine B-drug
given O
before O
the O
evening O
meal O
would O
not O
result O
in O
a O
significant O
decrease O
in O
the O
clinical O
effect O
of O
cerivastatin B-drug
sodium I-drug
. O

However O
, O
there O
were O
16 O
% O
and O
32 O
% O
increases O
in O
the O
AUC O
and O
Cmax O
, O
respectively O
, O
of O
the O
combined O
moieties O
of O
threohydrobupropion B-drug_n
and O
erythrohydrobupropion B-drug_n
. O

The O
permeability O
of O
the O
cell O
membrane O
was O
changed O
as O
evidenced O
by O
the O
leakage O
of O
260-nm O
absorbing O
materials O
, O
amino O
acids O
, O
proteins O
, O
and O
inorganic O
cations O
. O

Therefore O
, O
caution O
should O
be O
used O
when O
administering O
nitazoxanide B-drug
concurrently O
with O
other O
highly O
plasma O
protein-bound O
drugs O
with O
narrow O
therapeutic O
indices O
, O
as O
competition O
for O
binding O
sites O
may O
occur O
( O
e.g. O
, O
warfarin B-drug
) O
. O

The O
plasma O
maximum O
concentration O
and O
area O
under O
the O
plasma O
concentration-time O
curve O
of O
diltiazem B-drug
, O
desacetyldiltiazem B-drug_n
, O
and O
desmethyldiltiazem B-drug_n
were O
unchanged O
after O
coadministration O
of O
sirolimus B-drug
, O
and O
no O
potentiation O
of O
the O
effects O
of O
diltiazem B-drug
on O
diastolic O
or O
systolic O
blood O
pressure O
or O
on O
the O
electrocardiographic O
parameters O
was O
seen O
. O

Prothrombin O
time O
was O
not O
affected O
by O
levetiracetam B-drug
. O

Noncardioselective B-group
beta-blockers I-group
( O
nadolol B-drug
, O
porpranolol O
, O
timolol B-drug
) O
may O
exacerbate O
rebound O
hypertension O
when O
guanfacine B-drug
is O
withdrawn O
. O

**No O
significant O
effect O
. O

Data O
from O
in O
vitro O
studies O
of O
benzodiazepines B-group
other O
than O
alprazolam B-drug
suggest O
a O
possible O
drug O
interaction O
for O
the O
following O
: O
ergotamine B-drug
, O
cyclosporine B-drug
, O
amiodarone B-drug
, O
nicardipine B-drug
, O
and O
nifedipine B-drug
. O

An O
interacting O
drug O
which O
leads O
to O
a O
decrease O
in O
prothrombin O
time O
necessitating O
an O
increased O
dose O
of O
oral O
anticoagulant B-group
to O
maintain O
an O
adequate O
degree O
of O
anticoagulation O
may O
, O
if O
abruptly O
discontinued O
, O
increase O
the O
risk O
of O
subsequent O
bleeding O
. O

Among O
these O
patients O
, O
the O
incidence O
of O
upper O
gastrointestinal O
adverse O
experiences O
in O
the O
patients O
treated O
with O
Ibandronate B-drug
was O
similar O
to O
that O
in O
placebo-treated O
patients O
. O

Corticosteroids B-group
, O
Methylxanthines B-group
and O
Diuretics B-group
: O
Concomitant O
treatment O
with O
xanthine B-group
derivatives I-group
, O
steroids B-group
, O
or O
diuretics B-group
may O
potentiate O
a O
possible O
hypokalemic O
effect O
of O
beta2-agonists B-group
. I-group

Drug/Laboratory O
Test O
Interactions O
The O
presence O
of O
labetalol O
metabolites O
in O
the O
urine O
may O
result O
in O
falsely O
elevated O
levels O
of O
urinary O
catecholamines O
, O
metanephrine O
, O
normetanephrine O
and O
vanillylmandelic O
acid O
when O
measured O
by O
fluorimetric O
or O
photometric O
methods O
. O

Eight O
healthy O
volunteers O
were O
randomized O
in O
an O
open-label O
, O
two-way O
crossover O
study O
to O
receive O
oxycodone B-drug
, O
5 O
mg O
p.o O
. O

Patients O
taking O
coumarin-derivative B-group
anticoagulants I-group
concomitantly O
with O
capecitabine B-drug
should O
be O
monitored O
regularly O
for O
alterations O
in O
their O
coagulation O
parameters O
( O
PT O
or O
INR O
) O
. O

Cytokines B-group
( O
interferon B-group
, O
interleukin B-group
) O
: O
Cytokines B-group
have O
been O
reported O
to O
induce O
both O
hyperthyroidism O
and O
hypothyroidism O
. O

Corticotropin B-drug
may O
accentuate O
the O
electrolyte O
loss O
associated O
with O
diuretic B-drug
therapy O
. O

Because O
of O
the O
low O
dietary O
cobalt B-drug
concentration O
as O
compared O
to O
the O
iron B-drug
contents O
of O
the O
diets O
, O
no O
effect O
of O
cobalt B-drug
on O
iron B-drug
absorption O
and O
excretion O
occurred O
. O

Tricyclic B-group
Antidepressants I-group
: O
Concurrent O
use O
may O
increase O
the O
therapeutic O
and O
toxic O
effects O
of O
both O
drugs O
, O
possibly O
due O
to O
increased O
catecholamine O
sensitivity O
. O

Drug-Drug O
Interactions O
: O
The O
pharmacokinetic O
and O
pharmacodynamic O
interactions O
between O
UROXATRAL B-brand
and O
other O
alpha-blockers B-group
have O
not O
been O
determined O
. O

The O
administration O
of O
SUPRAX B-brand
may O
result O
in O
a O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
using O
Clinitest O
** O
, O
Benedict O
s O
solution O
, O
or O
Fehling O
s O
solution O
. O

thyroid B-group
drugs I-group
; O

No O
formal O
drug-drug O
interaction O
studies O
, O
however O
, O
have O
been O
conducted O
. O

The O
reduction O
in O
MAC O
was O
correlated O
with O
brain O
levels O
of O
ketamine B-drug
or O
metabolite O
I O
, O
suggesting O
a O
ketamine B-drug
: O
metabolite O
I O
potency O
ration O
of O
3:1 O
. O

In O
vitro O
studies O
demonstrated O
no O
evidence O
of O
incompatibility O
of O
heparin B-drug
with O
EXTRANEAL B-brand
. O

The O
action O
of O
colchicine B-drug
is O
potentiated O
by O
alkalinizing B-group
agents I-group
. O

In O
male O
Sprague-Dawley O
rats O
fasted O
for O
18 O
h O
, O
concomitant O
administration O
of O
caffeine B-drug
( O
0.1 O
g/kg O
, O
i.p O
. O
) O

If O
combination O
therapy O
is O
needed O
, O
careful O
consideration O
should O
be O
given O
to O
the O
pharmacology O
of O
all O
agents O
to O
be O
used O
. O

Zalcitabine B-drug
inhibited O
lamivudine B-drug
phosphorylation O
at O
high O
concentration O
ratios O
( O
10 O
and O
100 O
) O
; O

Lithium B-drug
generally O
should O
not O
be O
given O
with O
diuretics B-group
because O
they O
reduce O
its O
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium B-drug
toxicity O
. O

Valdecoxib B-drug
caused O
a O
statistically O
significant O
increase O
in O
plasma O
exposures O
of O
R-warfarin B-drug
and O
S-warfarin B-drug
( O
12 O
% O
and O
15 O
% O
, O
respectively O
) O
, O
and O
in O
the O
pharmacodynamic O
effects O
( O
prothrombin O
time O
, O
measured O
as O
INR O
) O
of O
warfarin B-drug
. O

Lithium B-drug
: O
NSAIDs B-group
have O
produced O
an O
elevation O
of O
plasma O
lithium B-drug
levels O
and O
a O
reduction O
in O
renal O
lithium B-drug
clearance O
. O

Mutagenicity O
studies O
were O
conducted O
in O
vitro O
and O
in O
vivo O
; O

The O
relative O
risk O
of O
myocardial O
infarction O
during O
sexual O
activity O
is O
not O
significantly O
higher O
than O
for O
healthy O
persons O
. O

Those O
for O
which O
effectiveness O
is O
reported O
includes O
diphenhydramine B-drug
, O
hydroxyzine B-drug
, O
orphenadrine B-drug
, O
pyrilamine B-drug
, O
phenyltoloxamine B-drug_n
, O
promethazine B-drug
, O
methdilazine B-drug
, O
and O
tripelennamine B-drug
. O

Heart O
rate O
increased O
initially O
and O
returned O
to O
normal O
40 O
minutes O
after O
ethanol B-drug
challenge O
. O

The O
concentration O
of O
AMICAR B-brand
necessary O
to O
maintain O
inhibition O
of O
fibrinolysis O
is O
0.99 O
mMol/L O
or O
0.13 O
mg/mL O
. O

Therefore O
, O
unless O
otherwise O
specified O
, O
appropriate O
dosage O
adjustments O
may O
be O
necessary O
. O

Pharmacokinetic O
data O
suggest O
that O
absorption O
, O
metabolism O
, O
and O
elimination O
of O
each O
of O
these O
drugs O
are O
unchanged O
when O
they O
are O
used O
together O
. O

Short-Acting B-group
beta2-agonists I-group
: O
Aerosol O
bronchodilators B-group
of O
the O
short-acting O
adrenergic O
stimulant O
type O
may O
be O
used O
for O
relief O
of O
breakthrough O
symptoms O
while O
using O
formoterol B-drug
. O

It O
is O
recommended O
that O
gabapentin B-drug
be O
taken O
at O
least O
2 O
hours O
following O
Maalox B-brand
administration O
. O

ethacrynic B-drug
acid I-drug
; O

Warfarin B-drug
: O
When O
healthy O
subjects O
were O
administered O
Starlix B-brand
120 O
mg O
three O
times O
daily O
before O
meals O
for O
four O
days O
in O
combination O
with O
a O
single O
dose O
of O
warfarin B-drug
30 O
mg O
on O
day O
2 O
, O
there O
were O
no O
alterations O
in O
the O
pharmacokinetics O
of O
either O
agent O
. O

Cerubidine B-brand
should O
not O
be O
used O
in O
patients O
who O
have O
previously O
received O
the O
recommended O
maximum O
cumulative O
doses O
of O
doxorubicin B-drug
or O
Cerubidine B-brand
. O

However O
, O
L-NAME B-drug_n
( O
100 O
and O
300 O
micromol/l O
) O
did O
not O
alter O
the O
effects O
of O
reseveratrol B-drug_n
on O
arteries O
from O
dietary-obese O
rats O
, O
giving O
superimposed O
concentration-responses O
curves O
. O

- O
a O
sulfa-based O
drug O
such O
as O
sulfamethoxazole-trimethoprim B-drug
( O
Bactrim B-brand
, O
Septra B-brand
) O
, O
sulfisoxazole B-drug
( O
Gantrisin B-brand
) O
, O
or O
sulfasalazine B-drug
( O
Azulfidine B-brand
) O
; O

Concomitant O
use O
of O
SPRYCEL B-brand
and O
drugs O
that O
inhibit O
CYP3A4 O
( O
eg O
, O
ketoconazole B-drug
, O
itraconazole B-drug
, O
erythromycin B-drug
, O
clarithromycin B-drug
, O
ritonavir B-drug
, O
atazanavir B-drug
, O
indinavir B-drug
, O
nefazodone B-drug
, O
nelfinavir B-drug
, O
saquinavir B-drug
, O
telithromycin B-drug
) O
may O
increase O
exposure O
to O
dasatinib B-drug
and O
should O
be O
avoided O
. O

Patients O
should O
be O
cautioned O
against O
engaging O
in O
hazardous O
activities O
requiring O
complete O
mental O
alertness O
such O
as O
operating O
machinery O
or O
driving O
a O
motor O
vehicle O
. O

If O
a O
diuretic B-group
is O
also O
used O
, O
the O
risk O
of O
lithium B-drug
toxicity O
may O
be O
increased O
. O

Insulin B-drug
or O
Oral O
Hypoglycemics B-group
: O
Agents B-group
with I-group
b-blocking I-group
properties I-group
may O
enhance O
the O
blood-sugar-reducing O
effect O
of O
insulin B-drug
and O
oral O
hypoglycemics B-group
. O

The O
following O
drug O
interactions O
were O
studied O
with O
ketoprofen B-drug
doses O
of O
200 O
mg/day O
. O

The O
gonadotropin O
levels O
may O
be O
transiently O
elevated O
by O
spironolactone B-drug
, O
minimally O
elevated O
by O
levodopa B-drug
, O
and O
suppressed O
by O
oral O
contraceptives B-group
and O
digoxin B-drug
. O

Careful O
observations O
on O
hepatotoxicity O
are O
suggested O
when O
acetaminophen B-drug
is O
prescribed O
with O
caffeine B-drug
. O

Lipids O
: O
Pretreatment O
and O
follow-up O
blood O
lipids O
should O
be O
obtained O
under O
fasting O
conditions O
. O

This O
effect O
should O
be O
kept O
in O
mind O
when O
bleeding O
times O
are O
determined O
. O

Trecator B-brand
may O
potentiate O
the O
adverse O
effects O
of O
other O
antituberculous B-group
drugs I-group
administered O
concomitantly O
. O

Immunodeficiency-associated O
lymphocyte O
disorders O
( O
plasmacytic O
hyperplasia O
, O
polymorphic O
proliferation O
, O
and O
B-cell O
lymphomas O
) O
occur O
in O
patients O
who O
have O
congenital O
or O
acquired O
immunodeficiencies O
including O
those O
resulting O
from O
immunosuppressive B-group
therapy O
. O

Prescribing O
. O

- O
Hydroxychloroquine B-drug
( O
e.g. O
, O
Plaquenil B-brand
) O
or O

The O
risk O
of O
myopathy O
is O
also O
increased O
by O
the O
following O
lipid-lowering O
drugs O
that O
are O
not O
potent O
CYP3A4 O
inhibitors O
, O
but O
which O
can O
cause O
myopathy O
when O
given O
alone O
. O

Codeine B-drug
in O
combination O
with O
other O
narcotic B-group
analgesics I-group
, O
general O
anesthetics B-group
, O
phenothiazines B-group
, O
tranquilizers B-group
, O
sedative-hypnotics B-group
, O
or O
other O
CNS B-group
depressants I-group
( O
including O
alcohol B-drug
) O
has O
additive O
depressant O
effects O
. O

Potential O
for O
serious O
reactions O
such O
as O
risk O
of O
myopathy O
including O
rhabdomyolysis O
. O

Heparin B-drug
: O
Since O
heparin B-drug
is O
contraindicated O
in O
patients O
with O
heparin-induced B-drug
thrombocytopenia O
, O
the O
co-administration O
of O
Argatroban B-drug
and O
heparin B-drug
is O
unlikely O
for O
this O
indication O
. O

If O
these O
products O
are O
needed O
, O
they O
should O
be O
given O
at O
least O
2 O
hours O
before O
cimetidine B-drug
administration O
. O

Terfenadine B-drug
: O
Administration O
of O
terfenadine B-drug
with O
VIRACEPT B-brand
resulted O
in O
the O
appearance O
of O
unchanged O
terfenadine B-drug
in O
plasma O
; O

increased O
levels O
of O
fibrinogen O
and O
fibrinogen O
activity O
; O

Probenecid B-drug
: O
Probenecid B-drug
is O
known O
to O
interact O
with O
the O
metabolism O
or O
renal O
tubular O
excretion O
of O
many O
drugs O
( O
e.g. O
, O
acetaminophen B-drug
, O
acyclovir B-drug
, O
angiotensin-converting B-group
enzyme I-group
inhibitors I-group
, O
aminosalicylic B-drug
acid I-drug
, O
barbiturates B-group
, O
benzodiazepines B-group
, O
bumetanide B-drug
, O
clofibrate B-drug
, O
methotrexate B-drug
, O
famotidine B-drug
, O
furosemide B-drug
, O
nonsteroidal B-group
anti-inflammatory I-group
agents O
, O
theophylline B-drug
, O
and O
zidovudine B-drug
) O
. O

The O
data O
suggest O
that O
18-MC B-drug_n
has O
a O
narrower O
spectrum O
of O
actions O
and O
will O
have O
a O
substantially O
greater O
therapeutic O
index O
than O
ibogaine B-drug_n
. O

Cyclopentolate B-drug
may O
interfere O
with O
the O
anti-glaucoma O
action O
of O
carbachol B-drug
or O
pilocarpine B-drug
; O

Anticonvulsants B-group
( O
carbamazepine B-drug
, O
felbamate B-drug
, O
phenobarbital B-drug
, O
phenytoin B-drug
, O
topiramate B-drug
) O
: O
Increase O
the O
metabolism O
of O
ethinyl B-drug
estradiol I-drug
and/or O
some O
progestins B-group
, O
leading O
to O
possible O
decrease O
in O
contraceptive O
effectiveness O
. O

Anticoagulants B-group
: O
While O
studies O
have O
not O
shown O
diclofenac B-drug
to O
interact O
with O
anticoagulants B-group
of I-group
the I-group
warfarin I-group
type I-group
, O
caution O
should O
be O
exercised O
, O
nonetheless O
, O
since O
interactions O
have O
been O
seen O
with O
other O
NSAIDs B-group
. O

Methenamine B-drug
therapy O
Urinary O
excretion O
of O
amphetamines B-group
is O
increased O
, O
and O
efficacy O
is O
reduced O
by O
acidifying O
agents O
used O
in O
methenamine B-drug
therapy O
. O

Dose O
adjustment O
of O
lapatinib B-drug
should O
be O
considered O
for O
patients O
who O
must O
receive O
concomitant O
strong O
inhibitors O
or O
concomitant O
strong O
inducers O
of O
CYP3A4 O
enzymes O
. O

Short-term O
controlled O
studies O
failed O
to O
show O
that O
taking O
the O
drug O
significantly O
affects O
prothrombin O
times O
when O
administered O
to O
individuals O
on O
coumarin-type B-group
anticoagulants I-group
. O

Monitoring O
of O
plasma O
phenytoin B-drug
concentrations O
may O
be O
helpful O
when O
possible O
drug O
interactions O
are O
suspected O
. O

SUSTIVAhas O
the O
potential O
to O
decrease O
serum O
concentrations O
of O
amprenavir B-drug
. O

Interaction O
of O
gentamycin B-drug
and O
atracurium B-drug
in O
anaesthetised O
horses O
. O

This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O

Although O
not O
observed O
in O
this O
study O
, O
adverse O
effects O
could O
potentially O
arise O
from O
co-administration O
of O
cephalexin B-drug
and O
metformin B-drug
by O
inhibition O
of O
tubular O
secretion O
via O
organic O
cationic O
transporter O
systems O
. O

In O
bioavailability O
studies O
with O
normal O
subjects O
, O
the O
concurrent O
administration O
of O
antacids B-group
at O
therapeutic O
levels O
did O
not O
significantly O
influence O
the O
bioavailability O
of O
TRANXENE B-brand
tablets O
. O

Nitroglycerin B-drug
: O
DynaCirc B-brand
( O
isradipine B-drug
) O
has O
been O
safely O
coadministered O
with O
nitroglycerin B-drug
. O

Even O
though O
such O
interactions O
were O
not O
seen O
during O
clinical O
studies O
with O
nicardipine B-drug
HCl I-drug
, O
an O
increased O
volume O
of O
circulating O
fluids O
might O
be O
required O
if O
such O
an O
interaction O
were O
to O
occur O
. O

Patients O
receiving O
concurrent O
administration O
of O
substrates O
of O
C.P.A O
. O
were O
not O
excluded O
from O
clinical O
trials O
of O
grepafloxacin B-drug
. O

Warfarin B-drug
Keppra B-brand
( O
1000 O
mg O
twice O
daily O
) O
did O
not O
influence O
the O
pharmacokinetics O
of O
R O
and O
S B-drug
warfarin I-drug
. O

Hepatotoxic O
Drugs O
Increased O
side O
effects O
may O
occur O
when O
leflunomide B-drug
is O
given O
concomitantly O
with O
hepatotoxic O
substances O
. O

Physicians O
needing O
to O
treatpatients O
co-infected O
with O
tuberculosis O
andusing O
a O
nevirapine B-drug
containing O
regimen O
mayuse O
rifabutin B-drug
instead O
. O

In O
a O
pharmacokinetic O
study O
, O
38 O
healthy O
female O
subjects O
received O
ketoconazole B-drug
200 O
mg O
twice O
daily O
for O
7 O
days O
, O
with O
coadministration O
of O
alosetron B-drug
1 O
mg O
on O
the O
last O
day O
. O

ketoconazole B-drug
) O
, O
macrolide B-group
antibiotics I-group
( O
e.g O
. O
erythromycin B-drug
) O
, O
and O
HIV B-group
protease I-group
inhibitors I-group
( O
e.g O
. O
ritonavir B-drug
, O
indinavir B-drug
and O
saquinavir B-drug
) O
should O
have O
their O
dose O
of O
SUBUTEX B-brand
or O
SUBOXONE B-brand
adjusted O
. O

It O
may O
be O
necessary O
to O
adjust O
the O
dosage O
of O
oral O
anticoagulants B-group
upon O
beginning O
or O
stopping O
disulfiram B-drug
. O
since O
disulfiram B-drug
may O
prolong O
prothrombin O
time O
. O

Caution O
is O
advised O
nonetheless O
, O
since O
interactions O
have O
been O
seen O
with O
other O
nonsteroidal O
agents O
of O
this O
class O
. O

The O
simplest O
inference O
is O
that O
the O
toxicity O
and O
effectiveness O
of O
polyenes O
are O
determined O
by O
their O
relative O
avidities O
for O
the O
predominant O
sterol O
in O
cell O
membranes O
. O

In O
Study O
1 O
, O
patients O
receiving O
bolus-IFL O
plus O
AVASTIN B-brand
had O
a O
higher O
incidence O
of O
Grade O
3-4 O
diarrhea O
and O
neutropenia O
. O

Plasma O
TCA B-group
concentrations O
may O
need O
to O
be O
monitored O
and O
the O
dose O
of O
the O
TCA B-group
may O
need O
to O
be O
reduced O
if O
a O
TCA B-group
is O
co-administered O
with O
Duloxetine B-drug
. O

Although O
there O
is O
little O
risk O
for O
loss O
of O
contraceptive O
efficacy O
, O
the O
clinical O
significance O
of O
these O
increased O
exposures O
in O
terms O
of O
safety O
is O
not O
known O
. O

Additional O
clinical O
experience O
may O
reveal O
other O
drugs O
affected O
by O
the O
concomitant O
administration O
of O
Tagamet B-brand
. O

Tricyclic B-group
Antidepressants I-group
: O
Use O
of O
thyroid B-group
products I-group
with O
imipramine B-drug
and O
other O
tricyclic B-group
antidepressants I-group
may O
increase O
receptor O
sensitivity O
and O
enhance O
antidepressant O
activity O
transient O
cardiac O
arrhythmias O
have O
been O
observed O
. O

Effects O
of O
Felbatol B-brand
on O
Low-Dose O
Combination B-group
Oral I-group
Contraceptives I-group
A O
group O
of O
24 O
nonsmoking O
, O
healthy O
white O
female O
volunteers O
established O
on O
an O
oral O
contraceptive B-group
regimen O
containing O
30 O
mg O
ethinyl B-drug
estradiol I-drug
and O
75 O
mg O
gestodene B-drug
for O
at O
least O
3 O
months O
received O
2400 O
mg/day O
of O
felbamate B-drug
from O
midcycle O
( O
day O
15 O
) O
to O
midcycle O
( O
day O
14 O
) O
of O
two O
consecutive O
oral O
contraceptive B-group
cycles O
. O

The O
median O
survival O
for O
CHOP-HAART O
patients O
was O
not O
reached O
, O
whereas O
the O
medial O
survival O
of O
CHOP O
patients O
was O
7 O
months O
( O
P O
= O
0.03 O
) O
. O

increased O
platelet O
count O
; O

Tadalafil B-drug

Cisapride B-drug
was O
well O
tolerated O
when O
administered O
alone O
or O
with O
fluoxetine B-drug
. O

H2 B-group
Blockers I-group
and O
Proton B-group
Pump I-group
Inhibitors I-group
( O
PPIs B-group
) O

Antihistamines B-group
may O
partially O
counteract O
the O
anticoagulation O
effects O
of O
heparin B-drug
or O
warfarin B-drug
. O

Since O
FOSCAVIR B-brand
decreases O
serum O
concentrations O
of O
ionized O
calcium O
, O
concurrent O
treatment O
with O
other O
drugs O
known O
to O
influence O
serum O
calcium O
concentrations O
should O
be O
used O
with O
particular O
caution O
. O

Beta-adrenergic B-group
blocking I-group
drugs I-group
add O
some O
further O
antihypertensive O
effect O
to O
captopril B-drug
, O
but O
the O
overall O
response O
is O
less O
than O
additive O
. O

chymotrypsin B-drug
; O

In O
vitro O
studies O
in O
human O
liver O
microsomes O
indicate O
that O
ertapenem B-drug
does O
not O
inhibit O
metabolism O
mediated O
by O
any O
of O
the O
following O
six O
cytochrome O
p450 O
( O
CYP O
) O
isoforms O
: O
1A2 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
2E1 O
and O
3A4 O
. O

These O
events O
required O
medical O
intervention O
in O
some O
patients O
. O

- O
Digoxin B-drug
: O
Interaction O
studies O
in O
humans O
have O
shown O
no O
effect O
on O
digoxin B-drug
blood O
levels O
. O

Potassium-depleting B-group
diuretics I-group
are O
a O
major O
contributing O
factor O
to O
digitalis B-group
toxicity O
. O

Rhabdomyolysis O
has O
been O
observed O
in O
patients O
receiving O
HMG-CoA B-group
reductase I-group
inhibitors I-group
administered O
alone O
( O
at O
recommended O
dosages O
) O
or O
concomitantly O
with O
immunosuppressive B-group
drugs I-group
including O
cyclosporine B-drug
. O

Magnesium B-drug
and O
therapeutics O
. O

Interactions O
with O
lipid-lowering O
drugs O
that O
can O
cause O
myopathy O
when O
given O
alone O
. O

Geriatric O
Use O

Quetiapine B-drug
fumarate I-drug
( O
'Seroquel B-brand
' O
) O
is O
a O
newly O
introduced O
atypical B-group
antipsychotic I-group
with O
demonstrated O
efficacy O
in O
the O
treatment O
of O
positive O
and O
negative O
symptoms O
of O
schizophrenia O
. O

glucagon B-drug
; O

In O
the O
case O
of O
severe O
neutropenia O
( O
500 O
cells/mm3 O
for O
seven O
days O
or O
more O
) O
during O
a O
course O
of O
TAXOL B-brand
therapy O
, O
a O
20 O
% O
reduction O
in O
dose O
for O
subsequent O
courses O
of O
therapy O
is O
recommended O
. O

Based O
on O
adult O
data O
, O
lower O
doses O
of O
caffeine B-drug
may O
be O
needed O
following O
coadministration O
of O
drugs O
which O
are O
reported O
to O
decrease O
caffeine B-drug
elimination O
( O
e.g. O
, O
cimetidine B-drug
and O
ketoconazole B-drug
) O
and O
higher O
caffeine B-drug
doses O
may O
be O
needed O
following O
coadministration O
of O
drugs O
that O
increase O
caffeine B-drug
elimination O
( O
e.g. O
, O
phenobarbital B-drug
and O
phenytoin B-drug
) O
. O

- O
Disulfiram B-drug
( O
e.g. O
, O
Antabuse B-brand
) O
or O

Rifampin B-drug
: O
Coadministration O
of O
rifampin B-drug
and O
MEPRON B-brand
Suspension O
results O
in O
a O
significant O
decrease O
in O
average O
steady- O
state O
plasma O
atovaquone B-drug
concentrations O
. O

When O
digoxin B-drug
and O
BREVIBLOC B-brand
were O
concomitantly O
administered O
intravenously O
to O
normal O
volunteers O
, O
there O
was O
a O
10-20 O
% O
increase O
in O
digoxin B-drug
blood O
levels O
at O
some O
time O
points O
. O

Grapefruit O
juice O
increases O
ethinyl B-drug
estradiol I-drug
concentrations O
and O
would O
be O
expected O
to O
increase O
progesterone B-drug
serum O
levels O
as O
well O
; O

Rifabutin B-drug

Acetazolamide B-drug
and O
sodium B-drug
bicarbonate I-drug
used O
concurrently O
increases O
the O
risk O
of O
renal O
calculus O
formation O
. O

Efavirenz I-drug

Moreover O
, O
the O
basal O
and O
dmPGE2-induced B-drug_n
jejunal O
net O
fluid O
transfers O
were O
the O
same O
in O
cecectomized O
and O
in O
control O
rats O
. O

Antacids B-group
: O
In O
a O
clinical O
pharmacology O
study O
, O
coadministration O
of O
an O
antacid B-group
( O
aluminum B-drug
hydroxide I-drug
, O
magnesium B-drug
hydroxide I-drug
, O
and O
simethicone B-drug
) O
with O
fosinopril B-drug
reduced O
serum O
levels O
and O
urinary O
excretion O
of O
fosinoprilat B-drug_n
as O
compared O
with O
fosinopril B-drug
administered O
alone O
, O
suggesting O
that O
antacids B-group
may O
impair O
absorption O
of O
fosinopril B-drug
. O

The O
renal O
effects O
of O
nephrotoxic O
compounds O
may O
be O
potentiated O
by O
Carboplatin B-drug
. O

Further O
, O
in O
clinical O
studies O
with O
PROSCAR B-brand
( O
finasteride B-drug
, O
5 O
mg O
) O
when O
used O
in O
older O
men O
who O
have O
benign O
prostatic O
hyperplasia O
( O
BPH O
) O
, O
PSA O
levels O
are O
decreased O
by O
approximately O
50 O
% O
. O

Amiodarone B-drug
may O
suppress O
certain O
CYP450 O
enzymes O
, O
including O
CYP1A2 B-drug
, O
CYP2C9 B-drug
, O
CYP2D6 B-drug
, O
and O
CYP3A4 B-drug
. O

Influence O
of O
estradiol B-drug
and O
progesterone B-drug
on O
the O
sensitivity O
of O
rat O
thoracic O
aorta O
to O
noradrenaline B-drug
. O

Use O
of O
Cerubidine B-brand
in O
a O
patient O
who O
has O
previously O
received O
doxorubicin B-drug
increases O
the O
risk O
of O
cardiotoxicity O
. O

Because O
Anafranil B-brand
is O
highly O
bound O
to O
serum O
protein O
, O
the O
administration O
of O
Anafranil B-brand
to O
patients O
taking O
other O
drugs O
that O
are O
highly O
bound O
to O
protein O
( O
e.g. O
, O
warfarin B-drug
, O
digoxin B-drug
) O
may O
cause O
an O
increase O
in O
plasma O
concentrations O
of O
these O
drugs O
, O
potentially O
resulting O
in O
adverse O
effects O
. O

Olanzapine B-drug
: O
Coadministration O
of O
eszopiclone B-drug
3 O
mg O
and O
olanzapine B-drug
10 O
mg O
produced O
a O
decrease O
in O
DSST O
scores O
. O

METHOD O
: O
This O
study O
was O
a O
multicenter O
randomized O
double-blind O
study O
of O
101 O
patients O
who O
were O
randomly O
assigned O
1:1:1 O
to O
receive O
everolimus B-drug
tablets O
at O
doses O
of O
0.5 O
mg O
, O
1 O
mg O
, O
or O
2 O
mg O
twice O
daily O
with O
cyclosporine B-drug
and O
prednisone B-drug
. O

The O
onset O
of O
symptoms O
usually O
occurred O
within O
hours O
( O
most O
commonly O
1 O
to O
4 O
hours O
) O
following O
the O
administration O
of O
contrast O
media O
. O

The O
coadministration O
of O
aspirin B-brand
decreases O
the O
biologic O
half-life O
of O
fenoprofen B-drug
because O
of O
an O
increase O
in O
metabolic O
clearance O
that O
results O
in O
a O
greater O
amount O
of O
hydroxylated B-drug_n
fenoprofen I-drug_n
in O
the O
urine O
. O

If O
NovoLog B-brand
is O
mixed O
with O
NPH B-drug
human I-drug
insulin I-drug
, O
NovoLog B-brand
should O
be O
drawn O
into O
the O
syringe O
first O
. O

The O
fraction O
of O
STADOL B-brand
NS I-brand
absorbed O
is O
unaffected O
by O
the O
concomitant O
administration O
of O
a O
nasal B-group
vasoconstrictor I-group
( O
oxymetazoline B-drug
) O
, O
but O
the O
rate O
of O
absorption O
is O
decreased O
. O

Minor O
symptoms O
such O
as O
flushing O
, O
skin O
reactions O
, O
dyspnea O
, O
hypotension O
, O
or O
tachycardia O
do O
not O
require O
interruption O
of O
therapy O
. O

Spermine B-drug
, O
and O
to O
a O
lesser O
extent O
, O
spermidine B-drug_n
, O
enhanced O
the O
translocating O
action O
of O
oleate O
and O
increased O
its O
effectiveness O
in O
transferring O
the O
phosphohydrolase O
from O
the O
soluble O
to O
the O
microsomal O
fraction O
. O

Carcinogenesis O
, O
Mutagenesis O
and O
Impairment O
of O
Fertility O
A O
two-year O
carcinogenesis O
study O
was O
conducted O
in O
female O
and O
male O
rats O
, O
at O
intramuscular O
doses O
of O
15 O
mg/kg/30 O
days O
, O
10 O
mg/rat/30 O
days O
and O
10 O
mg/rat/15 O
days O
. O

Although O
in O
vivo O
studies O
have O
not O
been O
done O
to O
see O
if O
etodolac B-drug
clearance O
is O
changed O
by O
coadministration O
of O
phenylbutazone B-drug
, O
it O
is O
not O
recommended O
that O
they O
be O
coadministered O
. O

Products O
containing O
calcium B-drug
and O
other O
multivalent B-drug
cations I-drug
likely O
will O
interfere O
with O
absorption O
of O
alendronate B-drug
. O

Enoxaparin B-drug
dosed O
as O
a O
1.0 O
mg/kg O
subcutaneous O
injection O
q12h O
for O
four O
doses O
did O
not O
alter O
the O
pharmacokinetics O
of O
eptifibatide B-drug
or O
the O
level O
of O
platelet O
aggregation O
in O
healthy O
adults O
. O

These O
results O
indicate O
that O
the O
pancreatic O
alpha O
cell O
of O
the O
diabetic O
Chinese O
hamster O
responds O
excessively O
to O
arginine B-drug
, O
as O
is O
seen O
in O
the O
human O
diabetic O
. O

The O
mean O
AUC O
values O
of O
LNG O
were O
decreased O
by O
32 O
% O
[ O
90 O
% O
CI O
: O
20-45 O
] O
in O
one O
study O
and O
52 O
% O
[ O
90 O
% O
CI O
: O
42-52 O
] O
in O
another O
study O
. O

Cohort O
1 O
then O
received O
amprenavir B-drug
plus O
rifabutin B-drug
for O
10 O
days O
, O
and O
cohort O
2 O
received O
amprenavir B-drug
plus O
rifampin B-drug
for O
4 O
days O
. O

Protease B-group
Inhibitors I-group
: O
In O
vitro O
data O
indicate O
that O
indinavir B-drug
and O
ritonavir B-drug
markedly O
inhibit O
the O
metabolism O
of O
cisapride B-drug
which O
can O
result O
in O
an O
increase O
in O
plasma O
cisapride B-drug
levels O
and O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O

Death O
due O
to O
fulminant O
pancreatitis O
possibly O
related O
to O
intravenous O
pentamidine B-drug
and O
HIVID B-drug
has O
been O
reported O
. O

These O
findings O
should O
be O
taken O
into O
account O
for O
proper O
interpretation O
of O
serum O
PSA O
when O
evaluating O
men O
treated O
with O
finasteride B-drug
. O

The O
dosage O
of O
these O
medications O
should O
not O
be O
changed O
and O
they O
should O
not O
be O
stopped O
without O
consulting O
the O
physician O
, O
even O
if O
the O
patient O
feels O
better O
after O
initiating O
treatment O
with O
FORADIL B-brand
. O

Diuretic B-group
agents I-group
reduce O
the O
renal O
clearance O
of O
lithium B-drug
and O
add O
a O
high O
risk O
of O
lithium B-drug
toxicity O
. O

The O
action O
of O
the O
benzodiazepines B-group
may O
be O
potentiated O
by O
anticonvulsants B-group
, O
antihistamines B-group
, O
alcohol B-drug
, O
barbiturates B-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
narcotics B-group
, O
phenothiazines B-group
, O
psychotropic B-group
medications I-group
, O
or O
other O
drugs O
that O
produce O
CNS O
depression O
. O

Although O
there O
is O
no O
documentation O
of O
such O
, O
a O
similar O
interaction O
between O
ethotoin B-drug
and O
the O
coumarin B-group
anticoagulants I-group
may O
occur O
. O

if O
necessary O
, O
amiodarone B-drug
can O
continue O
to O
be O
used O
after O
insertion O
of O
a O
pacemaker O
in O
patients O
with O
severe O
bradycardia O
or O
sinus O
arrest O
. O

Although O
neither O
dexamethasone B-drug
nor O
retinyl B-drug
acetate I-drug
affected O
the O
proliferation O
of O
prostatic O
epithelium O
in O
RPMI1640 O
containing O
transferrin B-drug_n
alone O
, O
they O
modify O
the O
mitogenic O
effect O
of O
EGF B-drug_n
and O
insulin B-drug
. O

Barbiturates B-group
and O
glutethimide B-drug
should O
not O
be O
administered O
to O
patients O
receiving O
coumarin B-group
drugs I-group
. O

If O
pregnancy O
occurs O
while O
taking O
AMEVIVE B-brand
, O
continued O
use O
of O
the O
drug O
should O
be O
assessed O
. O

drugs O
affecting O
blood O
elements O
; O

Electrolyte O
Disturbances O
Patients O
with O
hypokalemia O
or O
hypomagnesemia O
should O
have O
the O
condition O
corrected O
whenever O
possible O
before O
being O
treated O
with O
Cordarone B-drug
I.V. I-drug
, O
as O
these O
disorders O
can O
exaggerate O
the O
degree O
of O
QTc O
prolongation O
and O
increase O
the O
potential O
for O
TdP O
. O

Potentially O
fatal O
drug O
interactions O
may O
occur O
when O
coadministered O
with O
digoxin B-drug
, O
as O
this O
may O
enhance O
cardiovascular O
depression O
and O
bradyarrhythmias O
may O
occur O
. O

Interacts O
with O
valproic B-drug
acid I-drug

Furthermore O
, O
arsenate B-drug_n
and O
phosphate B-drug
do O
not O
appear O
to O
share O
a O
common O
transport O
pathway O
in O
the O
duodenum O
and O
no O
evidence O
was O
obtained O
for O
any O
interaction O
between O
the O
two O
at O
this O
level O
. O

Ingestion O
of O
diclofenac B-drug
may O
increase O
serum O
concentrations O
of O
digoxin B-drug
and O
methotrexate B-drug
and O
increase O
cyclosporine B-drug
s O
nephrotoxicity O
. O

No O
dose O
adjustment O
is O
necessary O
when O
Simulect B-brand
is O
added O
to O
triple-immunosuppression O
regimens O
including O
cyclosporine B-drug
, O
corticosteroids B-group
, O
and O
either O
azathioprine B-drug
or O
mycophenolate B-drug
mofetil I-drug
. O

Inhibition O
of O
the O
other O
isozymes O
evaluated O
( O
CYPs O
2A1 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
3A4 O
, O
and O
3E1 O
) O
was O
0-16 O
% O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
the O
site O
of O
the O
inhibitory O
action O
of O
RR B-drug_n
is O
at O
the O
InsP O
( O
3 O
) O
receptor O
, O
or O
its O
closely O
associated O
proteins O
. O

Iodometric O
titration O
of O
the O
polymer O
conjugates O
was O
used O
to O
determine O
the O
extent O
of O
immobilised O
cysteine B-drug
. O

The O
duration O
of O
the O
period O
following O
treatment O
with O
AMEVIVE B-brand
before O
one O
should O
consider O
starting O
other O
immunosuppressive B-group
therapy O
has O
not O
been O
evaluated O
. O

Plasma O
membrane O
and O
intracellular O
mobilization O
of O
calcium O
ions O
are O
intimately O
related O
to O
platelet O
activation O
and O
release O
of O
platelet O
contents O
. O

Prior O
administration O
of O
succinylcholine B-drug
had O
no O
effect O
on O
the O
duration O
of O
neuromuscular O
block O
following O
initial O
or O
maintenance O
bolus O
doses O
of O
NIMBEX B-brand
. O

- O
Increased O
serum O
triglyceride O
and O
phospholipid O
concentration O
. O

Patients O
receiving O
flurbiprofen B-drug
and O
furosemide B-drug
or O
other O
diuretics B-group
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
is O
obtained O
. O

Quinolones B-group
, O
including O
nalidixic B-drug
acid I-drug
, O
may O
enhance O
the O
effects O
of O
the O
oral O
anticoagulant B-group
warfarin B-drug
or O
its O
derivatives O
. O

Coadministration O
of O
Itraconazole B-drug
and O
cyclosporine B-drug
, O
tacrolimus B-drug
or O
digoxin B-drug
has O
led O
to O
increased O
plasma O
concentrations O
of O
the O
latter O
three O
drugs O
. O

The O
administration O
of O
other O
potassium-sparing B-group
antihypertensives I-group
with O
NSAIDs B-group
has O
been O
shown O
to O
reduce O
the O
antihypertensive O
effect O
in O
some O
patients O
and O
result O
in O
severe O
hyperkalemia O
in O
patients O
with O
impaired O
renal O
function O
. O

Anastrozole B-drug
inhibited O
in O
vitro O
metabolic O
reactions O
catalyzed O
by O
cytochromes O
P450 O
1A2 O
, O
2C8/9 O
, O
and O
3A4 O
but O
only O
at O
relatively O
high O
concentrations O
. O

( O
Effects O
may O
be O
decreased O
when O
used O
concurrently O
with O
thiazide B-group
diuretics I-group
; O

Chloral B-drug
hydrate I-drug
and O
methaqualone B-drug
interact O
pharmacologically O
with O
orally O
administered O
anticoagulant B-group
agents I-group
, O
but O
the O
effect O
is O
not O
clinically O
significant O
. O

Standard O
therapy O
includes O
antibiotics B-group
, O
such O
as O
penicillin B-drug
and O
gentamicin B-drug
; O

This O
effect O
has O
been O
attributed O
to O
inhibition O
of O
prostaglandin O
synthesis O
. O

Leucovorin B-drug
: O
The O
concentration O
of O
5-fluorouracil B-drug
is O
increased O
and O
its O
toxicity O
may O
be O
enhanced O
by O
leucovorin B-drug
. O

Caution O
is O
warranted O
and O
therapeutic O
concentration O
monitoring O
is O
recommended O
for O
antiarrhythmics B-group
when O
coadministered O
with O
CRIXIVAN B-brand
. O

This O
slowing O
potentiates O
amphetamines B-group
, O
increasing O
their O
effect O
on O
the O
release O
of O
norepinephrine O
and O
other O
monoamines O
from O
adrenergic O
nerve O
endings O
; O

The O
majority O
of O
these O
reports O
concerned O
variable O
elevations O
in O
prothrombin O
times O
without O
clinically O
significant O
sequelae O
. O

Effects O
of O
Antacids B-group
on O
Felbatol B-brand
The O
rate O
and O
extent O
of O
absorption O
of O
a O
2400 O
mg O
dose O
of O
Felbatol B-brand
as O
monotherapy O
given O
as O
tablets O
was O
not O
affected O
when O
coadministered O
with O
antacids B-group
. O

There O
has O
been O
too O
little O
experience O
with O
the O
coadministration O
of O
TAMBOCOR B-brand
with O
nifedipine B-drug
or O
diltiazem B-drug
to O
recommend O
concomitant O
use O
. O

Because O
of O
the O
risk O
of O
increased O
exposure O
tonevirapine B-drug
, O
caution O
should O
be O
used O
inconcomitant O
administration O
, O
and O
patients O
should O
be O
monitored O
closely O
for O
nevirapine-associated O
adverse O
events O
. O

Cardiac B-group
Glycosides I-group
: O
In O
a O
study O
of O
young O
healthy O
male O
subjects O
no O
evidence O
of O
a O
direct O
pharmacokinetic O
captopril-digoxin B-drug
interaction O
could O
be O
found O
. O

Monitor O
cardiovascular O
status O
. O

This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O

methadone I-drug
concentration O

There O
is O
no O
information O
regarding O
the O
effect O
on O
lamivudine B-drug
pharmacokinetics O
of O
higher O
doses O
of O
TMP/SMX B-drug
such O
as O
those O
used O
to O
treat O
Pneumocystis O
carinii O
pneumonia O
. O

Based O
on O
known O
metabolic O
profiles O
, O
clinically O
significant O
drug O
interactions O
are O
not O
expected O
between O
VIRACEPT B-brand
and O
dapsone B-drug
, O
trimethoprim/sulfamethoxazole B-drug
, O
clarithromycin B-drug
, O
erythromycin B-drug
, O
itraconazole B-drug
or O
fluconazole B-drug
. O

Therefore O
, O
close O
monitoring O
of O
serum O
cyclosporin B-drug
level O
is O
recommended O
and O
, O
if O
necessary O
, O
chloroquine B-drug
should O
be O
discontinued O
. O

Lapatinib B-drug
inhibits O
human O
P-glycoprotein O
. O

Oral O
anticoagulants B-group
may O
potentiate O
the O
hypoglycemic O
action O
of O
hypoglycemic B-group
agents I-group
, O
eg O
, O
tolbutamide B-drug
and O
chlorpropamide B-drug
, O
by O
inhibiting O
their O
metabolism O
in O
the O
liver O
. O

The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-drug
; O

No O
formal O
drug/drug O
interaction O
studies O
with O
Plenaxis B-brand
were O
performed O
. O

Coadministration O
of O
warfarin B-drug
did O
not O
affect O
the O
pharmacokinetics O
of O
levetiracetam B-drug
. O

All O
antagonists O
decreased O
the O
time O
spent O
in O
the O
light O
zone O
in O
this O
test O
, O
which O
suggested O
that O
these O
compounds O
have O
anxiogenic O
effects O
. O

iv O
. O

Nucleoside O
Analogues O
Didanosine B-drug
Co-administration O
of O
COPEGUS B-brand
and O
didanosine B-drug
is O
not O
recommended O
. O

Glutathione-S-transferase O
( O
GST O
) O
activity O
, O
however O
, O
did O
not O
differ O
from O
control O
values O
for O
any O
dose O
or O
at O
any O
time O
point O
in O
cerebral O
and O
hepatic O
tissues O
. O

Thus O
, O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
of O
EQUETROTM B-brand
, O
and O
then O
begins O
a O
course O
of O
treatment O
with O
one O
of O
these O
CYP3A4 O
or O
epoxide O
hydrolase O
inhibitors O
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
reduction O
for O
EQUETROTM B-brand
may O
be O
necessary O
. O

In O
a O
ten-subject O
study O
, O
coadministration O
of O
diltiazem B-drug
( O
120 O
mg O
bid O
) O
with O
lovastatin B-drug
resulted O
in O
a O
3-4 O
times O
increase O
in O
mean O
lovastatin B-drug
AUC O
and O
Cmax O
vs. O
lovastatin B-drug
alone O
; O

. O

In O
clinical O
trials O
in O
patients O
undergoing O
PTCA/PCI O
, O
co-administration O
of O
Angiomax B-brand
with O
heparin B-drug
, O
warfarin B-drug
, O
thrombolytics B-group
or O
glycoprotein O
IIb/IIIa O
inhibitors O
was O
associated O
with O
increased O
risks O
of O
major O
bleeding O
events O
compared O
to O
patients O
not O
receiving O
these O
concomitant O
medications O
. O

Drug/Laboratory O
Test O
Interactions O
The O
urine O
of O
patients O
who O
take O
Lodine B-brand
can O
give O
a O
false-positive O
reaction O
for O
urinary O
bilirubin O
( O
urobilin O
) O
due O
to O
the O
presence O
of O
phenolic O
metabolites O
of O
etodolac B-drug
. O

Hormonal B-group
Contraceptives I-group
: O
It O
has O
not O
been O
established O
if O
there O
is O
a O
pharmacokinetic O
interaction O
between O
acitretin B-drug
and O
combined B-group
oral I-group
contraceptives I-group
. O

Beta-blockers B-group
not O
only O
block O
the O
therapeutic O
effects O
of O
beta-agonists B-group
, O
but O
may O
produce O
severe O
bronchospasm O
in O
COPD O
patients O
. O

A O
smaller O
24-week O
study O
has O
suggested O
nevirapine B-drug
may O
be O
superior O
to O
the O
PI B-group
nelfinavir B-drug
. O

Therefore O
, O
monitoring O
of O
theophylline B-drug
plasma O
levels O
should O
be O
considered O
and O
dosage O
of O
theophylline B-drug
adjusted O
as O
required O
. O

